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SUMMARY
The metabolism of aspirin has been investigated in man following a 
therapeutic (600 mg) dose and after overdose. The major urinary 
metabolite in volunteers after the therapeutic dose was salicyluric 
acid and a sex-related difference in its excretion and that of 
salicylic acid was observed. Capacity limited formation of 
salicyluric acid has been demonstrated for the first time in a 
substantial number of paients with aspirin overdose. Urinary 
excretion of gentisic acid, salicylic acid and salicyl phenolic 
glucuronide was higher in overdose patients compared with the 
volunteers. In addition, the urinary excretion rates of aspirin 
metabolites and in particular salicyluric acid and salicyl phenolic 
glucuronide in individual patients varied with time after admission 
and the maximum observed rates were often greatly in excess of those 
previously reported in the literature.
Depletion of plasma glycine also occurred after aspirin overdose. The 
in vivo plasma glycine pool was enriched by oral administration of 
glycine or N-glycylglycine. Glycine and N-glycylglycine treatments 
were as effective as the standard urine alkalinisation regimen in 
enhancing renal excretion of total salicylate after overdose but the 
mechanism of this action is unclear. Thus exogenous glycine may be of 
therapeutic value in salicylate overdose.
The metabolism of 14^-aspirin was also studied in rats over a ten fold 
dose range and was found to be dose dependent. The principal urinary 
metabolite after each dose was salicylic acid and salicyluric acid
formation was capacity limited. Oral administration of glycine 
concurrently with aspirin increases the urinary excretion of 
salicyluric acid. Gentisuric acid and salicyluric phenolic 
glucuronide have also been quantified in man and rat urine.
Metabolism of aspirin was found to be similar in man and rat, although 
there were quantitative differences; thus rat may serve as a useful 
experimental model to study man.
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1.1 History and Develppnait of the Salicylates
The naturally occurring forms of the salicylates, salicin (a 
glycoside) and methyl salicylate, are found in the leaves and bark of 
a number of trees and shrubs. The extracts of these species, 
particularly the bark of the willow (salix alba vulgaris), have been 
used medicinally by several cultures for centuries. About 2400 years 
ago, Hippocrates recommended juices of the poplar tree and willow bark 
for the treatment of eye diseases and pain in childbirth, 
respectively (Gross and Greenberg, 1948). Aulus Cornelius Celsus (in 
30 AD) in one of his encyclopaedic works. De re medica, recognized the 
four cardinal signs of inflammation: rubor, calor, dolor and tumor 
(i.e. redness, heat, pain and swelling, respectively). He stated that 
a boiled vinegar extract of willow leaves could be employed for the 
relief of pain from prolapse of the uterus and other conditions 
(Margotta, 1968). Galen (in the second century AD) employed the 
antiseptic properties of the salicylates in willow leaves for the 
treatment of various skin conditions including wounds, ulcers and 
erysipilas. Thus, by Roman times, there were many different 
therapeutic applications of salicylate-containing plants.
In England in the mid-eighteenth century. Reverend Edmund Stone 
of Chipping Norton first described the anti-pyretic action of willow 
bark in a letter to the President of the Royal Society,
Lord Macclesfield, dated 25th April 1763. This began:
"My Lord,
Among the many useful discoveries which this age has made, 
there are few which better deserve the attention of the public than
what I am going to lay before your Lordship. There is a bark of an 
English tree which I have found by experience to be a powerful 
astringent, and very efficacious in curing aguish (rheumatism) and 
intermitting disorders (bouts of fever) (taken from Fairley, 1978). 
Edmund Stone had accidentally tasted the bark of the common white 
willow (salix alba vulgaris), and the bitterness was, to him, strongly 
reminiscent of Cinchona bark (the source of quinine). He rationalized 
his finding on the grounds that since the willow grew in damp or wet 
areas "whereas agues chiefly abound", it would probably possess 
curative properties appropriate to that condition, "Doctrines of 
Signatures"".
The active ingredient in the willow bark was a bitter glycoside 
called salicin, first discovered by Leroux in 1827. Piria, in 1838, 
made salicylic acid from salicin. Six years later, salicylic acid was 
prepared from oil of gaultheria (oil of wintergreen) by Cahours. The 
chemical synthesis of salicy lie acid was pioneered in 1860 by Kolbe 
and Lautemann. It was used therapeutically as an anti-inflammatory 
and antipyretic agent for rheumatic fever by Buss in 1875, and in the 
following year by Strieker and MacLagan. In 1879, See observed that 
salicylates increased the urinary excretion of uric acid and this 
property was utilised in the treatment of gout by Campbell. Although, 
at the time both salicyclic acid and sodium salicylate were widely 
used they were found to be too great an irritant to the mounth, gullet 
and stomach. Hence, there was a great need for a "safer" salicylate 
(still a problem today!).
Aspirin (acetylsalicylic acid) was first synthesised chemically 
by Von Gerhart in 1853, while studying the acétylation reactions. The 
father of one of the chemists at Bayer suffered from severe rheumatoid 
arthritis and pleaded with his son, Felix Hoffmann, to search for a 
less irritating drug than sodium salicylate. Hoffmann tested several 
compounds and decided that aspirin was the most satisfactory, so he 
prepared samples of pure aspirin and gave them to his father to try.
At the time, Dreser then the director of pharmacological research at 
Bayer quickly recognized that they had an outstanding drug and 
subsequently the Bayer Company introduced aspirin in 1899. Dreser and 
Hoffmann decided to call the drug aspirin, the 'a* stood for acetyle, 
the *spir' for the spiraea plant family (also known as meadowsweet 
from which the salicylic acid was obtained) and the 'in* for good 
measure (Fairley, 1978). Today aspirin rates next to alcohol as being 
the most consumed drug in the world. Due to its wide availability it 
has remained one of the most extensively used analgesic, antipyretic 
and anti-inflammatory agent and its spectrum of therapeutic uses 
continues to widen (Barnett, Hirsh and Mustard, 1982).
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1.2 Physical and Chemical Properties of A^irin
Aspirin is a weak acid (pka 3.5) and exists primarily as the 
anion in the blood or body tissues. Salicyclic acid is also a weak 
acid with pka 2.9. The aqueous solubility of aspirin increases with 
pH. At pH 2.25 its solubility is reported to be 3.4 g/liter, whereas 
at pH 7 it is 8200 g/liter (Garrett, 1957a). The aqueous solubility 
also increases with temperature, but hydrolysis occurs. The rate of 
hydrolysis of aspirin increases markedly in the presence of 10-90 per 
cent aqueous ethanol mixtures (Garrett, 1957b). This is of relevance 
in view of the frequent consumption of alcohol with aspirin. The 
instability of aspirin even in the powder state is evident when a 
bottle of tablets is opened. The odour is that of acetic acid, a 
product of hydrolysis caused by moist air. Edwards (1950), 
investigating its aqueous hydrolysis at 17°C, found aspirin most stable 
at a pH close to 2.5 and saturated aqueous solutions exhibited such a 
pH. Increased hydrolysis was observed at pH values less than or 
greater than 2.5, becoming particularly exaggerated at a pH greater 
than 9. Thus, care must be taken in the preparation and use of 
aspirin solutions. A freshly prepared solution of pH 7.4, stored at 
17°C, exhibits 10% hydrolysis to salicylic acid after 1 day, or less 
than 2% if stored for only 4 hr. This subject has been reviewed 
recently in detail by Florey (1979).
1.3 Mechanism of action of Aspirin
In recent years, considerable progress has been made in 
elucidating the mechanism of action of aspirin and other non-steriodal 
anti-inflammatory drugs. Aspirin is rapidly metabolised to sali yclic 
acid (Cohen, 1976). Therefore, when considering the mode of action of
aspirin, the effects of both acetysalicylic acid and salicylic acid 
must be taken into account. These two drugs inhibit a wide variety 
of ï^ysiologic reactions (Moncada and Vane, 1979; Cohen, 1976;
Barnett, Hirsh and Mustard, 1982).
Anti-inflammatory effect: The processes of inflammation are 
complex and it is now well recognised that during such an event, 
inflammatory mediators such as histamine, 5-hydroxytryptamine (5-HT), 
slow-reacting substance of anaphylaxis (SRS-A), bradykinin, various 
chemotactic factors and prostaglandins are involved. The major 
inhibitory effects of aspirin and salicylic acid is on the bradykinin 
and prostaglandin systems i.e. on the synthesis and release of these 
mediators (Barnett, Hirsh and Mustard, 1982; Rainsford, 1984a). 
Nanogram amounts of prostaglandin E2 or I2 (which are likely to be 
generated in inflammation), when injected, cause erythema and increase 
local blood flow. They also increase vascular permeability. 
Prostaglandin Ej, E2 and A2 cause edema when injected into the hind 
paw of the rat.
Analgesic effect: Aspirin is a mild analgesic and is effective 
against pain of low to moderate intensity. Lim (1964) have
clearly demonstrated that aspirin acts mainly peripherally, whereas 
the analgesic action of morphine is more central. Thus, by preventing 
the synthesis and release of prostaglandins in inflammation (Ferreira 
and Vane, 1974), aspirin may avert the sensitization of pain receptors 
to mechanical stimulation or to other mediators. This hypothesis 
explains why aspirin is ineffective as an analgesic in non inflamed 
tissues. It has been found that milligram doses of PG E2 or F2a 
given to women by intramuscular or subcutaneous injection to induce
abortion, caused intense local pain. Prostaglandins can also cause 
headache and vascular pain when infused intravenously in man. Most 
data are consistent with the presumption that aspirin is only 
effective as an analgesic in pathological conditions or experimental 
models in which prostaglandins are synthesized locally. This concept 
also explains why aspirin is ineffective against sharp, severe pain, 
which is caused by direct stimulation of sensory nerves, but is 
effective in the moderate pain of inflammation, where prostaglandins 
apparently sensitise the nerve endings.
Antipyretic effect: Fever is a more generalized response of
inflammatory reactions. Recent evidence indicates that the responses 
of leucocytes (phagocytosis, leucocytosis) during inflammation are 
accompanied by release of endogenous pyrogen. Once released into the 
general circulation, they pass into the central nervous system (CNS) 
and stimulates the release of prostaglandins from discrete sites 
within the brain, probably including the preoptic hypothalamic area.
It is this latter step which is affected by antipyretic agents, 
including aspirin. Milton (1976) and more recently Cooper, et al 
(1982) concluded that prostaglandin E2 is a mediator of pyrogen fever 
and that anti-pyretic agents, such as aspirin, exert their effects in 
fever by inhibition of PG E2 production.
In conclusion, with the data available to date, it is not 
possible to state precisely what mechanisms are involved in the anti­
inflammatory, analgesic and antipyretic action of the salicylates. 
Some of the effects of aspirin are related to its ability to acetylate 
proteins, particularly the enzyme cyclo-oxygenase that is responsible 
for prostaglandin synthesis. The other effects of aspirin results 
from, first, the acétylation of proteins other than cyclo-oxygenase
and second, the actions of salicylic acid on a wide variety of 
physiological reactions. For a detailed account on the mechanisms of 
action of salicylates and other non-steroidal anti-inflammatories, the 
reader is referred to recent reviews by Rainsford (1984) and Barnett, 
Hirsh and Mustard (1982).
1.4 Therapeutic uses of aspirin
The naturally occurring salicylates in a form of plant extracts 
have been used medicinally by several cultures for centuries. Since 
its introduction some 90 years ago, aspirin has remained one of the 
most extensively used analgesic, antipyretic and anti-inflammatory 
agent. Thus, it has become something of a panacea in our society. 
There are many systemic and few local uses of salicylate.
Systemic uses: As an analgesic, salicylates are only effective
in relieving pain of moderate intensity, for example, headache, 
myalgia, arthralgia and dysemorrhea (Lim, 1966). Severe pain and that 
originating in the viscera are not alleviated by these drugs. They 
are particularly effective at controlling, chronic postoperative pain 
or pain arising from inflammation (Cooper, 1981). Although, they have 
much lower maximal effects than the opiates they do not lead to 
addiction and are mainly free of the unwanted effects of the opiates 
on the CNS.
Clinically, aspirin and salicylic acid are extremely effective at 
reducing elevated body temperatures during fever and also those 
induced experimentally. It has been reported that aspirin is 1.5 
times more potent than sodium salicylate in treating the fevers from 
cancer and low-grade episodes from chronic infections (Seed, 1965).
Aspirin is mainly used, clinically, as an anti-inflammatory agent in 
the treatment of musculoskeletal disorders, such as rheumatoid 
arthritis, osteoarthritis, and ankylosing spondylitis (Brooks and 
Buchanan, 1976). In such disorders, it only provides symptomatic 
relief from the pain and inflammation associated with the disease and 
does not arrest the progression of pathological injury to tissue.
In recent years, the possible role of aspirin as an 
antithrombotic agent, in the treatment of diseases associated with 
platelet hyperaggregability, such as coronary artery disease,
amyocardial infraction, and postoperative deep-vein thrombosis has 
received a great deal of attention in the literature. For a detailed 
account of the potential of aspirin in preventing and treating these 
conditions, a recent Canadian symposium should be consulted (Barnett, 
Hirsh and Mustard, 1982). It is well established that Thromboxane A2 
(a vasoconstrictor which induces platelet aggregation) and 
prostaglandin I2 (a powerful vasodilator and inhibitor of platelet 
aggregation) play a central role in the regulation of thrombosis. 
Hence, by using a suitable dose (50-150 mg/day) of aspirin it may be 
possible to selectively inhibit the synthesis of Thromboxane A2 but 
not prostaglandin I2 and thus prevent platelet aggregation. Various 
clinical trials have been conducted to assess the value of aspirin in 
prevention of secondary myocardial infraction, various cardiovascular 
(stroke, transient ischaemic attacks and venous embolic) conditions 
(Barnett, Hirsh and Mustard, 1982). The interpretation of data from 
such studies has led to a great deal of controversy regarding the 
efficacy of aspirin.
Other uses: Salicylic acid has long been successfully used as a
keratolytic agent to control callosités, hyperkeratosis and warts
(Weinrich, 1975). Aspirin and salicylic acid has also been used for 
various other conditions including, Still's disease. Gout, Diabetes 
Mellitus, Thyroiditis, Obesity, Bartter's Syndrome, Cystic Fibrosis, 
Diarrhoea, Ductus arteriosus and Sickle-cell anaemia (Rainsford,
1984b). However, the efficacy of salicylic acid or its derivatives in 
treating some of these conditions is still questionable.
1.5 Iharmcokinetics and Metabolism of Aspirin
The metabolism and pharmacokinetics of aspirin in therapeutic 
doses has been well studied both in man (for reviews see Davison,
1971; Levy, 1978; Levy, 1979; Hucker et al 1980; and Rainsford, 1984a) 
and in various animal species (Haberland, Medenwald and Koster, 1957; 
Davis and Westfall, 1972; Davis, Westfall and Short, 1973; Yue and 
Varma, 1982).
1.5.1 Absorption and Distributions
The absorption of therapeutic doses of aspirin is rapid and 
occurs, partly in the stomach but mainly in the upper small intestine 
(due to large surface area). The absorption occurs by passive 
diffusion primarily of the non-ionised, lipid-solute molecules 
(aspirin and salicylic acid) across gastrointestinal membranes. The 
gastrointestinal absorption of the drug is governed by many factors,
(a) its physiochemical properties, (b) the surface area of the gastric 
and intestinal tract available for absorption, (c) the pH at the 
absorbing cell surface, (d) the rates of gastric emptying and 
intestinal transit times (e) the presence of food in the GI tract, and 
(f) its pharmaceutical dosage form (tablet, capsule) and dissolution
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rate (Levy, Leonards and Procknal, 1965). Aspirin ingested orally, 
either in a solid dosage form (tablets or capsules) or as an aqueous 
solution is very rapidly absorbed (Rowland, Riegelman and Harris,
1972). The rectal absorption of the drug is usually slower, 
incomplete, and unreliable (Levy and Jusko, 1967).
Aspirin is rapidly hydrolysed in the body to salicy lie acid and 
its biological half-life in man is only about 15-20 minutes (Rowland 
and Riegelman, 1968; Rowland et al 1972; Rance, Jordon and Nichols, 
1975). The drug is subject to first-pass hydrolysis by esterases in 
the intestinal wall (Harris and Riegelman, 1969; Rowland et al 1972; 
Spenney, 1978) and in the liver (Ali and Kaur, 1983). Only a fraction 
of the dose approximated to 60% (Rowland and Riegelman, 1968; Rowland 
et al 1972) is absorbed as intact aspirin. In blood, the drug is also 
rapidly hydrolysed to salicylic acid mainly by red blood cell aspirin 
esterase (Costello and Green, 1983). There appears to be clinically 
significant sex-and age-related differences in aspirin esterase 
activity in various tissues, because it has been observed that the 
blood of neonates, children, and adults exhibits different activity 
and the erythrocytes of adult females are less active than those of 
males (Winderfer, Keuenzer, and Urbanek, 1974).
The predominant chemical species in plasma is SA, although small 
quantities of SUA, SPG and SAG have also been detected (Schachter and 
Manis, 1958). In therapeutic doses, both ASA and SA is tightly bound 
to plasma proteins, mainly albumin and account for between 80-85% 
[Aarons et al 1980] and 90-95% (Borga et al 1976; Ernest et al; 1984) 
respectively of the total salicylate in plasma. Unlike most drugs, 
the binding of salicylate to plasma proteins is dose-dependent 
(Ekstrand, Alvan and Borga, 1979). It has been observed that a 50%
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increase in the daily dose of ASA (from 65 to 100 mg/kg) can result in 
a 300% rise in the plasma SA (unbound) concentrations [Paulus et al., 
1971] and is due to saturation of two metabolic pathways of salicylic 
acid (Section 1.5.2.)
Single oral doses of 1000 mg of ASA were found to produce an 
average peak plasma SA concentrations of 77 pg/ml (range 31-114 yg/ 
ml), 2 hours after ingestion (Hollister and Kauler, 1965). Tmavska 
and Trnavsky (1983), recently reported a significant sex-differences 
in plasma concentration of SA in male and female volunteers following 
both single and mutiple oral doses of ASA (14.3 mg/kg). A 
signific^ly lower plasma level of SA was found in men, resulting from 
slower absorption and higher elimination rates. Rheumatoid arthritis 
patients maintained on a daily dosage of between 4-8 g ASA, a plateau 
plasma SA concentrations ranging from 100-350 yg/ml have been reported 
(Gupta, Sarkissian and Paulus, 1975; Gibson et al, 1975; Rumble,
Brooks and Roberts, 1980; Gunsberg et al, 1984) and concentrations 
exceeding 400 yg/ml are indicative of salicylate toxicity (which is 
discussed in Section 1.6).
Following absorption, SA is distributed throughout most body 
tissues and transcellular fluids, mainly by pH-dependent passive 
processes (Davison, 1971). It has been detected in synovial, spinal, 
and peritoneal fluids (Soren, 1978); and in saliva (Graham and 
Rowland, 1972); and breast milk (Levy, 1975). SA crosses the blood- 
brain barrier only slowly because of the large fraction of drug in the 
ionised form and is also actively transported into the placenta 
(Palmisano and Cassady, 1969; Rudolph, 1981). The volume of 
distribution (Vĵ) of SA increases with increasing plasma
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concentrations; it usually ranges between 0.1 and 0.35 I/kg at 
therapeutic concentrations, but can be higher in newborn infants (Levy 
and Yaffe, 1974).
1.5.2 Metabolism and Excretion
In the body, ASA is rapidly metabolised to SA by the intestinal 
wall, liver and blood (see 1.5.1). Further metabolism of SA to more 
polar compounds, occurs primarily in the hepatic and renal 
endoplasmic reticulum and mitochondria (Rainsford, 1984). The 
metabolic fate of salicylic acid was first described by Kapp and 
Coburn (1942). Except for quantitative differences in the known 
metabolites of SA amongst species (Hucker, Kwan and Duggan, 1980) 
under various experimental conditions, no new metabolite(s) has been 
reported in recent years.
Salicylic acid (SA) is conjugated with glycine to form 
salicyluric acid (SUA). Additional, conjugation of SA with glucuronic 
acid results in the formation of both the ether or phenolic (SPG) and 
ester or acyl (SAG) glucuronides. Together, they represent the major 
metabolites of the drug. Gentisic acid, the minor metabolite, is 
formed by ring hydroxylation of the parent drug. Small amount of free 
SA is also excreted. Recently, Zimmerman et al (1981) have 
characterised, by GC-mass spectrometry, a double conjugate of SA as an 
endogenous product in the body fluids of uraemic paitents, namely 
phenolic glucuronide of salicyluric acid (SUA-PG). In addition,
Wilson et al (1978) have reported the formation of another glycine 
conjugate, that of gentisic acid (gentisuric acid, GUA), in urine from 
patients treated with aspirin. The current understanding of aspirin 
metabolism in man is depicted in Fig. 1.1.
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FIG. 1.1 - METABOLIC PATHWAY OF ASPIRIN
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In the body, the major route of SA elimination is via renal 
excretion of both the parent drug and the metabolites. Following 
single oral dose of ASA (14̂ --labelled, Ig) in four health volunteers, 
a rapid and extensive urinary elimination of radioactivity was 
reported by Hutt, Caldwell and Smith (1982). A mean recovery of 96.2% 
of the administered dose was observed in 0-24h urine. The chief 
urinary metabolite was SUA (63.9%). The remainder of the excreted 
dose comprised; GA (1.3%); SPG (5.9); SAG (4.0%); SUA-PG (6.2%); and 
SA (13.5%). The excretion of unmetabolised SA is extremely sensitive 
to urine pH (Smith et al, 1946; Levy, 1980). The renal clearance of 
the drug increases almost exponentially with increase in pH above 
5.5-6.5. The metabolism of SA is dose dependent due to the capacity 
limited formation of two primary metabolites, namely SUA and SPG 
(Levy, 1979). Hence, as the dose is increased, the relative 
proportion of the minor metabolites, including SA also increases. 
Under properly controlled conditions, an administered dose of ASA or 
SA can be recovered quantitatively in the urine as SA and its various 
metabolites, provided the drug is administered in fully bioavailable 
form.
1.5.3 Pharmacok inetics
Rowland and Riegelman (1968) provided the first definitive 
description of the compartmentalised pharmacokinetics of ASA and SA 
based on plasma levels in man. Table 1.1 summarises the mean 
parameters obtained after administration of 650 mg or less of either 
drug intravenously. The fraction of each salicylate bound to plasma 
proteins (fb) applies to total concentrations less than 10 yg/ml. In
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therapeutic doses, the biological half-life of ASA (15 minutes) is 
considerably shorter than SA (4 hours). SA is distributed in and is 
eliminated from the body more slowly than ASA, and is also more 
extensively bound to plasma proteins.
Table 1.1 Summary of mean pharmacokinetic parameters obtained for ASA 
and SA following intravenous administration of 650 mg of each 




tl/2a (min) 2.7 3.8
tl/2e (min) 14.9 238
Vp (1) 6.6 5.5
Vdss (1) 11.3 9.4
TBC (ml/min) 680 27
fb ~0.7 ~0.9
tl/2a and tl/2g are initial and terminal half-lifes of the drug 
respectivley. Vp is the volume of central compartment and Vdgg, the 
volume of distribution at steady state of equilibrium. TBC is total 
body clearance.
In recent years considerable advances have been made in the 
understanding of salicylate kinetics in man (Boreham and Martin, 1969;
e t  alLevy, Tsuchiya and Amsel, 1972; Levy, 1979; Bochner-^ 1981). With the 
data available to date, there is good evidence that at low doses
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(i.e. when the levels of salicylate in the body is less than 300 mg), 
the overall elmination of salicylate proceeds by first-order kinetics 
(Bedford, Cummings and Martin, 1965; Levy, 1965). However, at 
therapeutic and higher doses it occurs by a combination of first-order 
and capacity-limited processes (Levy, Tsuchiya and Amsel, 1972). The 
first order processes involve the formation of GA and SAG and the 
excretion of unconjugated SA, whereas the capacity-limited processes 
involve the formation of SUA and SPG. A pharmacokinetic model has 
been proposed by Levy, Tsuchiya and Amsel (1972), which satisfactorily 
describes the urinary kinetics of SA and primary metabolites after 
oral doses of SA up to 3 grams. The kinetic parameters from this 
study are presented in Table 1.2.
Table 1.2 Kinetic parameters of salicylate disposition in man 
estimated from urinary excretion rate data (Levy, TSuchiya and Amsel, 
1972).

















K is the elimination rate constant, is the theoretical maximum 
rate of metabolic formation and Km is the apparent in vivo Michaelis- 
Menten constant.
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1.6 Acute Aq)irin Poiscxiing
Since its introduction, aspirin has remained one of the most 
commonly used mild analgesic, antipyretic and anti-inflammatory agent 
and its spectrum of therapeutic indications continues to widen. Due 
to its wide availability acute salicylate poisoning remains a common 
medical emergency; usually resulting from accidental ingestions in 
children; suicidal overdose in adults and teenagers; and 
therapeutically acquired intoxication in all ages (for reviews see 
Done, 1978; Temple, 1981; Snodgrass et al, 1981; Brenner and Simon, 
1982).
1.6.1 Epidemiology of salicylate overdose
In the last ten years many analgesic and anti-inflammatory 
compounds have been introduced for clinical use. However, salicylate, 
paracetamol or more recently, the widely available paracetamol/dextro- 
propoxyphene combinations are still the drugs of choice for a 
potential suicide. Recently the National Poisons Information Service 
(NPIS) monitoring Group (1981) undertook a prospective survey of 
analgesic poisoning in five hospitals over the period, April 1978 - 
November 1979, and provided detailed information on 878 patients.
Drug formulations involved and the incidence of ingestion of alcohol 
and other drugs with each type of analgesic are shown in Table 1.3. 
Aspirin (45%) was taken more frequently than paracetamol (29%).
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Table 1.3 Drug formulations involved in 878 cases of analgesic 




Analgesic formulation Alone +  Alcohol +  Alcohol — Alcohol Total {% )
Aspirin only 249 42 39 123 453 (45.2)
Paracetamol only 126 29 93 41 289 (28.8)
Aspirin with paracetamol — — — 1 1 (0.1)
Narcotic only
> 1 0  mg of narcotic with
11 5 6 12 34 (3.4)
aspirin or paracetamol 
< 1 0  mg of narcotic with
63 23 22 64 172 (17.2)
aspirin and/or paracetamol 12 4 3 11 30 (3.1)
Other analgesics 8 4 10 1 23 (2.3)
Total 469 107 173 253 1002 (100)
Over the past 12 years there have been considerable changes in 
the epidemiology of analgesic poisoning (Meredith and Vale, 1984). 
Since the mid-seventies, there has been a gradual decline in the 
number of deaths from salicylate poisoning, but in contrast, the 
mortality from paracetamol related toxicity has increased sharply 
(Figure 1.2). A similar trend was also observed in the annual sale 
and consumption of these drugs over the same period [Figure 1.3]. The 
introduction of child resistant containers (since 1 January 1976 in 
England and Wales), smaller pack sizes, and the elimination of 
attractively coloured products have probably all helped in reducing 
the hospital admissions from analgesic poisoning.
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Figure 1.2. Deaths from three commonly used analgesics following 
overdose in England and Wales, 1974-1982. ▲, Aspirin; ■, Paracetamol 
along; #, Paracetamol and dextropropoxyphene only. The data for the 
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Figure 1.3 Annual sales of analgesic tablets containing aspirin (a) 
and Paracetamol (•), (excluding hospital use) in the UK (except 
Northern Ireland), 1979-1983. The data for the diagram are taken, by 
permission, from Meredith and Vale (1984).





















801978 79 8382 84
Y ear
21
1.6.2 Pathophysiology of Salicylate T&slcity
The major toxic effects of salicylates may be grouped as;
(a) Gastrointestinal; (b) Central Nervous System (CNS); (c) Metabolic 
effects and acid-base balance; and (d) Haematological.
Gastrointestinal effects. These include vomiting, the vomitus 
often containing blood, and accompanying severe substernal and 
epigastric pain. Vomiting in turn contributes to dehydration.
Central Nervous System (CNS) effects. Nausea and vomiting are 
induced by salicylates as a result of direct stimulation of CNS. 
Initially, tinnitus, deafness and vomiting occurs, followed by 
delirium, convulsions and ultimately, coma. In overdose salicylates 
also directly stimulate the respiratory centre to produce both 
increased depth and rate of respiration, thereby causing a respiratory 
alkalosis to develop (Smith 1968; Brem et al, 1973).
Metabolic effects and acid-base balance. Another primary effect 
of salicylates is to uncouple mitochondrial oxidative phosphorylation 
(Smith, 1968). As a result, a number of adenosine triphosphate (ATP)- 
dependent reactions are inhibited. Derangement of carbohydrate, amino 
acid and lipid metabolism leads to hypersecretion in the blood of 
ketone bodies, as well as amino and organic acids (Smith, 1968;
Temple, 1981). Excretion of these acids depletes bicarbonate 
concentrations in the blood thereby causing metabolic acidosis.
Glucose Metabolism also suffers as a result of uncoupled oxidative 
phosphorylation because of increased tissue glycolysis and peripheral 
demand for glucose. Thus hyperglycemia occurs, while hypoglycemia is 
less common, it is found mainly in chronic salicylate intoxication or 
late in the course of acute intoxication (Cotton and Fahlberg, 1964). 
Another well-recognised problem associated with salicylate
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intoxication is water and electrolyte imbalance (Segar, 1969; Done and 
Temple, 1971). Dehydration occurs quickly and is due to the 
combination of sweating, vomiting, overbreathing and an osmotic 
diuresis due to the presence of excess bicarbonate, sodium and 
potassium in the urine. Hypokalaemia may also be prominent and is due 
principally to the effects of the respiratory alkalosis.
Haematological effects. The coagulation defects (prolonged 
bleeding tissue and impairment of platelet aggregation) observed in 
aspirin overdose occurs due to many factors including, inhibition of 
platelet aggregation, increased capillary fragility, decreased factor 
VII levels and hypoprothrombinaemia (Temple, 1978; Pearson, 1978). 
Aspirin-induced hypoprothrombinaemia is due mainly to decreased 
hepatic synthesis of factor VII, an action similar to that of 
Warfarin. This effect is believed to be due to competition of aspirin 
with vitamin K and is reversed by the intravenous administration of 
vitamin K. Gastric erosions and gastrointestinal bleeding appear to 
be uncommon following salicylate overdose.
1.6.3 Assessment of the degree of Toxicity.
For an optimum treatment for salicylate intoxication, early 
assessment of the degree of toxicity is vital. In the case of an 
acute ingestion, this can be done by assessing the amount of the drug 
reported to be ingested, by evaluating the clinical status of the 
patient, and by measuring blood salicylate levels (Temple, 1981). The 
lethal acute dose in an adult is about 20-25g, and 4g is likely to be 
fatal as a single overdose in a small child, but considerably less 
than this can cause serious toxicity in infants.
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Blood salicylate concentrations are the best guide to the severity 
of salicylate poisoning and should be determined six hours after 
ingestion of an overdose, and this should be repeated at frequent 
intervals to ensure that the concentration is not continuing to rise 
because of slow absorption. Generally speaking, blood salicylate 
concentration of less than 500 mg/1 six hours after ingestion of an 
overdose are associated with only mild toxicity; concentrations 
between 500 and 750 mg/1 are associated with moderate toxicity; 
concentrations in excess of 750 mg/1 at six hours may be associated 
with severe toxicity. Blood salicylate are also frequently used in 
conjunction with the Done "nomogram" (Fig. 1.4) for estimating 
severity of toxicity from acute salicylate overdose (Done, 1960). 
Unfortunately, it appears that this nomogram cannot be used in chronic 
salicylate intoxication and in cases of poisoning from enteric coated 
or sustained-release aspirin preparations because of the delayed 
release. The acid base status of the patient should also be 
established together with the blood urea and electrolytes.
1.6.4 Treatment
Gastric Aspiration and Lavage. Large, potentially lethal doses of 
aspirin taken accidentally or with suicidal intent may be absorbed 
much more slowly than therapeutic doses of the drug, partly due to 
the inhibitory effects of aspirin on gastric emptying and impied 
dispersion of the drug in gastrointestinal fluids. Ihus, plasma 
salicylate concentrations in acutely overdosed patients may rise 
continually for as long as 24 hours, and the appearance of toxic 
effects may be delayed (Kaufman and Dubansky, 1972; Ferguson and 




























Figure 1-4 Nomogram for estimating the severity of poisoning from the 
serum salicylate level at varying intervals after ingestion of a 
single dose (adapted from Done, 1960).
25
or emesis induced in all overdose patients as soon as possible. Young 
children should be given syrup of ipecacuanha (10-15 ml) instead of 
gastric lavage. Gastric lavage is effective at removing ingested 
aspirin from the stomach but not from the intestine; whereas activated 
charcoal is effective in preventing aspirin absorption from the 
stomach and intestinal tract. Unfortunately, the quantity of 
activated charcoal required for maximum absorption is quite high, 
between 50-100 g as a slurry for adults (Brenner and Simon, 1982).
Fluid and Electrolyte Replacement. Fluid and electrolyte 
replacement is of paramount importance. Dehydration and hypokalaemia 
can easily be corrected by using appropriate fluid regime supplemented 
with sodium and potassium. In addition, some dextrose (5-10%) should 
also be included in the fluid to prevent the development of 
hypoglycaemia (Temple, 1981). Severe hyperpyrexia can easily be 
controlled by tepid sponging.
Correction of Acid-Base Disturbances. The presence of a 
respiratory alkalosis requires no specific treatment, but a servere 
metabolic acidosis may require at least partial correction with 
bicarbonate. However, patients with severe metabolic acidosis usually 
recieve a urine alkalinisation and this serves to correct the acidosis 
as well as to enhance excretion of the drug.
Hypoprothrombinaemia. This may readily be corrected by the use 
of intravenous vitamin K (Pearson, 1978).
Urine Alkalinisation. Mild cases of salicylate poisoning may be 
managed with either oral or parenteral fluid and electrolyte 
replacement. However, more severely poisoned patients who exhibit 
marked symptoms or signs of salicylism and whose blood salicylate 
concentrations are in excess of 500 mg/1 (and particularly if acidosis
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is present) should receive urine alkalinisation (Prescott et al,
1982). Forced alkaline diuresis has also been used (Temple, 1981; 
Brenner and Simon, 1982; Prescott et al, 1982; Schofield and"Pi
Williams, 1984), however, such treatment may cause pulmonary and 
cerebral oedema due to fluid overload (Temple et al, 1976; Tweeddale, 
1974; Snodgrass et al, 1981) and even death (Ferguson and Boutros, 
1970). Consequently, the treatment has shifted from forced alkaline 
diuresis to urine alkalinisation.
Haemodialysis. In serious salicylate poisoning (plasma 
salicylate over 800 mg/ 1 after rehydration or 1 0 0 0  mg/ 1 before 
rehydration) or when other complications occur such as renal failure 
or pulmonary oedema, haemodialysis is preferred since it can be used 
to correct fluid and electrolyte imbalance and at the same time 
remove salicylate effectively. Peritoneal dialysis and haemoperfusion 
are alternative treatments but are less efficient (
Brenner and Simon, 1982).
1.7 Chronic Aspirin Toxicity and Adverse Drug Reactions
1.7.1 Gastrointestinal effects
Salicylates vary in their propensity to induce gastric ulceration 
and haemorrhage in man and laboratory animals (for an excellent review 
see Rainsford, 1984c). Aspirin has been found to be the most 
ulcerogenic of salicylates, while certain of its alkyl or aryl esters 
of salicylic acid (as the sodium, salt or the free acid) are less 
irritant to the gastric mucosa. These effects have mainly been 
reported in patients recieving high-dose therapy. The salicylate-
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induced gastric bleeding is painless and frequently leads to blood 
loss in the stool and occasionally to an iron-deficiency anemia.
1.7.2 Nephrotoxicity
Evidence in the literature suggests that aspirin alone, may cause 
a transient shedding of renal tubular cells, alterations in urate 
excretion and induce a reversible decline in some aspects of renal 
function (i.e. reduced glomerular filtration with some water, sodium 
and potassium retention), in high-dose therapy (Plotz and Kimberly, 
1981). However, severe renal failure is most rate. Some patients 
with arthritic conditions such as systemic lupus erythematosus and 
juvenile rheumatoid arthritis may be particularly predisposed to renal 
failure from their high-dose aspirin therapy. In addition, high 
incidence of analgesic nephropathy has been reported in patients 
consuming large amounts of drug mixtures (including aspirin), as in 
arthritis (Plotz and Kimberly, 1981).
1.7.3. Hepatotoxic effects
In recent years a large number of reports have appeared in the 
literature suggesting that aspirin is capable of producing liver 
damage (Zimmerman, 1981). Hepatotoxic reactions produced by aspirin 
therapy usually requires days or weeks to develop, presumably due to 
cumulative effect. It also appears that patients with active 
rheumatic or collagen disease, as well as children, are especially 
susceptible. The aspirin-induced hepatic damage results in 
significant elevation of the plasma amino transferases (e.g. SOOT and 
SGPT). Plasma salicylate concentrations higher than 250 ̂ g/ml are 
particularly likely to lead to hepatotoxicity. The biochemical
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mechanism of aspirin-induced hepatotoxicity is unclear, but it may 
occur as a result of conversion of salicylic acid to "active" 
metabolite(s) (Mitchell, McMurtry, Statham and Nelson, 1977).
1.7.4 Miscellaneous side-effects
Allergy to Aspirin. Aspirin hypersensitivity reactions occur 
most commonly in patients with chronic urticaria and in asthmatic 
individuals (Settipane, 1981). Adverse drug reactions associated 
symptoms such as acute, urticaria-angioedema, bronchospasm, severe 
rhinitis, or shock generally occurs within three hours of aspirin 
ingestion. The incidence of "aspirin intolerance" has been estimated 
at less than 0.3 per cent of the population consuming aspirin. There 
is no definite evidence that aspirin allergy is mediated by an 
immunologic reaction.
Maternal and Foetal effects. The possibility that salicylates 
may produce fetal abnormalities, retard fetal growth and cause 
untoward effects on the maintenance of pregnancy, still remains 
controversial (Rudolph, 1981). Turner and Collins (1975) noted a 
significantly greater incidence of stillbirths in women who took 
aspirin. They also found the birth weights were lower and that 
perinatal mortality was higher in the infants born to these mothers.
Reye's syndrome. There have been several reports recently of 
aspirin ingestion being associated with the development of Reye's 
syndrome (Starko, Ray, Dominguez, Stromberg and Woodall, 1980;
Miller, 1981), a condition characterised by the development of acute 
encephalopathy and fatty degeneration of the viscera associated with a 
virus infection.
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1-8 Pathways of Glycine Metabolism in Man
Glycine, a non-essential amino acid in man is involved in the 
biosynthesis of a very large number of nitrogen-containing components 
of living tissues [Neuberger, 1961]. Its metabolism is intimately 
connected with that of serine, and at least in animals almost all the 
glycine is believed to be derived from serine. Gersovitz et al (1980) 
have recently measured the glycine flux with 15N-Glycine in healthy 
young adults and found that the rate of endogenous glycine was about 
350 ymol/kg/h.
The reversible conversion of serine to glycine is catalysed by L- 
serine hydroxymethyl transferase. This enzyme is widely distributed 
in animals, plants and micro-organisms, where it is found both in the 
cytoplasm and mitochondria (Akhtar, El-Obeid and Jordan, 1975). The 
reaction if as follows;
Tetrahydrofolate + L-serine - ►  5,10-methylene-tetrahydrofolate
+ Glycine------------------ 1
The physiological importance of this enzyme is two-fold. On the one 
hand it is probably the most important reaction for the formation of 
glycine, but in addition, it also supplies 1 -carbon units which are 
necessary for a very large number of 1 -carbon biological reactions.
The Glycine Cleavage Complex
The presence of glycine cleavage complex in mammalian liver was 
reported by Kikuchi (1973). This enzyme system degrades glycine to 
serine by a complex series of reactions and requires pyridoxal 
phosphate, a compound containing a disulphide group, FAD, NAD and
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tetrahydrofolate as co-factors. The overall reaction is as follows:
2 Glycine + J O2 - ►  1 Serine + CO2 + N Hg------------------II
The system, working under oxidative conditions in the mitochondria 
will oxidise two molecules of glycine with the formation of one 
molecule of serine, one of carbon-dioxide and one of ammonia. 
Therefore, one would expect reactions I and II to play an important 
role in regulating the concentrations of glycine in specific organs 
(e.g. liver and kidney) and the circulating blood. The study of non­
ketotic hyperglycinaemia in human infant (Kikchi, 1973) has provided 
conclusive evidence regarding the importance of glycine cleavage 
complex in degradation of glycine. This condition is characterised by 
extremely high levels of glycine in the blood and urine and the 
metabolic block involved is almost certainly either the absence of 
the glycine cleavage system in the liver, or a great reduction in its 
activity.
1.9 Scope of the study
Despite the introduction of many analgesic and anti-inflammatory 
agents in recent years, aspirin remains one of the most commonly used 
analgesics and is found in most households in this country. It is not 
surprising, therefore, that aspirin poisoning is a common cause for 
admission to hospital, involving accidental ingestion in children and 
intentional overdose in adults. Current treatments for salicylate 
poisoning are directed at correcting dehydration and metabolic 
disturbances, while at the same time enhancing renal elimination of 
salicylate by forced alkaline diuresis and more recently by urine
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alkalinisation. However, even in otherwise fit young patients, there 
are hazards associated with such treatments including alkalosis, 
hypokalemia and oedma (pulmonary and cerebral) primarily due to fluid 
overload. In the light of this the metabolism of aspirin was studied 
in a wide-age range of human volunteers following therapeutic doses 
and in patients with overdose to establish possibility of new modes of 
treatment.
The major metabolic pathway of aspirin in man is the formation 
of salicyluric acid (SUA), the glycine conjugate of salicylic acid 
(SA). However, in patients with aspirin overdose, the proportion of 
SUA in the urine is significantly reduced because its formation 
becomes saturated. Consequently, the possible role of orally 
administered glycine and N-glycylglycine in the prevention and 
treatment of salicylate intoxication was investigated, on the basis 
that following overdose SUA formation process becomes saturated due to 
the depletion of glycine stores at the site(s) of conjugation. The 
efficacy of these agents were also compared with the standard urine 
alkalinisation treatment for salicylate poisoning. In addition, 
plasma glycine concentrations were determined in human volunteers, in 
volunteers after therapeutic dose of aspirin and in aspirin overdose 
patients to see if significant changes occur.
The metabolism of aspirin was studied in the rat over a ten fold 
dose range to determine, if like man, the formation of salicyluric 
acid is saturable. The rat would thus serve as a useful experimental 
animal for studies which could not conveniently or safely be carried 
out in man. The effect of oral administration of glycine on the 
metabolism of aspirin was also investigated in the same animal.
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Survey of the literature indicates that in addition to the known 
metabolities of aspirin (Section 1.5.2), salicylic acid forms a number 
of other products (Fig. 1.4) the metabolism of which has not been 
fully elucidated. Consequently, a comprehensive qualitative and 
quantitative investigation of aspirin metabolism in the rat and man 
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SECTION 2 Materials and Methods
2.1 Materials
2.1.1 Drugs and Reagents
The drugs and reagents used in the present investigation were 
purchased from a variety of sources and were used as received, without 
further purification. These chemicals were of analytical grade purity 
and are listed, with their sources in Table 2.1. In addition, glycine 
and N-glycylglycine used for human studies were obtained from the 
Pharmacy, Royal United Hospital, Bath.
2.1.2 Acids and Salts
Acids. Hydrochloric acid (HCl); acetic acid (glacial); 
trichloroacetic acid (TCA); and orthophosphoric acid (8 8 %, SG 1.75) 
were all purchased from Fisons, Loughborough, U.K.
Salts. The following chemicals were all of Analar Grade and were 
purchased from Fisons, Loughborough, U.K. NaCl; Na2HP0 ;̂ KH2 PO4 ; KCl; 
H3 BO3 ; CH3COONa; and NaOH.
2.1.3 Solvents
Methanol, acetonitrile and acetic acid (glacial) were used for 
high performance liquid chromatography and these solvents were of HPLC 
grade. Ethanol, propylene glycol, chloroform, dichloromethane, ether 
and acetic anhydride were also used during the course of the present 
invetigation and were of analytical grade purity. All the above 
solvents were obtained from Fisons, Loughborough, U.K. Deionised 
water was used throughout the study and was obtained from the Milli-Q 
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i) glucurage (e-glucuronidase, sigma)
The enzyme was prepared from bovine liver and buffered at pH 5.0. 
^proximate activity of the enzyme was 5,000 sigma units/ml. One 
sigma unit will hydrolyze 1 . 0 y g of phenolphthalein from 
phenolphthalein glucuronide per hour at pH 5 at 37°C (30 minute 
assay). The enzyme was stored at 4®C.
ii) Sulphatase (sigma)
The enzyme was prepared from Helix-pomatia, type H-1. The 
approximate activity of the enzyme was 15-40 units per mg solid. This 
enzyme also contains 3-glucuronidase activity (approx. 300 units per 
mg solid at pH 5.0). One sigma unit of sulfhatase will hydrolyze 
1.0 y mole p-nitrocatechol sulphate per hour at pH 5.0 at 37®C (30 
minute assay). The enzyme was stored at 4°C.
2.2 Instrumentation
2.2.1 High Performance Liquid Chromatography System (HPI/:)
HPLC system was assembled from commercially available components.
Fig. 2.1 shows a typical HPLC system used. The mobile phase was 
pumped to the column at a constant flow rate by means of a, laboratory 
Data Control (LDC) constametric III pump. Samples were injected 
through a Rheodyne, Model 7125, six port sample loop Injection Valve. 
The eluted samples were detected, either using a LDC model 
spectromonitor III variable wavelength U.V. spectrophotometer (UV 
range 190-350 nm) or a IDC model 1311 fluoromonitor III, fluorescence 
spectrophotometer. All the above instruments were purchase from Jones 










model CR-6505 strip chart recorder (JJ Lloyds Instruments Ltd).
Ihe chromatography columns consisted of 4.5 mm internal diameter 
(I/4 " external diameter) stainless steel tubes of 15 and 25 cm in 
length. The column end fitting (female) consisted of a low dead- 
volume Swagelok connection with a l/^g" outlet which was connected to 
the detector by microbore (internal diameter 0.15 mm) Teflon tubing. 
Low dead volume l/^g" stainless steel tubing (internal dimeter 0.15 mm) 
was used to connect the injection valve to the top of the column. All 
the other connections were made using stainless steel tubing and 
standard Swagelok fittings. The equipment was operated at ambient 
temperature throughout.
During the present investigation the mobile phase was always 
filtered through a 0.45 yM membrane filter (Millipore Ü.K. Ltd.,
London) before use and subsequently degassed by purging Helium for 5 
minutes.
2.2.2 Liquid Scintillation Counter
Radioactivity was measured in a LKB-Wallac Model 1215 Rack Beta 
liquid Scintillation Counter. This automatic, microcomputer 
controlled four channel scintillation counter is ideal for counting 
beta emissions over the energy range 1 kev to 2800 kev. The samples 
were counted with external standard channels ratio method (ESCR).
The counter also has a built in DPM package which allows completely 
automatic quench calibration and subsequent calculation of dpm values 
using the "spline" function to fit the calibration curve.
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of quench curve
A series of ten quenched samples were prepared as follows. To 
each of the 10 polyproylene vials (minivials, 5 ml volume) 110,000 
dpm 14^-Salicylic acid was added followed by scintillation fluid (4.5 
ml) (Optiphase Safe - Fisons). To vials number 2-10 add 5, 10, 15, 
20, 30, 50, 75, 100 and 150 yl CCl^ (quenching agent), respectively. 
Vials capped, vortex-mixed and loaded into the counter which had been 
programmed to count the samples and to construct automatically a 
quench curve. This curve was stored into the counters memory so that 
dpms for all subsequent samples were calculated automatically.
2.2.3 ^  measurements
^  measurements were made with a pw9418/20 ga meter using a glass 
electrode (Philips, Ü.K.). The meter was calibrated before use with 
appropriate buffers.
2.3 Animal Experiments
a) Wistar albino rats (University of Bath strain) weighing 
between 240 and 260 g were used. In total there were 4 study groups, 
each comprising 4 rats (2 males and 2 females). The rats were housed 
individually in metabolism cages, which allowed the separate 
collection of urine and faeces, and were acclimatised in the cages for 
at least 24 hours before dosing. Food was withheld from animals for 
16 hours (overnight) prior to dosing and for a further four hours 
after dosing. Study group 1 to 4 received, 14Q-aspirin by gastric 
intubation to give a final dose concentrations of 10, 20, 50 and 100 
mg/kg respectively per rat. Each rat received 0.5 ml dosing solution.
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which comprised of 5 yCi 14Q-aspirin and unlabelled aspirin dissolved 
in ethanol/propylene glycol/water mixture (2/1/1 by volume). All the 
urine passed was collected at 024, 24-48 and 48-72 hours after 
dosing. The volume of each urine aliquot noted and the pH measured. 
Throughout the experiment water was allowed sd libitum and the rats 
were provided with their standard laboratory diet (Labsure diet CRM). 
The animals were maintained on a constant light-dark cycle (12h 
light, 07.00 - 19.00 and 12h darkness, 19.00 - 07.00). All 
experiments were carried out in the animal house which was maintained 
at an ambient temperature of 23°C. Urine samples were assayed for 
aspirin metabolites by radio-TLC.
b) Male Wistar rats (University of Bath strain) weighing between 
250-280 g were used. In all there were two glycine treatment and two 
control groups, each comprising 4 rats. The animals were housed 
individually in metabolism cages and starved as described above. The 
control and glycine treatment group each received 14^-aspirin by 
gastric intubation to give a final dose of 10 and 100 mg/kg. Each rat 
received 0.5 ml dosing solution, which comprised of 5 y Ci 14ç.-aspirin 
and unlabelled aspirin dissolved in ethanol/propylene glycol/water 
mixture (2/1/1 by volume). One hour prior to the aspirin dose, 1 ml 
of either normal saline (control group) or glycine solution (500 mg/kg 
in water) were administered orally by gastric intubation. This was 
repeated at 2, 5 and 8 hour after aspirin dose. All the urine passed 
was collected at 0-24, 24-48 and 48-72 hours after dosing. The volume 
of each urine aliquot was noted and the pH measured. All the other 
experimental conditions were as described previously (Section 2.3a). 
Urine samples were assayed for aspirin metabolites by radio-TLC.
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c) A group of 20 male Wistar rats (University of Bath strain) 
weighing between 210-285g (2493 ± 30.8, mean ± SJD) were used. Blood 
samples (8 . 0 ml) were obtained from groups of 2 rats at 1 hour 
intervals throughout the day by aortic puncture under ether 
anaesthesia. Blood centrifuged at 2500 rpm for 5 minutes to obtain 
the plasma which was subsequently assayed for glycine by HPLC.
d) Male Wistar rats weighing between 210-270 g were used. Food 
was withheld from animals for 16 hours (overnight) prior to dosing. 
Rats were orally dosed with aspirin at 10 and 100 mg/kg as described 
previously. For each aspirin dose, groups of 2 rats were sacrificed 
at 1, 2, 4, 6 , 8 , 10, 12 and 18 hours after dosing and blood sample 
(8 . 0 ml) obtained from each by aortic puncture under ether 
anaesthesia. Blood centrifuged at 2500 rpm for 5 minutes to obtain 




Three groups of university, hospital or ministry of defence 
personnel (Bath) were studied.
a) Fourty-five subjects (28 males and 17 females) were studied. 
They were mainly University or Ministry of Defence staff. Volunteers 
were selected so that the numbers in each 1 0  year period of age were 
approximately equal and the distribution of ages was as follows, 1 1 - 2 0  
yr (n=5); 21-30 yr (n=ll); 31-40 yr (n=7); 41-50 yr (n=7); 51-60 yr 
(n=9) and 61-70 yr (n=6 ). The mean age was 39.71 ± 2.35 yr (mean ±
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SEM). Seven volunteers smoked cigarettes; 3 took oral contraceptives;
2 took propranolol; 1 took Indomethacin regularly but no other 
volunteers smoked or took regular medication. Each volunteer took 
soluble aspirin BP, 600 mg [2 x 300 mg Disprin tablets (Reckitt &
Colman) dissolved in Water] after fasting overnight and emptying the 
bladder. All urine passed in the subsequent 0-8 hr period was collected 
and pH measured. Aspirin metabolites (i.e. GA, SUA, SA and SPG) were 
assayed in urine by HPLC.
b) Eighteen volunteers (14 males aged 22-66 yr (35.7 ± 3.6 yr, 
mean + SEM) each gave a single blood sample for estimation of plasma 
glycine. These samples were collected at different times throughout 
the working day. The volunteers stated that they had not taken 
salicylate in the previous 7 days.
c) Seven male volunteers aged 24-42 yr (29.14 ± 2.25 yr, mean ± 
SEM) each took by mouth, aspirin 500 mg, as aspirin BP, soluble 
aspirin BP or effervescent aspirin (Alka-seltzer). Plasma glycine 
concentration was measured in each volunteer at 0 , 0.33, 1, 2, 3, 4,
5, 6 and 9 hr after aspirin dose.
In addition, absorption of glycine in a healthy volunteer 
following oral administration of glycine (lOg) and N-glycylglycine 
(4g) was also studied as follows. After an overnight fast a 27 year 
old, healthy male volunteer took 1 0  g of glycine by mouth dissolved in 
50 ml of water. Venous blood samples (5 ml) were taken at 0., 0.25,
0.5, 0.75, 1, 1.5, 2, 3 and 4 hr after glycine dose. Plasma was 
obtained by centrifugation of whole blood at 2,000 rpm for 5 min and 
assayed for glycine by HPLC, following pre-column derivatisation with
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fluorescamine. Following the glycine dose, the volunteer fasted for 
further 4 hours and water was allowed freely throughout the study. 
After a one week interval, the above procedure was repeated in the 
same volunteer using 4g of N-glycylglycine.
2.4.2 Patients
Four groups of patients who were admitted to the Clinical 
Pharmacology Unit of the Royal United Hospital, Bath, with self­
administered overdose of aspirin were studied. On admission to the 
hospital, gastric lavage was performed on each patient in the 
Casualty Department. A venous blood sample was also taken for 
estimation of total plasma salicylate by the method of Trinder (1954) 
by the biochemistry laboratory at the R.U.H. Patients were then 
transferred to the Clinical Pharmacology Unit where they received one 
of the following treatments after emptying the bladder.
a) Twelve patients in this group (1 male and 11 females) were 
aged 14-57 yr (24.83 ± 3.57 yr, mean + SEM) and their plasma 
salicylate on admission was 240-620 mg/1 (419 ± 38.60 mg/1, mean ± 
SEM). Patients were treated with oral fluids only and did not receive 
urinary alkalinisation regimen. All the urine passed was collected in 
serial 2 hr periods (whenever possible) for the first 24 hr after 
admission and thereafter at 6 hourly intervals until discharge. Urine 
pH was measured and the quantity of aspirin metabolites (i.e. GA, SUA, 
SA and SPG) present in each collection determined.
b) Twenty-six patients with mild or moderate aspirin poisoning 
took part in a clinical trial of glycine. Each patient whose plasma 
salicylate on admission fell in the range 250-690 mg/1, took part in
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the trial and were randomly allocated to receive either glycine by 
mouth ( 2 0 g dissolved in water initially, followed by 1 0  g every 2 hr 
for a total of 10 hr), n=14 or no glycine, n=12. Both groups were 
encouraged to take fluids by mouth. All urine passed was collected in 
serial 2 hr periods for the first 12 hr after admission, in serial 4 
hr periods for ther next 24 hr and thereafter in serial 6 hr periods 
until discharge. Samples of venous blood were taken when possible, at 
4 hourly intervals and plasma obtained by centrifugation which was 
subsequently assayed for glycine, SUA and SA by HPIXZ. Urine pH was 
measured and the quantity of aspirin metabolites (i.e. GA, SUA, SA and 
SPG) present in each collection &ayed.
In addition, if during the trial the plasma salicylate 
subsequently increases above 690 mg/1 or if the clinical condition of 
patients gave rise to concern then urinary alkalinisation treatment 
(1500 ml sodium bicarbonate 1.26% by constant i.v. infusion over 90 
minutes) was started and the patients withdrawn from the trial.
c) Nineteen patients with moderate salicylism took part in a 
clinical trial of N-glycylglycine (diglycylglycine) or bicarbonate 
(urinary alkalinisation) treatment for aspirin poisoning. Each 
patient whose plasma salicylate on admission fell in the range 400-690 
mg/1 , took part in the trial and were randomly allocated to receive 
either diglycylglycine by mouth (n=ll) or bicarbonate (n=9) according 
to the study protocol. All the urine passed was collected in serial 2 
hr periods for the first 16 hours and subsequently at 16-20, 20-24 and 
24-36 hours from admission in separate collections. Urine jSi was 
measured at the end of each collection period and GA, SUA, SA, SPG,
SAG and SUA-PG assayed by HPLC. Samples of venous blood were taken at
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T r ia l  o f  g ly c in e  o r  b icarb o n ate  f o r  s a l ic y la t e  overdose
2. Adm ission:
2. T rc a tn e n t:
all patients with plasma salicylate concentration in the ranoe 
40-69 mg% are to be included. Patients allociated to receive plycine 
may in.addition receive bicarbonate if the plasma salicylate subseouently 
increases above 69 mg% or if the clinical condition give rise to concern.
open the next in the series of numbered envelopes and the enclosed slip 
of paper will indicate whether the patient is to receive bicarbonate or 
glycine.
BICARBONATE
plasma salicylate 40-50 mq% - administer Na bicarbonate 1.26%, 500 ml. 
intravenously in 30 mins.
plasma salicylate 50-60 mg% - administer Na bicarbonate 1.7.6%, 1000 ml. 
intravenously in 60 mins.
plasma salicylate 60-69 mq% - administer Na bicarbonate 1.26%, 1500 ml. 
intravenously in 90 mins.
GLYCINE
administer by mouth diglycylglycine 8 g immediately, followed by 4 g every
2 hours for 16 hours and if:-
plasma salicylate 40-50 mg% - administer dextrose 5%, 500 ml. intravenously 
in 30 mins.
plasma salicylate 50-60 mq% - administer dextrose 5%, 1000 ml. intravenously 
in 60 mins.




1. take samples of venous blood for estimation of plasma salicylate on 
admission to Casualty and at intervals thereafter as is judged 
necessary on clinical grounds.
2. take venous blood 10 ml. and place it in heparinised tubes on admission 
to C.P.U. and every 4 hours for 16 hours. Separate the plasma by 
centrifugation and keep it in the freezer, utility room. This plasma 
will be used to measure plasma glycine (on a 11 patients) and is not
to be sent to the lab.
URINE
collect all urine passed in the time intervals below and measure and 
record the pH and the volume. Retain 20 ml. in a urine container and 
place in the freezer.
a) get the patient to empty the bladder on admission to C.P.U. and retain 
the urine.
b) collect all urine passed subseouently in 2 hourly amounts for 16 hours.
c) subseouently collect urine 16-20; 20-24 and 24-36 hours from admission 
in separate collections.
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frequent intervals, whenever possible and plasma assayed for glycine, 
SUA and SA by HPLC. Patients allocated to receive glycine may in 
addition receive bicarbonate (1500 ml sodium bicarbonate 1.26% by 
constant i.v. infusion over 90 minutes) if the plasma salicylate 
subsequently increases above 690 mg/1 or if the clinical condition 
give rise to concern and consequently they were withdrawn from the 
trial.
d) Thirteen patients in this group (2 males and 11 females) with 
severe aspirin poisoning were aged between 15-77 yr (43.77 ± 6.08 yr, 
mean ± SEM). Their plasma salicylate on admission was 715-870 mg/1 
(792.92 ± 13.18 mg/1, mean ± SEM). Two patients from this group had a 
plasma salicylate on admission of 250 and 400 mg/1, which 
subsequently increased to 870 and 780 mg/1 in 11 and 4 hours 
respectively after admission to the C.P.U. Patients were treated with 
urinary alkalinisation regimen (1500 ml sodium bicarbonate 1.26% by 
constant i.v. infusion over 90 minutes). All urine passed was 
collected in serial 2 hr periods for the first 1 2 hr after admission, 
in serial 4 hr periods for the next 24 hr and thereafter in serial 
6 hr periods until discharge. Urine pH was measured at the end of each 
collection period and GA, SUA, SA, SPG, SAG and SUA-PG quantified by 
HPLC. Samples of venous blood were taken at frequent intervals, 
whenever possible and plasma assayed for glycine, SUA and SA by HPLC.
In addition, six patients who ini tally took part in the trial of 
glycine for salicylate overdose where later withdrawn from the trial 
because of persistent vomiting after oral administration of glycine 
(n=4) and non-cooperation with the nursing staff (n=2). During the 
clinical trial of diglycyglycine or bicarbonate for salicylate
ti
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overdose six more patients failed to meet the admission criteria to 
the trial (i.e. plasma salicylate on admission was less than 400 
mg/1 ).
2.5 Storage of biological sarnies
Whenever possible fresh samples were analysed, but where storage 
was necessary prior to analysis, samples were kept at -20Pc. 
^proximately, 2 0  ml aliquotes of urine samples were stored until 
required for analysis. All plasma samples were stored in 
unheparinised tubes.
2.6 Deteminaticxi of radioactivity in biological samples
Radioactivity was measured in a LKB-Wallac Model 1215 Rack Beta 
liquid scintillation counter. All samples were assayed for 
radioactivity in triplicate.
Rat urine samples (100 yl) were mixed with Aqua Luma or optiphase 
safe, scintillation fluid (4.5 ml) in plastic minivials and assayed 
directly for radioactivity. Each sample was counted for a maximum of 
10 minutes. DPM values were calculated using the quench curve and 
external standard channels ratio method as previously described (see 
Section 2.2.2).
2.7 Analysis of Rat Urine by Thin Layer Chromatography
Rat urine samples were chromatographed on Merck (E. Merck A.G., 
Darmstadt, FR Germany) polygram plastic sheets (20 x 20 mm) precoated 
with silica gel (0.2 mm) with U.V. 254 indicator (TLC plates obtained 
through BDH chemicals, cat. No. 5554). The developing solvents were.
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(a) Chloroforiiv/ether/acetic acid/methanol (120:60:18:1, by volume) and
(b) Dichloromethane/ether/acetic acid (120:60:18, by volume). Samples 
were applied on TLC plates as thin bands and the plates subsequently 
developed for 14 cm in each solvent system. Authentic reference 
metabolites (i.e., GA, SUA and SA) were also chromatographed and co­
chromatographed with the rat urine sample on the same plate. On 
examining the plate under uv light (254 nM), various bands both drug 
related and endogenous were clearly visible (due to quenching of 
fluorescence). The preliminary information on the identity of 
metabolites was obtained by comparison of the Rf values with the 
authentic reference compounds (see Table 2.2). Drug related bands in 
the urine were identified and marked in pencil on the TLC plate.
Areas of silica corresponding to each sample, divided into 
approximately equal segments, chopped and counted directly with Aqua- 
Luma or optiphase safe (scintillation fluid, 4.5 ml) in plastic 
minivials. Prior to adding the scintillation fluid, 0.5 ml of 
distilled water was added to each vial to deactivate the silica. From 
the counting results the percentage distribution of radioactivity in 
each sample was calculated.
In addition, glycine conjugates were also located by reaction 
with p-dimethyl amino benzaldehyde (Ig) in acetic anhydride (25 ml) 
and sodium acetate (100 mg); after spraying the TLC plate with the 
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2.8 Method Development and Assay of Glycine in Plasma by HPLC
Introduction
In recent years a number of methods have been developed for 
analysis of glycine in biological samples (Felix and Terkelsen, 1973; 
Ohmori, Ikeda and Hiroia, 1978; Lin and Wang, 1980). However, they 
were inadequate for practical use because of lack of sensitivity and 
specificity or the procedure involved was extremely elaborate and 
lengthy. More recently, glycine has been routinely determined using 
an amino acid analyser but again, the procedure is time-consuming when 
glycine concentration is to be determined in a biological sample 
containing other amino acids. In the light of this, the author has 
developed a novel HPLC procedure for the determination of glycine in 
plasma. The method is based on pre-column derivatisation of glycine 
with fluorescamine followed by HPLC analysis with fluorescence 
detection. The assay is sensitive, simple and rapid; and with minor 
modifications may have wide applicability in the analysis of chemical 
or biological species possessing a primary amino group.
Reaction of Fluorescamine with primary amines
Fluorescamine [4-^enylspiro (furan-2(3H), l'-^thalan)-3,
3'-dione, Fig. 2.2(1)] was introduced as a novel reagent for the 
fluorometric quantitation of primary amines (Weigele, DeBernardo,
Tengi and Leimgruber, 1972). This remarkable reagent; itself non- 
fluorescent, reacts with primary amines (RNH2 ) to form pyrrolinones of 
type (2) which upon excitation at 390 nM emit strong fluorescence at 475 
to 490 nM (Fig. 2.2). At pH 9, reaction with primary amines proceeds 
at room temperature, with a half-time of a fraction of a second.
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seconds, Fluorescamine, as well as its hydrolysis products, is non- 
ffluorescent. Studies with small peptides have shown that the reaction 
goes to near completion (about 80 to 95 percent of theoretical yield) 
even when fluorescamine is not present in large excess.
This unique properties of fluorescamine make the reagent suitable 
for the assay of a wide variety of structurally diverse primary amines 
in pmole concentrations. However, in order to obtain optimal results, 
the reaction conditions must be adapted to the specific requirements 
of the amine under study. Some of the conditions and variables which 
influence the rate and extent of fluorofiior formation are discussed 
elsewhere [De Bernardo et al, (1972) and (1974)].
Stability of Fluorescamine in solvent
Fluorescamine is generally added to the assay sample dissolved in 
water-miscible, non hydroxylic solvents. Acetone and dioxane have 
been found particularly suitable, since they are commercially 
available in grades which are low in fluorogenic impurities. Other 
solvents which are useful include acetonitrile, dimethylsulj^oxide, 
and tetrahydrofuran. De Bernardo et al (1974) investigated the 
stability of fluorescamine in acetone, acetonitrile and dioxane over a 
period of 12 weeks at 4°C and 25°C. They showed that the reagent is 
stable for at least 1 2  weeks in acetone and acetonitrile, but for only 
2 weeks in dioxane. Hydroxyl ic solvents such as methanol are 
unsuitable in most situations.
In the present study fluorescamine was added to the assay sample 
dissolved in acetonitrile at concentration of 5 mg/ml and stored at 
4°C for a maximum of 8 weeks.
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Assay procedure
To aliquots of plasma sample (0.3 ml) in 2 ml polypropylene 
centrifuge tube; 0.1 ml phosphate buffer, pH 7.0 (0.07 M) and 0.6 ml 
acetonitrile was added. The tube was capped and vortex-mixed for 60 
sec, followed by centrifugation at 1700 g for 7 min. A 0.2 ml 
aliquot of the supernatant was transferred to another 2 ml 
polypropylene centrifuge tube; to which 0.25 ml borate buffer, pH 9.0 
(0.05 M) was added. While vortex-mixing the content of the tube, 50 
ul of fluorescamine stock solution (5 mg/ml in acetonitrile) was added 
and the mixing was continued for 60 sec. Finally 0.5 ml phosphate 
buffer, pH 7.0 (0.07 M) was added and again the content of the tube 
was vortex-mixed for further 30 sec. A 20 ul aliquot of the solution 
was injected onto the HPLC column and assayed using fluorescence 
detection. If a derivatised sample was not injected within 10 min 
after derivatisation, the tube was kept in ice until injection to 
minimise fluorophore degradation.
HPLC conditions
Column; Separations were carried out on a 5 um ODS
spherisorb, 25 cm x 4.5 mm ID, reversed-phase 
column (Jones Chromatography, Llanbradach).
Mobile Phase: 0.07 M Phosphate buffer, pH 7.0/aceonitrile (90:10
by volume).
Flow Rate: 1.5 ml/min, which generated a back pressure of
2,500 - 3,000 psi.
Detection: The column effluent was monitored fluorometrically
at an excitation wavelength of 370 nm and emission 
wavelength between 418-700 nm.
Chart Speed: 0.4 cn/min.
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Under these conditions, retention time of glycine in plasma was 3.5 
minutes. All the separations were carried out at ambient 
temperatures.
Fig. 23 shows typical chromatograms of plasma samples 
derivatised with fluorescamine; (A) control plasma, (B) plasma (10 hr) 
from aspirin overdose patient treated with glycylglycine (see protocol 
for trial of glycylglycine or bicarbonate for salicylate overdose), 
and (C) plasma (0.5 hr) from human volunteer (male) following oral 
administration of glycine ( 1 0 g).
2.9 Analysis of Salicyluric acid and Salicylic acid in plasma
Salicyluric acid (SUA) and Salicylic acid (SA) were assayed in 
rat and human plasma by high performance liquid chromatography. The 
method was modification of that reported by Reidl (1983) with o-anisic 
acid as the internal standard.
Assay Procedure
Prior to analysis, the plasma samples were extracted twice with 
ethyl acetate ( 2 x 5  ml) as follows. To aliquots of plasma sample 
(0.3 ml) in screw top glass tubes, add 0.1 ml internal standard (0- 
anisic acid, 100 yg/ml in acetonitrile) followed by 0.6 ml TCA 
solution (15%, w/v) and the tubes vortex-mixed for 1 min. Add 5 ml 
ethyl acetate to each tube, vortex-mix for 2 min and centrifuge at 3000 
rpm for 1 0  min. Ihe ethyl acetate layer transferred to another tube 
and the above procedure repeated for second extraction. The two 
ethyl acetate fractions were combined and evaporated to dryness under 
a gentle stream of air or nitrogen on a water bath at 40°C. The
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FIG. 2.3 - Typical chromatograms of plasma samples
derivatised with fluorescamine, (A) control 
plasma, (B) plasma (10 hr) from patient with 
aspirin overdose treated with glycyI'glycine 
and (C) plasma (0.5 hr) from a human volunteer 
(male) following oral administration of 










residue was redissolved in 0.5 ml of mobile pdiase 
(acetonitrile/methanol/acetric acid (glacial)/water, 25:10:4:61 by 
volume), centrifuged at 3000 rpm for 10 min, and 20 yl of the solution 
injected directly onto the column and assayed.
HPLC Conditions
Column: Separations were carried out on a 5 pm APEX ODS,
25 X 0.45 cm ID reversed-phase column (Jones 
Chromatography, Llanbradach).
Mobile Phase: acetonitrile/methanol/acetic acid (glacial)/water
(25:10:4:61 by volume), pH 2.7.
Flow Rate: 1 ml/min, which generated a back pressure of 2,000
psi.
Detection: 298 nm.
Chart Speed: 0.4 cn/min.
All the separations were carried out at ambient temperatures. SUA and 
SA were identified on the basis of their retention times. Under the 
above conditions, retention times for SUA, IS and SA in plasma 
extracts were 3.88, 4.63 and 6.38 minutes respectively.
A typical chromatogram of SUA (30 yg/ml), IS (20 pg/ml), and SA 
(120 yg/ml) spiked in mobile phase is depicted in Fig. 2.4A. Analysis 
of extracted plasma sample (0.5hr) from a aspirin overdose patient gave 
the chromatogram in Fig. 2.4B.
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F I G .  2 . 4  - Chromatograms of (A) SUA (30 yg/ml), IS 
(20 yg/ml) and SA (120 yg/ml) spiked in 
mobile phase and (B) extracted plasma 
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2.10 Analysis of Aspirin Metabolites in Drine
Gentisic acid (GA), salicyluric acid (SUA) and salicylic acid 
(SA) were assayed in human urine by high performance liquid 
chromatography. The method was modification of that reported by Cham 
et al (1980) with o-anisic acid as the internal standard.
Assay Procedure
1 ml aliquots of human urine were added to 1 ml of internal 
standard (o-anisic acid, 500 yg/ml in mobile phase-acetonitrile/0.1 % 
Phosphoric acid; 20:70 by volume) and made up to 10 ml with mobile 
jtese in screw top glass tubes. For aspirin overdose patients 
receiving bicarbonate treatment, a 1 / 2 0  dilution of urine was 
required. The content of the tube vortex-mixed for 1 min and 
centrifuged at 3000 rpm for 10 min. A 100 yl of the supernatent was 
injected on to the HPLC column.
HPLC Conditions
Column: all separations were carried out on a 5 ym APEX
ODS, 15 X 0.45 cm ID reversed-phase column (Jones 
Chromatography, Llanbradach).
Mobile Phase: acetonitrile/0.1 % Phosphoric acid (20:70 by
volume), pH 2.5.
Flow Rate: GA, SUA and IS were eluted at a flow rate of 1.0
ml/min and then 7 min after the injection of 
sample the flow rate was increased to 2 . 0 ml/min 
to elute SA. The operating pressure at 1.0 and 
2.0 ml/min was 1,500 and 2,000 psi respectively.
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Dectection: the column effluent was monitored at 298 nm.
Chart Speed: 0.4 cn/min.
All the separations were carried out at ambient temperatures. GA, SUA 
and SA were identified on the basis of their retention times. Under 
these conditions, rentention times for GA, SUA, IS and SA in human 
urine were 3.25, 4.5, 5.5 and 8.75 minutes respectively. During the 
course of analysis of human urine samples, it was found that an 
endogenous peak was also eluted from the column at the same time as 
GA, thus masking the GA peak. However, when the urine samples were 
incubated with e-glucuronidase at 37°C for 24 hr to estimate the 
salicyl phenolic glucuronide, this endogenous peak disappeared 
completely and thereby allowing quantitation of GA. The stability of 
GA spiked in control urine under the same conditions was also 
investigated and found to be stable.
A typical chromatogram of GA (40 yg/ml), SUA (40 yg/ml, IS (50 
yg/ml) and SA (50 yg/ml) spiked in control human urine is shown in 
Fig. 2.5A. Analysis of urine sample from an aspirin overdose patient 
gave the chromatogram in Fig. 2.5B.
2.11 Deconjugation of urine samgdLes with eizymes and chemicals
Since authentic samples of aspirin metabolite conjugates (i.e. 
SPG, SAG, SUA-PG, GUA and sulphate conjugates) were not available they 
were quantified by first hydrolysis of the conjugates with specific 
enzymes or chemicals with subsequent analysis. Rat urine samples 
were analysed by TLC (Section 2.7) and human urine by HPLC (Section 
2.10) before, and after one of the following treatments. Urine
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FIG. 2.5 - Chromatograms of (A) GA (40 yg/ml), SUA 
(40 yg/ml), IS (50 yg/ml) and SA (50 yg/ml) 
spiked in control human urine and (B) urine 
sample from a typical patient with aspirin 
overdose. x represents time at which flow 













samples without the enzymes or chemicals were also set up under the 
same treatment conditions, to act as controls.
(a) 6-Glucuronidase: (for estimating phenolic glucuronides)
An aliquot of urine sample (1 ml) adjusted to pH 5.0 with diluted 
acetic acid and incubated with 6-glucuronidase (0.3 ml - Glucurase, 
Sigma) at 37°C for 24 hours. As a positive control, a tube containing 
phenolphthalein glucuronide (1 mg/ml in urine) and 6 -glucuronidase was 
set up. After incubation, the appearance of a purple colour on- 
addition of alkali confirmed enzyme activity. The urine samples were 
then reassayed for SA and SUA. The amounts of SPG and SUA-PG present 
were taken to be the difference in SA and SUA measured before and 
after treatment with 6-glucuronidase, respectively.
(b) Sulphatase; (for estimating sulphate conjugates)
An aliquot of urine sample (1 ml) adjusted to pH 5.0 with diluted 
acetic acid and was incubated with sulphatase (10 mg) at 37®C for 24 
hours. Since this enzyme also contained 6 -glucuronidase activity;
1 0 0  yl of saccharolactone (0.4M in water, the inhibitor of B- 
glucuronidase) was also added to the incubation mixture prior to 
adding the enzyme.
(c) Alkaline hydrolysis: (for estimating acyl glucuronides)
In drug metabolism studies, base or alkali hydrolysis is commonly 
employed when acyl or ester type glucuronides are suspected. An 
aliquot of urine (1 ml) was incubated with 2 M NaOH (1 ml) at 37°C for 
24 hours. At the end of incubation period, the mixture was neutralised 
by addition of 2M HCl and subsequently assayed for salicylic acid.
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The amount of SAG present was taken to be the difference in salicylic 
acid measured before and after treatment with alkali.
(d) Acid hydrolysis; (for estimating total conjugates)
Acid treatment is a general method for the hydrolysis of sugar, 
sulphate and amino acid conjugates. An aliquot of urine sample (1 ml) 
and 6 M HCl (1 ml) were heated in an oven maintained at 100°C for 20 
hours, in sealed ampoules. At the end of the treatment period, the 
mixture was neutralised by addition of 6 M NaOH and subsequently 
assayed.
2.12 Quantitaticxi of glycine and aspirin metabolites in biological 
samples using standard curves
(a) Preparation ef standard curves
A calibration curve for glycine was constructed by determining 
the absolute peak height of 7 control plasma samples containing 
varying concentrations of glycine (0.1-40 pg/ml). These standards 
were injected for every 4 or 5 plasma samples assayed for glycine, thus a 
standard curve was derived on a daily basis.
Calibration curves for aspirin metabolites in plasma and urine 
were constructed by determining the peak height ratios (i.e. peak 
height of metabolite/peak height of internal standard) of 6 to 8 
control plasma and urine samples spiked with a range of metabolite 
concentrations. Standard curves were checked on a regular basis and 
no significant changes were observed.
All the above standards were injected at least in duplicate and 
the data fitted to the following equation using linear least-squares
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regression.
y = mx + c
where y is the peak height ratio or absolute peak height, x is the 
concentration of coirpound, and m and c are regression coefficients.
(b) Linearity of calibration curves
For each calibration curve, the correlation coefficient r, the slope 
m and the intercept c were determined by linear least-squares 
analysis. A typical data for each calibration curve i as follows.
i) Calibration curve for glycine in plasma
r m c Range ( yg/ml)
Glycine 0.9999 28.70 -6.36 0.1 - 40
The above data is depicted graphically in Fig. 2.6.
ii) Calibration curve for SUA and SA in plasma
r m c Range ( yg/ml)
SUA 0.9992 0.297 0.016 0.1 - 50
SA 0.9996 0.046 - 0.101 20 - 140
The above data are shown graphcially in Figs. 2.7 and 2.8 
respectively.
64















y = 28.70X -  0.636  

















.50̂ Regression equation: 






60 7010 20 30 0 500 4
SUA CONCENTRATION <pg/ml )
65
ill) Calibration curve £ 2 1  G&t 5IB m d  Sh io urine
r m c Range ( y g/ml)
GA 1 . 0 0 0 0 . 0 1 2 - 0.486 5 - 1 0 0
SUA 0.9997 0 . 0 2 2 - 0.356 5 - 1 0 0
SA 0.9981 0.014 - 0.143 10 - 250
The above data are shown gra^ically in Figs. 2.9, 2.10 and 2.11 
respectively. For assay of SA in urine following therapeutic dose of 
aspirin, a calibration curve in the range 1 - 2 0  pg/ml was used.
(c) Concentration determination
Peak heights were determined for glycine and peak height ratios 
for aspirin metabolites in urine and plasma samples and concentrations 
were calculated using the equation
= Yi - c
m
Where is the unknown concentration to be determined, y^ is the 
observed peak height ratio or peak height and c and m are regression 
coefficients calculated from the calibration curves.
2.13 Statistical Analysis and Treatmait of Data
Statistical analysis of data were carried out using a computer 
Statistical Package Minitab. The results are expressed as the mean ± 
standard error of the mean. Statistical significance between mean was 
determined by Student's t-test (two tailed) for unpaired data. A 
probability, p < 0.05 was taken to denote significant difference. In
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addition, Mann-Whitney test was also used for statistical comparison 
of data from rat studies.
The absolute quantities (mg) of each aspirin metabolite excreted 
in the urine were expressed as the equivalent weight of salicylic acid 
and the following conversion factors were used;
SA (mg) X 1.000 SA
SUA (mg) x 0.708 SUA as the equivalent weight of SA
GA (mg) x 0.896 GA as the equivalent weight of SA
A 600 mg dose of aspirin is, therefore, equivalent to 460.2 mg salicylic 
acid. Since salicyl glucuronides (SPG and SAG) and salicyluric acid 
phenolic glucuronide (SUA-PG) were measured as salicylic acid after 
hydrolysis with 3-glucuronidase (for SPG and SUA-PG) and alkali (for 
SAG) no correction was required. The quantities of each aspirin 
metabolite excreted in the urine between individuals in each 
collection period was highly variable, thus a direct comparison could 
not be made. Therefore all the data in the present investigation have 
been expressed as the percentage of the total metabolites excreted in 
the urine.
Calculation of Pharmacokinetic parameters
From the linear portion of the log^Q plasma concentration against
time plot, slope was calculated by least square analysis.
The slope = - kel 
2.303
where kel is the elimination rate constant.
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The biological half-life, tl/n = 0.693
kel
The area under the plasma concentration time curve (ADC) was 
calculated by the trapezoidal method for the observed values (AUCq_|.) 
and then extrapolated to infinity (ADC^.» ) as follows;
AUCq_„ = ADCo_t + Cpt
kel
where Cpt is the plasma concentration of the last observed value.
SECTION 3 
RESDLTS - HOMAN STGDIES
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SECTION 3 RBSniÆS - HUNAN STUDIES
3 J. Metabolism of aspirin in healthy volunteers following therapeutic
(600 mg) dose
Fourty-five subjects were studied of which there were 28 males 
and 23 females. Volunteers were selected so that the numbers in each 
1 0  year period of age were approximately equal and the distribution of 
ages was as follows, 11-20 yr (n=5); 21-30 yr (n=ll); 31-40 yr (n=7); 
41-50 yr (n=7); 51-60 yr (n=9) and 61-70 yr (n=6 ). The mean age was 
39.71 ± 2.35 yr (mean ± SEM). Aspirin metabolites, gentisic acid , 
(GA), salicyluric acid (SUA), salicylic acid (SA) and salicylic acid ; 
and phenolic glucuronide (SPG) were assayed in urine by HPLC as 
previously described (Section 2.10). All figures for quantities of 
metabolites recovered are expressed as the equivalent weight of 
salicylic acid using the appropriate correction factor (Section 2.13).
3.1.1 Urine Metabolite Pattern
Following oral administration of a therapeutic (600 mg) dose of 
aspirin to human volunteers a mean value of 53.17 ± 1.76% (mean ± SEM) 
of the ingested dose was recovered in 0 - 8  hour urine collection 
period. The major urinary metabolite in the 45 volunteers was the 
glycine conjugate, salicyluric acid (SUA) which accounted for between 
58 and 91% of the excreted dose (75.01 ± 1.19%, mean + SEM).
Salicylic acid (8.82 ± 0.5^); gentisic acid (5.13 ± 0.39%); and 
salicylic acid phenolic glucuronide (11.45 ± 0.52%); were recovered 
as minor metabolites (Table 3.1.1 and Fig. 3.1.1). Details of 
volunteers and individual recovery of metabolites in urine (0 - 8 hr) 
are given in Appendix 2.
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Table 3.1.1 - Percentage urinary (0-8 hr) recovery of aspirin 
metabolites in healthy volunteers following therapeutic (600 mg) dose
Aspirin Metabolite n Percentage recovery 
(mean ± SEM)
Gentisic acid 43 5.13 ± 0.39
Salicyluric acid 45 75.01 ± 1.19
Salicylic acid 43 8.82 ± 0.56
Salicylic acid Phenolic 
glucuronide
45 11.45 ± 0.52
Urine pH was measured in all volunteers and a positive correlation was 
found between percentage recovery of salicylic acid in 0 - 8 hour urine 
and pH (r=0.476, P < 0.01) (Fig. 3.1.2). Regression coefficients were 
calculated for the percentage recovery of each metabolite (i.e. GA, 
SUA, SA and SPG) on age but no significant correlation was found.
3.1.2 Correlation of metabolites
When the correlation of each aspirin metabolite are examined, 
percentage recovery of salicylic acid was found to relate negatively 
to the recovery of salicyluric acid (r= -0.8625, P < 0.001) (Fig. 
3.1.3). Percentage recovery of salicylic acid phenolic glucuronide 
was also found to relate negatively to the recovery of salicyluric 
acid (r = -0.8655, P < 0.001) (Fig. 3.1.4). There was a positive 
correlation between percentage recoveries of salicylic acid and 
salicylic acid phenolic glucuronide (r = 0.6941, P < 0.001) (Fig. 
3.1.5). Percentage urinary recovery of salicylic acid was unrelated 
to that of gentisic acid.
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FIG 3.1.1 - Percentage recoveries of aspirin 
metabolites in urine from healthy 
volunteers who took a therapeutic 






















FIG. 3.1.2 - Percentage recovery of salicylic acid 
against urine pH from volunteers who 












FIG. 3.1.3 - Percentage recovery of salicylic acid 
against percentage recovery of salicyluric 
acid in urine (0 - 8  hr) from volunteers who 













FIG. 3.1.4 - Percentage recovery of salicylic acid 
phenolic glucuronide against percentage 
recovery of salicyluric acid in urine 
(0 - 8  hr) from volunteers who took 







25^ r = -0.8655






FIG. 3.1.5 - Percentage recovery of salicylic acid 
against percentage recovery of salicylic 
acid phenolic glucuronide in urine (0 - 8  hr) 
from volunteers who took therapeutic (600 















3.2 Metabolism of aspirin in overdose
The data is presented here of thirty-seven patients who were 
admitted to the Clinical Pharmacology Unit (C.P.U.) of the Royal 
United Hospital, Bath, with self-administered overdose of aspirin.
The first twenty-four patients from this group suffering from mild or 
moderate aspirin poisoning served as controls and were treated with 
oral fluids only. The remaining thirteen patients were suffering from 
severe aspirin poisoning and were treated with a urinary 
alkalinisation regimen (Section 2.4.2 (d)).
3.2.1 Urinary metabolite profile in patients with moderate aspirin 
poisoning treated with oral fluids only
Data from twelve control patients who took part in the clinical 
trial of glycine for salicylate overdose (Section 2.4.2 (b)) are also 
included in this group (n = 24, 3 males and 21 females). Patients 
were aged between 14-51 yr (24.5 ± 2.36 yr, mean ± SEM) and their 
plasma salicylate on admission was 240-630 mg/1 (430.27 ± 25.91 mg/1, 
mean ± SEM). In this group of patients, the major urinary metabolite 
was salicyluric acid (46.66 ± 3.22%, mean ± SEM), but in significantly 
lower amounts (P < 0.001) compared to the therapeutic (600 mg) dose of 
aspirin. In contrast, all other metabolites were excreted in 
significantly higher amounts (P < 0.001); gentisic acid (9.99 ± 2.10%); 
salicylic acid (31.38 ± 4.02%); and salicylic acid phenolic 
glucuronide (22.85 ± 1.93%) (Table 3.2.1). Reduced fractional 
excretion of salicylate as salicyluric acid after overdose (Patients 
treated with oral fluids and alkali) as compared to the therapeutic 
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The total urinary recovery of salicylate (all aspirin metabolites) was 
0.69 - 9.41 g (2.99 ± 0.37 g, mean ± SEM). Details of patients and 
individual percentage recovery of metabolite are presented in Appendix 3.
3.3.2 Urinary metabolite profile in patients K Ü h  severe aspirin 
poisoning treated with sodium bicarbonate 
Thirteen patients (2 males and 11 females) in this group were aged 
15-77 yr (43.77 ± 6.08 yr, mean ± SEM) and their plasma salicylate on 
admission was 715-870 mg/1 (792.92 ± 13.18 mg/1, mean ± SEM). In 
patients treated with urinary alkalinisation regimen, the total 
urinary recovery of salicylate was 2.61-23.31 g (8.09 ± 1.47 g, mean ± 
SEM). A mean value of 64.72% (64.72 ± 4.8%, mean ± SEM) of the 
total salicylate excreted was accounted for by salicylic acid.
Percentage recovery of other metabolites was as follows, gentisic acid 
(7.22 ± 1.55); salicyluric acid (21.57 ± 3.65); and salicylic acid 
phenolic glucuronide (14.99 ± 4.38) (Table 3.2.2). Details of 
patients and individual recovery of metabolite are presented in 
Appendix 4.
Table 3.2.2 - Percentage urinary recovery of metabolites in 13 
patients with severe aspirin poisoning treated with urine 
alkalinisation.
Aspirin Metabolite Percentage Recovery 
(mean ± SEM)
Gentisic acid 7.22 ± 1.55
Salicyluric acid 21.57 ± 3.65
Salicylic acid 64.72 ± 4.82
Salicylic acid phenolic 14.99 ± 4.38
glucuronide
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33 Metabolism of aspirin in overdose following treatment with 
glycine, N-glycylglycine or sodium bicarbcxiate
3.3.1 Age and gex distribution of patients
During the course of the present investigation a total of seventy 
patients, 21 males and 49 females, with moderate or severe aspirin 
poisoning (self-administered overdose) were studied. Their age and 
sex distribution is shown in Fig. 3.3.1. Female patients (70%) 
predominate in all age ranges, except those in the group aged 20-34 
years, and the majority of the patients were aged 14-34 years (64%).
33.2 Distribution of plasma salicylate concentrations ^  admission 
and ingestion-admission time interval of patients 
The distribution of plasma salicylate concentrations on admision 
of all patients studied is shown in Fig. 3.3.2. Approximately 58% of 
the patients had plasma concentrations of between 400-690 mg/1 and 
were classified as suffering from moderate aspirin poisoning. The 
finding of a higher level (̂  700 mg/1) in 20% of the patients was 
accepted as indicative of severe poisoning. In two patients (Nos. 12 
and 13 Appendix 4) the plasma salicylate on admission were 250 and 400 
mg/1 , which subsequently increased (even after performing gastric 
lavage) to 870 and 780 mg/1 in 11 and 4 hours respectively after 
admission to the C.P.U. On admission to the hospital patients were 
asked to give information regarding the time at which they had taken 
the overdose, from which the ingestion-admission time interval for 
each patient was calculated and is shown in Fig. 3.3.3. The majority 
of the patients (76%) were admitted to the hospital within 9 hours 
after taking aspirin,of these 50% were admitted within 4 to 6  
hours. Three patients were admitted some 20 hours after overdose.
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FIG. 3.3.1 - Histogram showing the age and sex 
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FIG. 3.3.2 - The distribution of plasma salicylate
concentrations on admission of patients 
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FIG. 3.3.3. - The Ingestion-admission time interval 
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3.3.3 Comparability of treatment groups
The control, glycine and bicarbonate treatment groups were 
comparable in respect of age, plasma salicylate on admission, total 
salicylate recovered, urine output and ingestion-admission interval 
(Table 3.3.1). Patients in the Gly-Gly (N-glycylglycine) treatment 
group were aged 16-70 yr (37.18 ± 6.42 yr, mean ± SEM) and their 
plasma salicylate concentrations on admission were higher. As a 
result and according to the study protocol (Section 2.4.2 (c)), the 
total fluid infused in this group was also higher (mean value of 3.18 
litres) compared to the bicarbonate group (1.87 litres), as is 
reflected in increased urine output. The control and glycine 
treatment groups received oral fluid only and were comparable (data 
not shown). When the total fluid infused was compared with the total 
urine output in patients from Gly-Gly and bicarbonate groups a net, 
negative fluid balance was observed indicating that the fluid 
retention had not occurred.
3.3.4 Changes in plasma glycine in volunteers and patients 
Glycine concentrations in random plasma samples obtained at
different times throughout the working day from 18 healthy volunteers 
ranged between 8.5 - 24.85 yg/ml (15.72 ± 1.08 yg/ml, mean ± SEM) 
(T^perdix 1). In 3 volunteers, repeated estimations of glycine during 
9 hours were within the normal range of volunteers as above, and gave 
no indication of diurnal variation.
Following oral administration of glycine (10 g) to a single 
healthy male volunteer (27 yr) peak glycine concentration in plasma of 
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with half-lives of 0.93 (initial j^se, a) and 3.3 hours (terminal 
phase, 3 ) respectively. (Fig. 3.3.4.1) (Appendix 5). In the same 
volunteer, after oral administration of N-glycylglycine (4 g), peak 
glycine concentration in plasma of 86.94 pg/ml was achieved 0.75 hour 
after dose and again declined in two phases, with half-lives of 0.72 
and 7.16 hours respectively. Relevant pharmacokinetic parameters are 
summarised in Table 3.3.4.1 (for calculation of pharmacokinetic 
parameters refer to Section 2.13).
Table 3.3.4.1 - Pharmacokinetic parameters of glycine in plasma 
following oral administration of glycine and N-glycylglycine to a 
single healthy volunteer.
Parameter Glycine 
( 1 0 g)
N-Glycylglycine 
(4 g)
Cp Max (yg/ml) 165.34 86.94
t max (hr) 1 . 0 0.75
tl/ 2  a (Initial) (hr) 0.93 0.72
tl/ 2  3 (Terminal) (hr) 3.3 7.16
AUCQ_„(yg/ml x hrs) 503.8 400.7
(pMax is the maxium plasma concentration and tmax is the time at which 
this maximum is observed. a and 3 are half-lives and AUC is the area 
under the plasma concentration time curve.
Followingj^therapeutic (500 mg) dose of aspirin to seven healthy 
volunteers, plasma glycine concentrations measured initially and at 
various times up to 9 hours after aspirin dose, remained relatively
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FIG. 3.3.4.1 - A semilogarithmic plot of plasma glycine 
concentrations as a function of time 
following oral administration of glycine 
(10 g) and N-glycylglycine (4 g) to a 
single healthy volunteer (male, 27 yr)
a  
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constant (12.82 ± 0.54, mean + SEM) and were within the normal range. 
Individual data for each volunteer is given in Appendix 6 .
Table 3.3.4.2 summarises changes in plasma glycine 
concentrations in volunteers and in patients with aspirin overdose. 
After acute aspirin poisoning a significant (P < 0.001) decrease in 
plasma glycine was observed in control patients compared to the normal 
range in volunteers, and as expected, the concentrations increased 
significantly (P < 0.001) after treatment with oral glycine or N- 
glycylglycine (individual plasma glycine concentrations are given in 
Appendix 7 and 8). %>ical plasma glycine against time plots for 
control (Nos. C7, C8 and CIO) or glycine treated patients (Nos. G4, G7 
and Gll) and N-glycylglycine (Nos. GG3 and GG6 ) or bicarbonate treated 
patients (Nos. Bl and B9) are shown in Figs. 3.3.4.2 and 3.3.4.3 
respectively. In all treatment groups, initial glycine concentrerons 
were significantly (P < 0.01) lower compared to the normal range and 
in the control group (oral fluids only) remained depleted throughout 
the treatment. In contrast, the glycine concentrations in the 
bicarbonate group remained relatively constant and in majority of the 
patients were comparable with the normal range. After oral 
administration with glycine or N-glycylglycine the levels increased 
significantly (P < 0.001) and remained elevated during treatment. 
Individual glycine concentrations measured in all the available plasma 
samples from control or glycine and bicarbonate or N-glycylglycine 
treatment groups are also shown in Fig. 3.3.4.4 and 3.3.4.5 
respectively.
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FIG. 3.3.4.2 - Semilogarithmic plots of plasma glycine 
concentrations as a function of time of 
control and glycine treated patients 
with aspirin overdose
500. Q Patients treated with glycine 
#  ̂m Control patients (oral fluids)
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FIG. 3.3.4.3 - Semilogarithmic plots of plasma glycine 
concentrations as a function of time of 
patients with aspirin overdose treated 
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FIG. 3.3.4.4 - Individual plasma glycine concentrations 
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FIG. 3.3.4.5 - Individual plasma glycine concentrations 
of patients with aspirin overdose 
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3.3.5 - Urinary excretion of metabolites
Since a large number of patients were studied, detailed clinic al 
data are presented on only three typical patients from each treatment 
group for clarity. These patients were chosen on the basis of their 
total salicylate recovery in the urine, such that those with high, 
intermediate and low recovery in the urine, are included. Individual 
aspirin metabolite excretion data for all the remaining patients in the 
control, glycine, N-glycylglycine and bicarbonate treatment groups are 
given in Appendix 9, 10, 11, and 12 respectively. Admission of 
patients to the C.P.U. was taken as zero time and after emptying their 
bladder serial urine samples (Section 2.4.2) were collected until 
discharge. Since doses ingested were usually unreliably reported, the 
individual quantity of aspirin metabolites (i.e. GA, SUA, SA and SPG) 
recovered in each serial sample are given for each patient expressed 
as equivalent weight of salicylic acid. In addition, salicyl acyl and 
salicyluric acid phenolic glucuronides (SAG and SUA-PG respectively) 
were also measured in patients treated with N-glycylglycine or 
bicarbonate.
Tables3.3.5.1 - 3.3.5.3 shows results from 3 control patients 
with aspirin overdose and the data are presented graphically in Figs.
3.3.5.1 - 3.3.5.3 respectively. Similarly, results in Tables and 
Figs. 3.3.5.4 - 3.3.5.6 are for patients treated with glycine. Tables 
and Figs. 3.3.5.7 - 3.3.5.9 for patients treated with N-glycylglycine 
and in Tables and Figs. 33.5.10 - 33.5.12 for patients treated with 
bicarbonate. In addition, results are also given for a single patient 
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FIG. 3.3.5.1 - Cumulative urinary excretion of 
(a) individual and (b) total aspirin 
metabolites for control patient,
C2 shown in Table 3.3.5.1
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FIG. 3.3.5.2 - Cumulative urinary excretion of 
(a) individual and (b) total 
aspirin metabolites for control 
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FIG. 3.3.5.3 - Cumulative urinary excretion 
of (a) individual and (b) total 
aspirin metabolites for control 
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FIG. 3.3.5.4 - Cumulative urinary excretion of 
(a) individual and (b) total 
aspirin metabolites for patient 
treated with glycine, G5 shown 
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FIG. 3.3.5.5 - Cumulative urinary excretion of 
(a) individual and (b) total 
aspirin metabolites for patient 
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FIG. 3.3.5.6 - Cumulative urinary excretion of 
(a) individual and (b) total aspirin 
metabolites for patient treated with 
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FIG. 3. 3. 5.7 - Cumulative urinary excretion of 
(a) individual and (b) total 
aspirin metabolites for patient 
treated with N-glycylglycine, GGl 
shown in Tale 3. 3.5. 7
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FIG. 3.3.5. 8 - Cumulative urinary excretion of 
(a) individual and (b) total 
aspirin metabolites for patient 
treated with N-glycylglycine, GG4 
shown in Table 3. 3.5.8
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FIG. 3. 3.5.9 - Cumulative urinary excretion of 
(a) individual and (b) total 
aspirin metabolites for patient 
treated with N-glycylglycine, GG5 
shown in Table 3. 3.5. 9
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FIG. 3.3.5.10 - Cumulative urinary excretion of
(a) individual and (b) total 
aspirin metabolites for patient 
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FIG. 3.3.5.11 - Cumulative urinary excretion of 
(a) individual and (b) total 
aspirin metabolites for patient 
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FIG. 3.3.5.12 - Cumulative urinary excretion of 
(a) individual and (b) total 
aspirin metabolites for patient 
treated with bicarbonate, B5 shown 
in Table 3.3.5.12
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FIG. 3.3.5.13 - Cumulative urinary excretion of 
(a) individual and (b) total 
aspirin metabolite for patient 
with severe salicylate poisoning 
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It is evident from Tables and Figs. 3.3.5.1 - 3.3.5.13 that the 
urinary recovery and the rate of excretion of individual aspirin 
metabolites were highly variable. There was no indication that the 
elimination of salicyluric acid (SUA) occurred at a constant rate. 
Salicylic acid (SA) excretion exhibited the well known sensitivity of 
urine pH. This can be seen in Table and Fig. 3.3.5.10, 3.3.5.11 and 
3.3.5.13, when urine 0 1  and salicylic acid excretion were relatively 
high and in Table and Fig. 3.3.5.2, 3.3.5.6 and 3.3.5.9, when urine pH 
and salicylic acid excretion were relatively low. Increase in 
excretion of salicyl phenolic glucuronide (SPG) was generally 
accompanied by a decrease in salicylic acid excretion and vice versa, 
since SA excretion and SPG synthesis are parallel and therefore 
competing process.
Urine metabolite profile
Table 3.3.5.14 compared the metabolism of aspirin in patients 
following overdose after various treatments. Salicyluric acid (SUA) 
is the principal metabolite in control and glycine treatment groups 
accounting for a mean value of 50.73% and 46*63% respectively of the 
total salicylate excreted. This metabolite was excreted in 
significantly lower amounts (P < 0.02) in the gly-gly (38.43%) and 
bicarbonate (34.72%) groups compared to the control. The fraction of 
ingested overdose recovered as free salicylic acid (SA) increased in 
all three treatment groups but only significantly (P < 0.05) after 
bicarbonate treatment (42.14%). In the same group a significant 
decrease (P < 0.02) in salicyl phenolic glucuronide (SPG) was 
observed. Gentisic was excreted in smaller (< 10%) amounts. In 
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glucuronides (SÜA-PG) were also measured in the gly-gly and 
bicarbonate treatment groups. In these groups, when present they were 
excreted in similar amounts with mean excretion of SAG and SUA-PG of 
12.95% and 2.43% respectively. In all patients, the total recovery of 
salicylate (i.e. GA + SUA + SA + SPG, expressed as equivalent weight 
of salicylic acid) in urine was considerably less than the reported 
intake, mainly due to successful gastric-wash out and possibly also 
because of exaggeration by the patients of the number of tablets they 
had ingested. However, a positive correlation was found between 
plasma salicyate on admission and total recovery of salicylate (r = 
0.752; P < 0.001; n = 47).
Urinary recovery of total salicylate - was calculated for each 
patient over the period 2 - 6 hours and 6-16 hours after admission 
from their cumulative total metabolic (GA + SUA + SA + SPG) against 
time plots to establish if any significant changes occurred during 
early and late stage of each treatment (Table 3.3.5.15) (individual 
recoveries for each patient are given in Appendix 17). During the 
early phase of the treatment, 2 - 6 hours after admission the mean 
recovery of total salicylate was only significantly higher (P < 0.05) 
in glycine group (1.03 g) compared to the control (0.55 g). However, 
over 6-16 hours mean recoveries were significantly higher (P < 0.05) 
in all groups compared to the control. Over the entire 2-16 hour 
period the mean recovery was greatest after bicarbonate treatment 
(2.54 g), intermediate after glycine (2.51 g) and gly-gly (2.36 g) 
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Changes in urine 0î
Figs. 3.3.5.14 and 3.3.5.15 shows changes in urine pH with time in 
patients with aspirin overdose following treatment with oral fluids 
(control) or glycine and N-glycylglycine or bicarbonate respectively.
It is evident that in the control patients urine pH ranged between 5.8 
- 7.0 over the first 4 hours after admission and thereafter became 
progressively more acidic. In control patient, C2 (see Table 3.3.5.1)
0 Î remained relatively high from 2-16 hours after admission; a possible 
explanation is that this patient received urinary alkalinisation 
treatment in error. In majority of the patients treated with N- 
glycylglycine urine pH was comparable with controls but after glycine 
treatment it was generally higher. In Fig. 3.3.5.15 data were also 
included from patients with severe aspirin poisoning (withdrawn from the 
trial since plasma salicylate on admission > 690 mg/1) also treated with 
urinary alkalinisation. In a large proportion of the patients given 
alkali urine pH ranged between 7.0 - 8.5 over the first 20 hours after 
admission. The mean ± SEM of urine 0i of all the measurements in each 
treatment group was, 5.85 ± 0.20 (control), 6.41 ± 0.11 (glycine),
6.15 ± 0.08 (gly-gly) and 7.02 ± 0.13 (bicarbonate).
3.3.6 Correlation between mean urine 01 and metabolites
Mean urine pB of serial samples in a group of patients was 
calculated both by taking arithmetic mean and by converting 0 î into 
hydrogen ion concentrations, taking arithmetic mean and then re­
converting into 0 i. The values obtained by each method were similar 
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combined data from all treatment groups [including 7 patients with 
severe aspirin poisoning^ see Appendix 4 (Nos. 7-13)] showed a highly 
significant positive correlation between mean urine pH and the 
percentage total salicylate (i.e. GA + SUA + SA + SPG) excreted as 
salicylic acid (r = 0.881; P < 0.001; n = 52). In contrast, mean urine 
pH was negatively correlated with the fraction excreted as gentisic 
acid (r = -0.303; P < 0.05; n = 52); salicyluric acid (r = -0.701; P < 
0.001; n = 52); and salicyl phenolic glucuronide (r = -0.659; P <
0.001; n = 52).
When the combined data from all treatment groups were examined for 
correlation of each aspirin metabolite, percentage total salicylate 
excreted as salicylic acid was nega tively correlated with percentage 
excretion of gentisic acid (r = -0.296; P < 0.05; n = 52); salicyluric 
acid (r = -0.829; P < 0.001; n = 52); and salicyl phenolic glucuronide 
(r = -0.719; P < 0.001; n = 52). There was a positive correlation 
between percentage recoveries of salicyl phenolic glucuronide and 
salicyluric acid (r = 0.288; P < 0.05; n = 52). Percentage urinary 
recovery of gentisic acid was unrelated to that of salicyluric acid and 
salicyl phenolic glucuronide.
3.3.7 Salicyluric acid excretion
lypical profiles of urinary excretion rate of salicyluric acid 
(SUA) against time in two control (see Table 3.3.5.1 and 3.3.5.2) and 
three patients each from glycine (see Tables 3.3.5.4 - 3.3.5.6), gly-gly 
(see Tables 3.3.5.7 - 3.3.5.9) and bicarbonate treatment groups (see 
tables 3.3.5.10 - 3.3.5.12) are shown in Figs. 3.3.7.1, 3.3.7.2,
3.3.7.3 and 3.3.7.4 respectively. SUA excretion rates in individual 
patients varied with time after admission and were greatest in
130
FIG. 3.3.7-1 - Plots of urinary SUA excretion rate
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FIG. 3.3.7.2 - Plots of urinary SUA excretion rate 
against time in patients with aspirin 
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FIG. 3.3.7.3 - Plots of urinary SUA excretion rate 
against time in patients with aspirin 
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FIG. 3.3.7.4 - Plots of urinary SUA excretion rate 
against time in patients with aspirin 
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patients treated with glycine or glycylglycine. However, in two 
patients (C7 and Bl) it remained relatively constant during the course 
of the treatment.
Urinary excretion of salicyluric acid is rate-limited by the 
formation process, therefore SUA excretion rate in serial urine samples 
essentially represents its formation rate. The maximum observed rate of 
excretion of SUA in individual patients from each treatment group is 
shown in Fig. 3.3.7.5. It is evident that the maximum rate was highly 
variable and within each treatment group there was some 3 fold 
variation. The mean of maximum observed rate of excretion of SUA 
( y moles/hr) was significantly higher (P < 0.02) in patients treated 
with glycine (735.9 ± 72.4, mean ± SEM) or gly-gly (775.6 ± 96.2) compared 
to the controls (492.4 ± 67.3). This mean value was also higher in 
patients treated with bicarbonate but the difference was not 
statistically significant. In addition, when the mean of mid-point of 
urine collection periods were compared it was found that this maximum 
observed rate of excretion of SUA occurred significantly earlier (Table 
3.3.7.1) in the glycine (P < 0.05) and gly-gly (P <0.002) treatment 
groups compared to the control. No significant changes were observed 
between the control and bicarbonate or glycine and bicarbonate groups in 
respect of time of maximum SUA excretion.
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FIG. 3.3.7.5 - Maximum observed rate of excretion of
SUA in individual patients with aspirin 
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SECTION 4 
RESDLTS - ANIMAL STUDIES
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SBCnON 4 RESDLTS - ANIMAL STUDIES
4.1 Capacity limited metabolism of Aspirin in rats
Metabolism of 14^-aspirin was studied in rats following single 
oral doses of 10, 20, 50 and 100 mg/kg (for experimental details refer 
to Section 23 (a)). Over a three day period of collection, a mean of 
94.41% of the administered dose was excreted in the urine with 85.73% 
in the first 24 hours (Table 4.1.1).
Table 4.4.1 - Percentage urinary recovery of radioactivity following 
oral administration of 14^,-aspirin in rats
Urine
collection
Percentage recovery of radioactivity
period
1 0  mg/kg 2 0  mg/kg 50 mg/kg 1 0 0  mg/kg
0 - 2 4 hr 80.14 ± 0.81 90.79 ± 2.3 85.41 ± 2.92 83.78 ± 1.94
24 - 48 hr 14.70 ± 0.76 6.81 ± 1.49 10.94 ± 2.66 11.38 ± 1.01
48 - 72 hr 0.75 ± 0.20 1.18 ± 0.72 1.70 ± 0.55 1.16 ± 0.67
Total 95.58 ± 1.76 98.78 ± 0.93 98.05 ± 1.69 96.32 ± 0.87
Figures represents mean ± SEM of 4 rats
Since most of the administered radioactivity (80-95%) was 
recovered in the urine in the first 24 hours, only 0-24 hr rat urine 
sample from each dose group was used for metabolite identification. 
Analysis of rat urine by radio-TLC revealed 4 major radioactive bands. 
A typical TLC radiochromatogram of rat urine after each aspirin dose
138
is shown in Fig. 4.1.1. The radioactive bands were identified by 
comparing their Rf values with the authentic aspirin metabolites 
(which were co-chromatographed with the urine sample on the same TLC 
plate) and by colour reaction (see section 2.7 and Table 2.2). It 
was concluded that band at Rf 0.28 (in solvent system A) was 
salicyluric acid; Rf 0.71-salicylic acid; Rf 0.48-gentisic acid and at 
the origin, salicylic acid glucuronides. There was no significant 
difference in rat urine TLC metabolite profile between solvent system 
A and B.
Table 4.1.2 summarises the metabolite profile in urine (0-24 
hour) following oral administration of 14^-aspirin to rats. At the 
lowest dose ( 1 0 mg/kg) the principal urinary metabolite was salicylic 
acid which accounted for a mean of 45.46% (45.46 ± 3.25%, mean ± SEM) 
of the total dose excreted in the first 24 hours. The remainder 
comprised, salicyluric acid (18.72 ± 0.59%); salicylic acid 
glucuronides (28.81 ± 2.73%) ; and gentisic acid in minor amounts 
(< 1%). The fraction of aspirin excreted in the urine as salicyluric 
acid (4.61 ± 0.16%) decreased significantly (P < 0.001) as the dose 
was increased from 10 to 100 mg/kg. Gentisic acid (P < 0.005) and 
salicylic acid glucuronides (P < 0.05) were excreted in significantly 
higher amounts. Rat urine samples were also assayed for sulphate 
conjugates (Section 2.11 (b)) of aspirin metabolites (particularly SA) 
but were not found. Individual percentage recovery of metabolite in 
urine (0-24 hr) following oral administration of 14^-aspirin (10, 20, 
50, and 100 mg/kg) to rats is given in Appendix 13.
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F I G .  4 . 1 . 1 A typical TLC radiochromatograms of rat 
urine
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4.2 Effect of oral administraticxi of glycine on the metabolism of
Aspirin in rats
Metabolism of 14̂ ,“aspirin after therapeutic (10 mg/kg) and toxic 
( 1 0 0 mg/kg) doses in control and glycine treated rats was 
investigated. One hour prior to the aspirin dose, 1ml of either 
normal saline (control group) or glycine solution (500 mg/kg in water) 
were administered orally to rats. This was repeated at 2, 5 and 8 hour 
after the dose of aspirin (Section 2.3 (b)).
After single oral doses of 14^-aspirin to rats, most of the dose 
was rapidly eliminated in the urine. Over a 3 day urine collection 
period, a mean of 95.61% of the administered dose was excreted in the 
urine with 82.4% in the first 24 hr and a further 9.73% during 24-48 
hr period. The results are summarised in Table 4.2.1.
Table 4.2.1 - Percentage urinary recovery of radioactivity in control 
and glycine treated rats following oral administraion of 14^-aspirin
Urine Percentage recovery of radioactivity
period Saline treatment Glycine treatement
1 0  mg/kg 1 0 0  mg/kg 1 0  mg/kg 1 0 0  mg/kg
0 - 24 hr 75.29 ± 7.50 83.50 ± 2.83 89.68 ± 0.13 81.12 ± 2.44
24 - 48 hr 9.71 ± 1.74 10.26 ± 2 . 1 2 4.89 ± 0.13 14.32 ± 2.87
48 - 72 hr 1.68 ± 0.38 1.58 ± 0.46 0.61 ± 0.27 1.83 ± 0.48
Total 8 6 . 6 8  ± 5.86 95.34 ± 1.73 95.17 ± 0.64 97.26 ± 1.72
Figures represents mean ± SEM of 4 rats
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Analysis of rat urine (0-24 hr) by radio-TLC in solvent system A 
revealed 4 major radioactive bands. Typical radiochromatograms of 
urine following oral administration of 14^-aspirin to control and 
glycine treated rats is depicted in Fig. 4.2.1.
Table 4.2.2 summarises urine metabolite profile in control and 
glycine treated rats following oral administration of aspirin 
(individual recovery of metabolites are given in Appendix 14). The 
same data are presented graphically in Fig. 4.2.2. The nature and 
extend of urinary excretion of aspirin metabolites in control rats 
after oral doses of 1 0  and 1 0 0  mg/kg of aspirin was similar to that 
reported in the previous study (Section 4.1 and Table 4.1.2). In 
glycine treated rats after 1 0  mg/kg dose of aspirin, the fraction of 
administered dose excreted as salicyluric acid (38.95 ± 1.08%, mean ± 
SEM) increased significantly (P < 0.001) compared to the control 
(23.67 ± 1.45%), accompanied by significant decrease (P < 0.05) in 
salicylic acid glucuronides. Salicylic acid and gentisic acid 
excretion were unaffected. After the higher dose (100 mg/kg) of 
aspirin, again in the presence of glycine urinary excretion of 
salicyluric acid increased significantly (P < 0.005) compared to the 
control. However, it only accounted for a mean of 8.28% of the total 
dose excreted in the urine compared to a mean value of 38.95% after 10 
mg/kg dose. Urinary recovery of salicylic acid glucuronides 
decreased, but not significantly. Oral administration of glycine (500
143
FIG. 4.2.1 - Radiochromatograms of urine following 
oral administration of 14^,-aspirin to 
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FIG. 4.2.2 - Urine (0-24 hr) metabolite pattern in control
and glycine treated rats following oral administration 
of 14^-aspirin
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mg/kg) to rats also dosed with aspirin does not result in any 
significant changes in urine pH (Table 4.2.3).
Table 4.2.3 - Urine pH after aspirin in control and glycine treated rats.
Urine pH (mean ± SEM of 4 rats)
Urine _____________________________________________________
collection Control Glycine treatment
period _____________________________________________________
ASA IQmg/kg lOQmg/kg 10 mg/kg 100 mg/kg
0 - 24 hr 6.44 + 0.14 6.18 + 0.13 6.21 + 0.05 6.43 + 0.11
43 Plasma glycine profile in rats following oral administration of 
aspirin at 1 0  and 1 0 0  mg/kg
Results presented in Section 3.3.4 suggested that depletion of 
plasma glycine occurred in patients with self administered overdose of 
aspirin compared to the healthy volunteers. Consequently, the effect of 
oral administration of therapeutic ( 1 0 mg/kg) and toxic 1 0 0  (mg/kg) doses 
of aspirin on the the plasma glycine concentrations in rats was 
investigated.
Plasma glycine concentrations were determined in a group of 20 
healthy adults ̂ ts at different times throughout the working day to 
establish a normal range. This was found to 10.68 - 16.85 yg/ml (12.53 
± 1.71) yg/ml, mean ± SEM). A semilogarithmic plot of salicylic acid 
and glycine concentrations as a function of time after single oral 
administration of 10 and 100 mg/kg of aspirin to rats is shown in Figs.
4.3.1 and 4.4.3, respectively. Peak plasma salicylic acid concentrations
147
FIG. 4.3.1 - A semilogarithmic plot of salicylic acid 
and glycine concentrations as a function of 
time after single oral administration of 











Each point represents data from a single 
rat. Line links mean value of two rats 
at each time point.
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FIG. 4.3.2 - A semilogarithmic plot of salicylic acid 
and glycine concentrations as a function 
of time after single oral administration 








Normal range (12.53 + yg/ml)







Each point represents data from a single 
rat. Line links mean value of two rats 
at each time point.
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were achieved in approximately 1 hour and declined with a terminal half- 
life of 4.86 hr and 5.23 hr respectively. At various times after each 
aspirin dose, plasma glycine concentrations remained relatively constant 
and were not significantly different from the normal range in control 
rats.
SECnCN 5 
OOMEARATIVE MEmBQLISH OF 
ASPIRIN IN MAN AND RAT
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SBCIKH 5 Comparative metabolism of aspirin in man and rat -
quantitation of salicyluric acid phaiolic glucuronide and 
gentisuric acid
5.1 Introduction
Recently, Zimmerman et al (1981) have characterised salicyluric 
acid phenolic glucuronide (a double conjugate of salicylic acid) as an 
endogenous product in the body fluids of uraemic patients. In 
addition, Wilson et al (1978) have reported the formation of 
gentisuric acid (glycine conjugate of gentisic acid) in urine from 
patients treated with aspirin. However, very little information is 
available regarding the relative urinary excretion of these 
metabolites in man and animal species during aspirin therapy or under 
toxic conditions. In view of this, a comprehensive analysis was 
undertaken of urine from man after therapeutic (600 mg) and toxic 
doses of aspirin and from rat after lO-lCXD mg/kg of aspirin.
5.2 Procedures
Salicylic acid phenolic and acyl glucuronides; salicyluric acid 
phenolic glucuronide; and gentisuric acid could not be assayed 
directly because authentic samples of these conjugates were not 
available. Consequently, these metabolites were quantified by first 
hydrolysis of the conjugates with specific enzymes and chemicals as 
previously described (Section 2.11). Rat urine samples were analysed 
by radio-TLC (Section 2.7) and human urine by HPLC (Section 2.10).
The following samples (maintained at -20®C) from previous studies were 
used.
a) Rat urine samples (0-24 hr) following administration of 10, 20, 50
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and 100 mg/kg of 14^aspirin (Section 4.1).
b) Urine samples (0-8 hr) from 10 healthy volunteers (Nos. 1-10, see 
Appendix 2) after therapeutic (600 mg) dose of aspirin.
c) A single urine collection period of 0-24 hour was obtained in each 
of 9 patients with aspirin poisoning by combining serial urine 
samples. All the patients had taken part in the clinical trial of 
glycine for salicylate overdose (Section 2.4.2 (b)), 4 were from 
control group (Nos. 02, 05, 010 and 012) and the remaining 5 from 
glycine treatment group (Nos. G3, G4, G7, G9 and Gil).
53 Results
Rat data
Analysis of rat urine (0-24 hr) by radio-TLO revealed the 
presence of 4 major radioactive bands. A typical radiochromatogram of 
rat urine before and after treatment with 3-glucuronidase (at 37°0 
for 24 hr) and 6 M HCl (at 100°0 for 20 hr) is shown in Fig. 5.3.1.
The radioactive bands were identified by comparison of Rf values with 
authentic aspirin metabolites and by colour reactions (see Section 2.7 
and Appendix 1). It was concluded that band at Rf 0.28 (in solvent 
system A) was salicyluric acid; 0.71 salicylic acid; 0.48 gentisic 
acid and at the origin, salicylic acid glucuronides (SG).
Treatment of rat urine with 3 -glucuronidase (Fig. 5.3.1 B) and 
2M NaOH at 37®C for 24 hr resulted in a decrease in radioactivity at 
the origin and a corresponding increase in salicylic acid. This 
strongly suggested that salicylic acid phenolic and acyl glucuronides 
were present, respectively. In addition, a small increase in SUA was 
also observed after treatment with 6-glucuronidase indicating the 
presence of salicyluric acid phenolic glucuronide. Incubation of
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FIG. 5.3.1 - Typical TLC radio chromatogram (solvent 
system A)of rat urine (0-24 hr) following oral 
administration of 14c-aspirin (100 mg/kg): (A) control
urine; (B) urine treated with e-glucuronidase; 
and (C) urine hydrolysed with acid. The relative 
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urine with sulphatase (Section 2.7) did not result in any significant 
changes in metabolite profile, indicating that the sulphate conjugates 
were not present. Deconjugation with acid resulted in total hydrolysis 
of all conjugates (Fig. 5.3.1 (c)); including the amino acid 
conjugate of gentisic acid (gentisuric acid), hence the observed 
increase in radioactivity associated with the gentisic acid band.
Rat urine metabolite profile
Table 5.3.1 summarises the urine metabolite profile following a 
single oral administration of 14^-aspirin to rats (individual 
percentage recovery of metabolite are given in Appendix 15).
Salicylic acid is the major urinary metabolite which accounts for a 
mean of 48% of the total dose excreted in 024 hr urine. As the dose 
was increased from 1 0  to 1 0 0  mg/kg there was a significant increase in 
excretion of gentisic acid (P < 0.005) and salicyl phenolic and acyl 
glucuronides (P < 0.02). Whereas salicyluric acid excretion was 
significantly decreased (P < 0.001). The urinary excretion of 
salicylic acid and salicyluric acid glucuronides does not appear to be 
dose dependent.
Volunteers and patients data
A typical HPLC trace of human volunteer urine before and after 
treatment with 6-glucuronidase (at 37°c for 24 hr) and 6 M Hcl (at 
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FIG. 5.3.2 - A typical HPLC trace of human volunteer 
urine (0-8 hr) following oral administration of 
therapeutic (600 mg) dose of aspirin : (A) control urine;
(B) urine treated with 6-glucuronidase ; and (C) urine 
hydrolysed with 6M HCl. Peak 1 is gentisic acid; 2 is 
salicyluric acid; 3 is internal standard (0-anisic acid) 
and 4 is salicylic acid, x represents a point at which 






















gentisic acid; 2 is salicyluric acid; 3 is internal standard (o-anisic 
acid) and 4 is salicylic acid. Treatment of urine with 3- 
glucuronidase (Fig. 5.3.2 (B)) resulted in an increase in salicylic 
acid, Peak 4; clearly indicating the presence of salicylic acid 
phenolic glucuronide which is thought to be eluted from the column with 
the solvent front. There was no significant change in the gentisic 
acid, peak 1 following acid hydrolysis. This strongly suggested that 
the amino acid conjugate of gentisic acid (GUA) was not present.
Table 5.3.2 summarises urine metabolite profile of aspirin in 
healthy volunteers (n=1 0 ) after therapeutic (600 mg) dose and in 
patients (n=9) with aspirin overdose (individual data are presented in 
Appendix 16). Following the therapeutic dose, the major urinary 
metabolite in volunteers was the glycine conjugate, salicyluric acid 
which accounts for between 49% and 72% of the excreted dose (63.07 ± 
2.65%, mean ± SEM). The remaining 37% of the excreted dose is 
accounted for by minor metabolites, which include gentisic acid 
(3.55%); salicylic acid (6.76%); salicyluric acid phenolic glucuronide 
(9.33%); and salicyl acyl and phenolic glucuronides (8.25% and 9.72% 
respectively). In patients with aspirin overdose, the fraction of 
aspirin excreted in the urine as salicyluric acid and its glucuronide 
conjugate (SLJA-PG) decreased significantly (P < 0.001) compared to the 
therapeutic dose. This was accompanied by significant increase in the 
excretion of salicylic acid (P < 0.005) and salicyl acyl glucuronide 
(P < 0.05). In addition, small amounts of gentisuric acid (5.31 ± 
0.90%, mean ± SEM) was also present. This metabolite could not be 
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SECTION 6  
DISCDSSICN
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SBCFKXî 6  - DISCDSSION
6.1 Aspirin Metabolism in Man
6.1.1 Aspirin metabolism in volunteers after therapeutic (600 mg) dose 
Urine Metabolite Pattern
The metabolism of aspirin was investigated in a wide-age range 
(18-63 yrs) healthy volunteers after a therapeutic (600 mg) dose. 
Following oral administration, a mean value of 53 percent of the 
ingested dose was recovered in the urine within the first 8 hours 
after aspirin dose. Analysis of urine revealed the presence of 
Gentisic acid (GA), salicyluric acid (SUA), salicylic acid (SA) and 
salicyl phenolic glucuronide (SPG) as the principal metabolites of 
aspirin (Table 3.1.1) and is in agreement with previous studies (Kapp 
and Coburn, 1942; Bedford, Cummings and Martin, 1965; Levy, 1965; 
Nelson, Hanano and Levy, 1966; Bochner et al, 1981; Hutt, Caldwell and 
Smith, 1982).
Salicylate elimination has been reported to be slower in human 
neonate (Levy and Garrettson, 1974) and in the elderly (Cuny et al, 
1979; Montgomery and Sitar, 1981) than in adults. Consequently, 
another purpose of this study was to determine whether age related 
differences in metabolism of aspirin existed in volunteers after 
therapeutic dose. The percentage excretion of individual aspirin 
metabolites was compared with age but no significant correlation was 
found. In contrast, Oldham (1983) reported a significant decrease in 
the percentage of the dose excreted in the urine (0 - 8  hr) and the 
fraction excreted as salicyl phenolic glucuronide with increase in age 
in 41 healthy volunteers following 600 mg oral dose of aspirin. A 
decrease in renal function with age may account for both effects since 
glomerular filtration rate and effective renal plasma flow has been
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found to diminish with increasing age (Davies and Shock, 1950). In 
the above study volunteers were aged 14-85 years and no significant 
changes were observed between urinary excretion of aspirin metabolites 
and age in range 21-65 years and is in agreement with the present 
study. However, in the higher age range 65-85 years a significant 
decrease in SA and SPG was observed with age which could not be 
demonstrated in the present investigation, since the age range was 18- 
63 years. Montgomery and Sitar (1981) have recently found that the 
plasma concentrations of salicyluric acid and gentisic acid increased 
in patients older than 60 years on chronic aspirin therapy and is 
thought to be due to lower renal clearance of these metabolites. 
However these workers did not measure urinary metabolites and 
therefore a direct comparison with the present work is not possible.
In the present study, although the absolute quantities of each 
aspirin metabolite varied, the values of each expressed as a 
percentage of the total metabolites excreted did not differ 
significantly between individuals. However, Alpen et al (1951) using 
14^-salicylic acid in four cancer patients reported a wide variation 
in the fraction of dose excreted in the urine as salicyluric acid (0 - 
50%) and salicylic acid (10-85%). It is possible that the presence of 
malignancy may affect the metabolism and thus account for the observed 
variability. Caldwell, O'Gorman and Smith (1980) also reported a 
large inter-subject variation in the urinary recovery of administered 
dose as salicyluric acid (range 5.9-71.6%, some 12-fold variation) and 
salicyl glucuronides (0.1-90%) in 85 healthy volunteers following oral 
dose of 900 mg aspirin. Such large inter-individual variations were 
not observed in the present study. Salicyluric acid excretion
160
accounted for between 58 and 91 percentage of the total dose excreted 
in the urine and salicyl phenolic glucuronide between 5-19 percentage 
(Appendix 2). It is possible that genetic differences in individuals 
capacity to conjugate glycine and glucuronic acid may account for some 
of these observed variations (Furst, Gupta and Paulus, 1977).
Although sex is recognised to influence drug disposition 
(O'Malley et al, 1971; Giudicelli and Tillement, 1977), such an 
influence on the disposition of salicylates has not been determined in 
any detail. However, Trnavska and Trnavsky (1983) have recently 
reported a significant sex-differences in plasma concentrations of 
salicylic acid in male and female volunteers following both single and 
multiple oral doses of aspirin (143 mg/kg). A significantly lower 
plasma level of salicylic acid was found in men, resulting from slower 
absorption and higher elimination rates. In the present study, 
urinary recovery of salicylic acid (0 - 8  hr) was significantly higher 
(P < 0.005) in female volunteers who took therapeutic (600 mg) dose of 
aspirin compared to male. A corresponding decrease in salicyluric 
acid recovery was also observed in female volunteers but the change 
was not statistically significant (P < 0.06).
It is now well established that salicyluric acid, the glycine 
conjugate is the major urinary metabolite after salicylate therapy. 
However, Altschule and Hegedus (1974) found large amounts of 
salicyluric acid in the urine of badly wounded men, of several 
Parkinsonian patients recieving levedopa, and of a patient with 
disseminated melanoma, none of whom had been given salicylate in any 
form. These new findings suggests that salicyluric acid can also be 
formed as an endogenous material in man and its physiological and 
clinical significance in disease state needs further investigation.
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Effect of urine ^  on SA excretion
Urine pH was measured in all volunteers and was found to 
correlate positively (P < 0.01; r = 0.476) with percentage urinary 
recovery of salicylic acid (Fig. 3.1.2). This is in agreement with the 
findings of MacPherson, Milne and Evans (1955); Gutman, Yu and Sirota 
(1955), that renal clearance of salicylic acid increases with urine 
pH. These authors revealed a linear relationship between log 
salicylate clearance and urine pH; as the urine pH is increased from 5 
to 8 , the renal clearance increases more than twenty fold. While this 
is likely to have a relatively small effect on the elimination 
kinetics of small single doses (< 0.65 g aspirin in adults), it has a 
profound effect on the elimination of larger doses, when the 
formation rates of salicyluric acid and salicyl phenolic glucuronide 
approach saturation. This is particularly apparent when urine pH 
increased from below 6.5 to 8.0 or higher. As a result, urine 
alkalinisation is currently the method of choice in the treatment of 
moderate salicylate poisoning in man (Prescott et al, 1982).
Correlation of Metabolites
In the present investigation, when the correlation of each 
aspirin metabolite was examined, the percentage recovery of salicylic 
acid was found to relate negatively to the recovery of salicyluric 
acid (Fig. 3.1.3). This indicates that salicylic acid excretion and 
salicyluric acid formation are parallel and therefore interdependent 
process. Percentage urinary recovery of salicyl phenolic glucuronide 
was also found to correlate negatively with percentage recovery of 




Salicylic acid is the predominant metabolite in plasma (Gibson et 
al, 1975; Bochner et al, 1981; Gunsberg, 1984), although the presence 
of low concentrations of salicyluric acid (SUA), salicyl acyl 
glucuronide (SAG) and salicyl phenolic glucuronide (SPG) has been 
demonstrated by Schachter and Manis (1958). They found that after 
single oral dose of 64 mg/kg sodium salicylate to healthy subjects, 
peak plasma concentrations of SA, SUA and SAG occurred at the same 
time, two hours after dose, but the peak concentrations of SPG 
occurred at 8 hours. The concentrations of SA and SAG fell 
progressively, while those of SUA and SPG remained fairly constant for 
24 hours. More recently, Bochner et al (1981) investigated the 
salicylate metabolite kinetics after several salicylates. In 
addition to measuring SA and SUA in plasma they followed the time 
course of gentisic acid after an oral dose of 1.5 grams of aspirin. 
Peak concentrations were observed at 4 hours after dose.
There have been several early reports which suggested that 
salicylic acid metabolism m y  be capkacity limited:
1) A review of the early literature (Levy, 1965) revealed that the 
biological half-life of salicylic acid in adult humans increased 
from about 2.4 to about 19 hours when the dose was increased from 
0.25 to 1 0  grams (as aspirin or sodium salicylate).
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2) The fraction of the dose recovered in the urine during the first 
24 hour after drug administration was found to decrease with 
increasing dose (Levy, 1965).
3) After single oral administration of sodium salicylate (65 mg/kg) 
plasma salicylic acid concentraitons declined by 75% from 2 to 24 
hour after drug administration, but the salicyluric acid 
concentrations remained essentially constant during this period of 
time.
4) The urinary excretion of salicyluric acid can be virtually 
suppressed by the continued oral administration of p-amino- 
benzoate (3 grams every 3 hours), resulting in a concomitant 
prolongation of high plasma salicylic acid concentrations 
(Salassa, Bollman and Dry, 1948).
6.1.2 Aspirin metabolism in overdose
The metabolism and pharmacokinetics of aspirin and salicylic acid 
in man after therapeutic doses have been extensively investigated 
(Section 1.5). However, specific data on the metabolism of aspirin 
after overdose are lacking and is particularly surprising, since acute 
salicylate poisoning resulting from accidental ingestion in children 
and intentional overdose in adults is a common form of admission to 
the hospital (Meredith and Vale, 1984). Current treatments of 
salicylate poisoning is based largely on measures which accelerate the 
elimination of this drug from the body (Prescott et al, 1982). In the 
light of this, a better understanding of metabolism after overdose may 
lead to a more effective and safe treatment for salicylate
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intoxication. Such a comprehensive investigation has been carried out 
in the present work and the results obtained are discussed herein for 
the first time in a substantial number of overdose patients. 
Consequently, direct comparision of present data with other similar 
work was not possible.
Epidemiology of aspirin overdose
Poisoned patients in the Bath area are mainly treated in the 
Clinical Pharmacology Unit (CPU) at the Royal United Hospital and this 
unit provided an excellent facility to study the metabolism of aspirin 
in overdose. A survey of all poisonings admitted to CPU indicated 
that Female to Male ratio was 1.65:1 and peak age incidence was 20-30 
years (Dr. P.N. Bennett, personal communication). Hie data from 
patients with aspirin overdose also reflect this trend, since majority 
of these patients were aged 14-34 years and the Female to Male ratio 
was 2.33:1. Similar observations were made by a recent survey of 
analgesic overdose in England and Wales (Meredith and Vale, 1984). 
Additionally, a large proportion of the patients (76%) was admitted to 
the hospital for treatment within the first 9 hours after drug 
overdose. However, this presumed time of ingestion may be unreliably 
reported and also assumes that all the tablets were taken at once 
because patients determined on committing suicide may consume the 
tablets over several hours.
Urine metabolite pattern
Following a therapeutic dose (600 mg) of aspirin to 45 healthy 
volunteers salicyluric acid (SUA), the glycine conjugate of salicylic
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acid was the major urinary metabolite accounting for a mean value of
75.01 percentage of the total salicylate excreted (Table 3.2.1). In 
contrast, after aspirin overdose the fraction of total salicylate 
excreted in the urine as SUA was significantly reduced (Fig.3.2.1). A 
mean recovery of 46.66% was found in patients with moderate poisoning 
(treated with oral fluids only) compared to 21.57% in patients with 
severe poisoning (treated with urine alkalinisation) (Table 3.3.2). 
This was accompanied by increases in excretion of gentisic acid, 
salicylic acid and salicyl phenolic glucuronide. Similar observations 
were made by other workers but at much lower doses (0.16-5.0 g, 
aspirin) (Bedford et al, 1965; Levy, 1965; Gibson et al, 1975). Urine 
recovery of unchanged salicylic acid was much higher in patients 
treated with urine alkalinisation compared to those treated with oral 
fluids. This was simply due to higher urine pH in the former, which 
causes a dramatic increase in renal clearance of salicylic acid above 
pH 7.0 (Gutman, Yu and Sirota, 1955; Schachter and Manis). The net 
effect is a decrease in unionised salicylic acid entering the systemic 
circular by passive tubular reabsorption for further metabolism, as is 
reflected by reduced fractional excretion of metabolites in this group 
compared to those treated with oral fluids. It can be concluded that, 
after aspirin overdose urinary excretion of gentisic acid, salicylic 
acid and salicyl phenolic glucuronide is increased and these 
metabolites therefore make a significantly greater contribution 
towards overall salicylate elimination.
Capacity limited formation of SUA
Reduced urinary excretion of SUA has been demonstrated here for 
the first time in a large number of overdose patients. This
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observation suggests that SUA formation and/or elimination may be 
capacity limited. There is evidence that the rate-limiting step is 
SUA formation rather than renal elimination. Since, following an 
intravenous dose of SUA, 95% of the dose is recovered in the urine 
unchanged; plots of plasma concentration or urinary excretion rate vs. 
time are log-linear with similar half-lives of about 20 minutes (Levy, 
Amsel and Elliott, 1969). In contrast, the terminal slope of the 
logarithm of the SUA excretion rate vs. time after salicylate 
administration has a half-life of about 3 hours (Bedford et al, 1965; 
Levy, 1965). After oral administration of SUA (500 mg), the decline 
of plasma concentations and urinary excretion rate of SUA followed a 
bifiiasic pattern, with an initial half-life of approximately 2 0  
minutes, and within 2 hours over half the dose was excreted in urine 
(Bochner et al, 1981). This is consistent with the overall conclusion 
that SUA elimination, at least in the dose range studied (0.1-0.5 
grams) is fast and not rate-limiting. Hence, the rate of SUA 
excretion in urine essentially represents its metabolic formation 
rate.
Direct evidence for capacity limited formation of SUA was 
provided by Bedford et al (1965) and Levy (1965) who studied the rate 
of urinary excretion of total salicylate and of salicyluric acid as a 
function of time following single oral doses of aspirin of 0.16-2.0 
grams. The formation of salicyl phenolic glucuronide (SPG) has also 
been shown to be capacity-limited after a single oral dose of 3 grams 
of salicylic acid and both SUA and SPG formation processess can be 
described by Michaelis-Menten kinetics (Levy et al, 1972). The 
theoretical maximum rate of formation of SUA, and km were
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calculated in terms of total amount of SA in the body. Their values 
were obtained from urinary excretion data, the total amount of SA in 
the body being determined at any time from the difference between the 
dose and the cumulative urinary recovery. Unfortunately this method 
could not be employed in the present investigation because of (a) 
unreliability of the patients estimate of the number of tablets they 
had ingested and (b) in approximately 40% of the patients plots of 
cumulative total aspirin metabolites against time were not found to be 
rectangular hyperbolas, indicating incomplete urinary excretion of 
salicylate and consequently an adequate estimate of the total 
salicylate absorbed could not be obtained.
Vĵ ax formation of SUA from SA has also been calculated from 
the plasma concentrations of SA (Bochner et al, 1981; Gunsberg et al, 
1984) but frequent blood samples are required over a long period of 
time which is distressing to the patient and therefore not feasible 
in the present investigation. Since the urinary excretion of SUA is 
rate limited by the formation process and not the renal excretion, the 
urinary recovery rate is in fact the metabolic formation rate. 
Consequently the metabolic rate of formation of SUA was calculated for 
each urine collection period for each individual patient and the 
maximum observed rate at which each patient formed SUA was noted.
This maximum observed SUA formation should therefore be a close 
approximation of the apparent in vivo as confirmed by Day, Shen
and Azarhoff (1983). After a single oral dose of salicylate (35 
mg/kg) to 4 rheumatoid arthritis patients the mean SUA maximum 
observed rates were 77.76 mg/hr compared to their mean theoretical 
maximum rate of formation of SUA (V̂ ^̂ ) of 93.15 mg/hr.
It has been suggested (Levy, 1965) that when the dose of aspirin
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exceeds 1 gram the rate of formation of SUA becomes maximal at 400 
y moles/hr and that synthesis of SUA will not increase beyond this 
fixed rate despite increasing doses of aspirin, ie. production follows 
zero-order kinetics. From the Michaelis-Menten kinetics of salicylic 
acid after single oral doses of 3 grams to four healthy volunteers.
Levy et al (1972) have calculated mean for SUA formation to be
309 y moles/hr (or 60.3 mg/hr). However, in the present investigation 
the maximum observed rate of formation of SUA in individual patients 
treated with oral fluids or urine alkalinisation (severe poisoning) 
ranged between 200 and 1600 y moles/hr (Fig. 6.1.1 (a) and (b), 
respectively). The highest value of 1600 y moles/hr observed in the 
present study is approximately 5 times the of SUA formation rate 
reported in the literature (Levy et al, 1972).
These new findings must therefore cast some doubt on the earlier 
suggestions that the SUA formation process becomes saturated after 
therapeutic doses of aspirin and salicylic acid (0 .5-3.0 grams)
(Bedford et al, 1965; Levy, 1965; Levy et al, 1972) or if the plasma SA 
increases above 40 wg/ml (Cummings, Martin and Renton, 1966). Similar 
conclusions were also made by Gibson et al (1975) while studying the 
kinetics of salicylate metabolism in nine arthritic patients treated 
with 65 mg/kg soluble aspirin daily (3.6-5.5 g) and subsequently 100 
mg/kg (6-8.4 g) daily in four patients. When the dose was increased 
urinary excretion (mg) of SUA and SPG also increased, hence the 
capacity to form these metabolites was not saturated at the lower dose 
(65 mg/kg).
169
FIG. 6.1.1 - Maximum observed rate of
formation of salicyluric acid 
(SUA) in individual patients with 
aspirin overdose treated with 
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Interpatient variation in urinary excretion of S 2A âDd BSQ
Results from the study has also demonstrated a large interpatient 
variation in the maximum observed rate of formation of SUA values 
(some 8 fold difference). Similar variations in values for SUA 
formation rate have been reported in healthy volunteers after 0.5-1.5 
g salicylate (29-56 mg/hr; Bochner et al, 1981) and in patients with 
rheumatoid disease treated with 2-8 g aspirin (47-118 mg/hr; Gunsberg 
et al, 1984). In an elegant study involving seven pairs of identical 
and six pairs of fraternal twins, Furst, Gupta and Paulus (1977) have 
shown that for SUA formation is in part genetically determined.
It is, therefore likely that genetic differences in individuals 
capacity to form SUA may account for some of these observed 
variations. It is, also possible that constraints on glucuronide 
formation, may be important as is discussed below. In addition, there 
was no correlation between individual maximum observed SUA formation 
rate and plasma salicylate concentrations on admission or total 
salicylate recovered in the urine.
It appears that like SUA, the formation of salicyl phenolic 
glucuronide (SPG) is also capacity limited in man (Levy et al, 1972). 
This was initially demonstrated by examining, the interaction between 
salicylic acid and salicylamide in human volunteers (Levy and 
Procknal, 1968). Concomitant administration of salicylic acid and 
salicylamide (major metabolic pathways are glucuronide and sulphate 
conjugation) causes a mutual inhibition of glucuronide formation, 
consistent with a competitive effect on a capacity limited process.
The competition was found to be specific in that salicylamide had no 
effect on the maximum SUA formation rate. Michael is-Menten kinetics 
using urinary excretion data following single oral doses of salicylic
171
acid (3 g) to four healthy volunteers have given mean and Km (the 
Micçelis-Menten constant, expressed in terms of amount of substrate in 
the body) values for formation of SPG of 32.25 (mg/hr) and 629 (mg), 
respectively. Corresponding mean values for SUA formation in the same 
volunteers were 60.25 (mg/hr) and 338 (mg) respectively, suggesting 
that saturation of SPG formation occurs at a higher body load of 
salicylate but the rate of formation is lower compared to SUA and is 
consistent with the results from the present study.
In comparison with SUA formation, relatively little is known of 
the pathways controlling the formation of SPG in man but it is thought 
that the rate limiting step is the formation mechanism rather than 
renal elimination (Levy et al, 1972). Consequently as with SUA, 
urinary excretion rate essentially represents metabolic formation 
rate. Results from the study show that the individual maximum 
observed SPG formation rates ranged between 14-92 (mg/hr) and in 6 8 % 
of patients were higher than the mean apparent in vivo value 
(32.25 mg/hr) quoted in the literature (Levy et al, 1972). It is 
likely that saturation of this pathway may have occurred in the 
remaining patients. It is conceivable that genetic variations in the 
capacity of the en2ymes involved in SPG formation may, again account for 
the marked interpatient variations in the urinary recovery of this 
metabolite and the maximum observed formation rate after aspirin 
overdose. However, this has not been demonstrated in the literature 
and is, therefore, worth exploring.
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6.1.3 Effect of glypjpo, N-glycylglycine ûl bicarbonate qd the 
metabolism of aspirin in overdose 
Comparability of treatment groups
Assessing the efficacy of a given treatment in acutely poisoned 
patients is never simple because of two important factors, (a) Dose 
and time of drug ingestion are either unknown or more commonly 
unreliably reported, (b) After drug overdose due to slow absorption 
the plasma concentrations of the drug may rise for several hours 
despite thorough gastric lavage. The appearance of the toxic effect 
may thus be delayed. In the present investigation all treatment
agroups were reasoiÿly well matched but the plasma salicylate 
concentrations on admission in the gly-gly and bicarbonate groups were 
a little higher compared to the other two groups. This was mainly due 
to the differences in the admission criteria used for entry in the 
trial. In the former groups, overdose patients were only included in 
the trial if their plasma salicylate concentrations on admission fell 
between 400-690 mg/1, whereas, in the other two groups (control and 
glycine) this admission range was extended to 250-690 mg/1. For 
ethical reasons patients with severe salicylate poisoning i.e. plasma 
salicylate on admission of 700 mg/1 and higher were excluded. These 
patients were treated with a urine alkalinisation regimen and the 
metabolic data obtained has already been discussed (Section 6.1.1).
Salicyluric acid excretion
Salicyluric acid (SUA) accounts for 75.01% of the total recovered 
salicyate in volunteers who took a therapeutic dose of aspirin. After 
overdose SUA accounted for 50.73% and 34.72% of the excreted 
salicylate in control and bicarbonate treatment groups, respectively
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(Table 3.3.5.14). Lower recovery of SUA in the bicarbonate group was 
a direct result of the alkalinisation treatment as explained 
previously (Section 6.1.1). Capacity-1 imitation of the glycine 
conjugation process has long been recognised (Secton 6.1.1) but the 
precise cause still remains to be elucidated. However, it has been 
established that the rate limited step in SUA excretion is the 
formation process rather than renal elimination (Levy, 1965; Levy et 
al, 1969; Bochner et al, 1981) and is consistent with the observations 
in this study.
The elimination of benzoic acid in man is due almost exclusively 
to the conjugation of this drug with glycine, resulting in the formation 
of hippuric acid and the formation process is capacity limited and 
approaches a maximum rate following high dose of benzoic acid (2 g)
Amsel and Levy, 1969). In addition, oral administration of glycine 
was found to "unsaturate" the hippurate formation process i.e. the 
elimination kinetics of benzoate changes from clearly Michaelis-Menten 
to first-order. This suggests that availabilty of glycine may be the 
rate limiting step in hippurate formation. It is, therefore, 
conceivable that after aspirin overdose, saturation of SUA formation 
occurs because of depletion of glycine and that administration of 
glycine may result in increased rate of elimination of salicylate.
Thus, the primary objective of the present investigation was to assess 
the availablity of glycine for conjugation. Accurate measurements of 
the glycine pool would involve tracer dilution studies (Gersovitz et 
al, 1980) which were beyond the scope of the present study. As a 
result, it was assumed that the plasma glycine concentrations reflects 
the amount of glycine available at the site(s) of conjugation and
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appears to be consistent with the observations of MacDermot et al 
(1981), investigating conjugation of benzoic acid with glycine in 
rats.
Changes in plasma glycine
During the initial stages of this study, the author was 
confronted with the problem of determining an optimum glycine dosage 
regimen which would sufficiently increase the plasma glycine 
concentrations and at the same time be free from glycine toxicity, if 
any, at high doses. Survey of the literature indicated a wide use of 
"glycine tolerance test" for investigation of the absorption and 
malabsorption of amino acids in man. Heath and Fullerton (1935) who 
devised the test used between 25-50 g of oral glycine followed by 
analysis of peripheral blood samples. This test was later modified by 
Craft, Geddes, Hyde, Wise and Matthews (1968) and they used 10 g of 
oral glycine. Since exogenously admlittered glycine is rapidly 
cleared from plasma (Craft et al, 1968) it was found necessary from a 
pilot study to administer large doses (Section 2.4.2 (b)) at frequent 
intervals (2 hr) to maintain high plasma glycine concentrations. The 
main problem resulting from this was a tendency for the patients to 
suffer from nausea due, partly to the amount of glycine given and also 
to the aspirin overdose (Temple, 1981). In man, the rate of 
absorption of glycine has been shown to be faster following oral 
administration of diglycine (gly-gly) compared to the equivalent units 
of free amino acid (Craft et al, 1968; Adibi and Morse, 1971). 
Consequently, in the second trial diglycine was used but in smaller 
quantities (Section 2.4.2 c).
Plasma glycine in healthy volunteers who had taken no aspirin
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showed little fluctuations throughout the day and was not affected by 
a therapeutic dose of aspirin (500 mg). However, following aspirin 
overdose, plasma glycine concentrations were significantly lower and 
remained so in all patients treated with oral fluids only (control 
group) for the duration of their stay in the unit; suggesting depletion 
of glycine in this circumstance. In the majority of patients treated 
with bicarbonate, plasma glycine concentrations were comparable with 
the normal range, suggesting glycine depletion had not occurred. This 
may be due to accelerated renal excretion of SA as a result of 
increasing the urine pH, which reduces the total SA in the body 
available for conjugation with glycine and hence, glycine is 
conserved. In one patient (B4) in this group, unusually high 
concentrations were found for reasons which were not clear. In 
patients given glycine or gly-gly, plasma glycine concentrations 
increased rapidly above the normal range and only declined several 
hours after termination of their respective treatment regimen.
Effect of glycine on SUA excretion
Results from this study also showed that oral administration of 
glycine or gly-gly to patients with aspirin overdose did not result in 
a significant increase in the fraction of total salicylate excreted as 
SUA compared to the control group. Similar observations were made in 
experiments with healthy volunteers where glycine was found to have no 
effect on the synthesis of SUA after therapeutic doses of aspirin 
(Bedford et al, 1965; Caldwell et al, 1980). However, at doses of 
0.64 g and 0 . 9 g aspirin used in these studies, it is unlikely that
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SUA formation becomes saturated, as already demonstrated in this 
study. Thus, glycine will not have any measurable effect on the 
extent of glycine conjugation after therapeutic doses of aspirin 
(< 1 g). In another study by Nelson et al (1966), the urinary 
excretion of SUA by two human volunteers after oral administration of
1.5 or 2.0 g of aspirin was, however, found to proceed by apparent 
zero-order kinetics for over 10 hours after the dose. Glycine 
administration had no effect on the total amount of SUA formed.
Closer examination of their urinary metabolite data showed that after
1.5 g of aspirin (without glycine) approximately 82% of the dose was 
recovered as SUA, this suggests that saturation of this pathway may 
not have occurred at this dose. On the basis of this and other 
studies in man. Levy (1979) has concluded that availability of glycine 
is not the rate-limiting factor in the formation of SUA.
Biochemical mechanism of formation of gUA
The enzymatic conjugation of salicylic acid (SA) with glycine is 
depicted in Fig. 6.1.3. The conjugation is a two step, energy (ATP)- 
dependent biosynthetic reaction, in which SA is first activated with 
Coenzyme A (CoASH) to form nucleotide intermediate, salicyl-Coenzyme 
A, which then reacts with glycine to form SUA. These reactions have 
been clearly demonstrated in vitro using beef and human liver 
mitochondrial preparations (Tishler and Goldman, 1970; Forman,
Davidson and Webster, 1971). The activity of enzymes involved in the 
synthesis of SUA (Acyl CoA synthetase and glycine-N-acyltransferase) 
vary in different species and in different organs (Liver and Kidney) 
within the same species and are located in the matrix of mitochondria 






























conjugation of SA with glycine will be affected by a number of
factors, such as enzyme specificity, availability of glycine and
cofactors (CoASH and ATP) and mitochondrial permeability to SA, SUA 
and glycine (Huckel and Millburn, 1982). Biochemical evidence 
suggests that the initial step of activation of benzoic acid and 
salicylic acid may be carried out by different enzyme systems 
(Schachter and Taggart, 1954; Forman et al, 1971) but the conjugation 
of both activated species with glycine is catalysed by the same 
glycine-N-acyltransferase (Forman et al, 1971).
High concentrations of SA has a powerful inhibitory effects on 
the activities of the transaminases, dehydrogenases and enzymes of 
gluconeogensis, both in man and animal species (for reviews see. Smith 
and Dawkins, 1971; Rainsford, 1984). SA at concentations in the range
0.2 to 2.0 mM; which is within that observed in the unbound form in
the plasma of patients either receiving high dose salicylate therapy 
or with acute salicylate poisoning, appears to act at a subcellular 
level by uncoupling oxidative f^iosp^orylation with much the same 
effect as 2,4-dinitrophenol. There is also evidence that SA can 
increase the activity of ATPase (Penniall, 1958)^
thereby further reducing the amount of ATP available for the 
energy-requiring processes associated with it's own disposition. Thus, 
SA appears to have a profound inhibitory effect on mitochondrial ATP 
production and the net result is a reduction in the ATP content of 
cellular system. Decreased availability of ATP could then decrease 
the formation of SUA by affecting the activating step i.e. formation 
of salicyl-CoA (Fig. 6.1.3). This inhibitory effect of high SA 
concentrations may, in part, account for the reduction in the 
synthesis of SUA observed in patients with aspirin poisoning. It is
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possible that availability of ATP and hence the energy requiring 
formation of the activated salicyl-CoA complex may be the rate 
limiting step in salicyluric acid formation in man. However, the 
subsequent formation of SUA from this complex through the action of 
glycine-N-acyltransferase is also dependent on the availability of 
glycine. Thus, the overall extent of SUA synthesis will be dependent 
on the availability of both ATP and glcyine but the precise mechanism 
still remains to be elucidated.
Renal excretion of SUA (and SPG) occurs primarily by active tubular 
secretion (Schachter and Manis, 1958; Moller and Sheikh, 1983). The 
tubular secretory mechanism is completely dependent upon ATP generated 
by aerobic metabolism and can be blocked by inhibitors of the 
cytochrome oxidase system or by inhibitors of the oxidative 
reactions of the tricarboxylic acid cycle (Taggart, 1958). Salicylates 
have been shown to inhibit proximal tubule secretion (Oyekan, Laniyonu 
and Ashorobi, 1984), presumably by blocking ATP synthesis as a result of 
uncoupling of oxidative phosphorylation in kidney mitochondria. It is 
therefore likely that reduction in renal excretion of SUA (and SA 
glucuronides) may have occurred in patients with aspirin poisoning.
In addition, evidence suggests that aspirin in overdose reduces renal 
blood flow and impares renal function as a result of inhibition of 
renal prostaglandin synthesis (Plotz and Kimberly, 1981).
Consequently, a further decrease in renal excretion of aspirin 
metabolites, including SUA, may have occurred after overdose.
Urinary excretion of metabolites
Although the extent of glycine conjugation of SA was not altered 
in the present study after treatment with glycine or gly-gly but the
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mean of the maximum individual observed rate of excretion of SUA was 
significantly higher after these treatments compared to the control or 
bicarbonate treatment (Fig. 3.3.7.5). The mean of the urine 
collection period during which this maximum rate was observed was also 
shorter after former treatments. In addition, the total salicylate 
recovered in the urine over the period 2-16 hours after admission (i.e. 
time interval during which patients received oral glycine or gly-gly) 
was significantly higher after glycine or gly-gly treatment and the 
increase was comparable with that observed after urine alkalinisation. 
This suggests that glycine, is in some way, enhancing salicylate 
removal and is as effective as standard urine alkalinisation 
treatment. In contrast, when the total salicylate recovered in each 
patient from admission to discharge was compared, no significant 
changes were observed between different treatment groups.
In the bicarbonate group this observed increase in the total 
salicylate excreted was largely accounted for by increase in renal 
excretion of free salicylic acid (SA) as a direct result of raising 
urine pH, which will be discussed more comprehensively, later in this 
section. It also appears that in the glycine and gly-gly groups the 
fraction of total salicylate excreted as unmetabolised salicylic acid 
was approximately 1 0 % higher compared to the control, although the 
increase was not found to be statistically significant due to large 
standard error of the mean. This, raises an interesting possibility, 
that increasing the in vivo glycine pool results in an increase in the 
rate of formation of SUA (presumably in the liver) but upon reaching 
the kidney it is enzymatically hydrolysed back to SA, hence accounting 
for higher excretion of SA without increasing the proportion of SUA in
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the urine. Indeed, this conversion of SUA to SA has been demonstrated 
in the isolated perfused rat kidney (Bekersky, Colburn, Fishman and 
Kaplan, 1980). These workers showed that when isolated rat kidneys 
were perfused with perfusate containing SUA (2.5 mg) and glycine (20 
mM), between 20-25% of the SUA was enzymatically converted to SA. To 
expand their observations, they also perfused rat livers with SUA but 
no SA was detected in the perfusate, suggesting that only the kidney 
exhibits this hydrolytic potential in the rat. These interesting 
observations are, therefore, worth exploring in man to establish if 
human kidneys also have the capacity to convert SUA to SA and whether 
such back-conversion limits the amount of salicylate that appears as 
SUA in the urine. Such a system, if in existence in man, is likely to 
be of great importance because of renal excretion of SUA being the 
major route of elimination after therapeutic and toxic doses of 
salicylate in this species.
Changes in urine ^  and excretion of gA
As far as the author is aware, there is no evidence in the 
literature to suggest that oral administration of glycine or gly-gly 
has any effect on urine pH. In the present work, however, 
approximately 60% of the patients treated with glycine and 27% of 
those treated with gly-gly appear to have a more alkaline urine 
compared to the controls (oral fluids only). The mean ± SEM of the 
urine pH over the period 2-16 hours after admission in each treatment 
group was as follows. Control (6.20 ± 0.12); glycine (6.70 ± 0.09) ; 
gly-gly (6.24 ± 0.11) ; and bicarbonate (7.19 ± 0.13). It is important 
to note that the mean urine jSî in the gly-gly group was very similar 
to the control, whereas in the glycine group it was slightly higher.
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It is also possible that those patients with alkaline urine may have 
developed a severe respiratory alkalosis and possibly alkaluria, which 
are well known to occur early in the course of adult salicylate 
poisoning (Temple, 1981). The body compensates for this by increasing 
the renal excretion of bicarbonate which will lead to alkaline urine. 
This is consistent with the present findings that the increases in 
urine pH was short-lived in some patients and did not extend to the 
full period of glycine or gly-gly treatment.
In addition the aspirin metabolite profile in urine between 2-16 
hours after admission was also compared between each treatment group 
to determine if these differences in urine pfl resulted in changes in 
excretion pattern of metabolites, in particular SA and is shown in 
Table 6.1.3. It is evident that in the glycine group, urinary 
excretion of SA was approximately 10% higher compared to the control 
but the increase was statistically not significant. It is possible 
that this increase in SA in the glycine group was partly due to higher 
mean urine pH in this group. No significant changes were observed in 
the urinary excretion of GA, SUA and SPG. Therefore, it can be 
concluded that minor changes in ionisation of SA is unlikely to have 
played a major part in the observed increase in the total salicylate 
excreted in the urine (2-16 hr) after gly-gly treatment but it may 
have made some contribution after glycine treatment. The mechanism of 
action of glycine in enhancing renal excretion of total salicylate in 
patients with aspirin overdose is still unclear. It is possible that 
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thereby increasing the excretion of aspirin metabolites. These 
questions warrant further study.
Another well recognised problem associated with salicylate 
intoxication is water and electrolyte imbalance resulting in increased 
renal output of sodium, potassium and water (Segar, 1969; Done and 
Temple, 1971). Both, glycine and gly-gly have been shown to enhance 
sodium and water absorption from the intestinal lumen, using jejunal 
perfusion in man (Hellier, Thirumalai and Holdsworth, 1973). Since 
dehydration in patients with mild salicylate poisoning is generally 
corrected by oral fluids, it is likely that in the present work 
treatment with glycine or gly-gly together with oral fluids may have 
resulted in a more effective mode of correcting dehydration and is 
therefore worth exploring for future clinical use.
SUA excretion rate
Prescott et al (1982) have recently reported that after aspirin 
overdose, SUA formation is completely saturated and the maximum rate 
of removal of salicylate by this route was only 50-60 mg/hr. However, 
the data presented herein shows that rates of excretion of SUA in 
individual patients varied with time after admission in all treatment 
groups (Figs. 3.3.7.1 - 3.3.7.4) and appear to vary more in patients 
given glycine or gly-gly. The observed fluctuations are, therefore, 
more consistent with the variations in the availability of glycine 
than with saturation of enzyme system(s). Furthermore, the individual 
maximum observed rate of excretion of SUA in these patients ranged 
from 51-270 mg/hr (Fig. 3.3.7.5) and in three patients were within the 
range reported by above workers but not in the group as a whole 
(n=44). It is of interest to point out that a further complexity in
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the elimination kinetics of salicylate was recently found, that the 
formation of SUA is inducible. This has clearly been demonstrated in 
volunteers consuming aspirin 65 mg/kg/day for 3 days (Furst et al 
1977) and in rheumatoid arthritis patients on a high dose salicylate 
therapy (Rumble et al, 1980; Day et al, 1983; Gunsberg et al, 1984).
A considerable proportion of rheumatoid arthritis patients given high 
dose salicylate therapy on daily basis fail to achieve or maintain 
steady-state plasma SA concentrations and could be due to enhanced 
rates of formation of SUA due to its induction.
Urine alkalinisation regimen
In recent years, urine alkalinisation has become the treatment of 
choice for salicylate poisoning (Prescott et al, 1982). The rational 
for using such a treatment is based on the profound effect of urine fÆî 
on renal excretion of salicylic acid and has been demonstrated in 
healthy volunteers after therapeutic dose of salicylate (MacPherson et 
al, 1955; Gutman et al, 1955; Schachter and Manis, 1958) and in 
patients with salicylate poisoning (Morgan and Polak, 1971; Prescott 
et al, 1982). Renal excretion of SA occurs by glomerular filtration 
of the unbound SA, active tubular secretion and passive tubular 
reabsorption (Schachter and Manis, 1958; Morgan and Polak, 1971). The 
passive tubular reabsorption phase depends on the pH of the urine, 
which controls the amount of unionised, free SA (pka 3.0) available to 
re-enter the plasma (the tubular epithelium is highly permeable to SA 
molecules, but it is much less permeable to SA ions). Morgan and 
Polak (1971) showed that in patients with salicylate poisoning renal 
clearance of SA increased from 16 to 64 ml/min as urine pH increased
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from 6.5 to 7.5 i.e. a four fold increase in clearance for each rise 
of one unit in urine pH. They also observed that the renal clearance 
of SA increased with increasing urine flow, an effect that diminished 
as urine ^  rose.
Although, renal clearance was not determined in the present work 
a highly significant positive correlation (r = 0.881; P < 0.001) was 
found between percentage urinary excretion of SA and mean urine pH 
(combined data from all treatment groups). Thus, if the urine pH is 
raised, there would be a decrease in the availability of SA for 
hepatic and renal conjugation, so causing a decrease in urinary output 
of SA conjugates (i.e. SUA and SPG) as a consequence of reduction in 
the total body levels of SA available for conjugation. This is 
consistent with the significant decrease in the urinary excretion of 
SUA and SPG observed in the patients treated with bicarbonate regimen 
compared to those treated with oral fluids (Table 6.1.3). There is no 
doubt that urine alkalinisation is an effective procedure. However, 
the amount of bicarbonate required to produce a strongly alkaline 
urine (pH 8.0-8.5) in patients with salicylate poisoning has been 
found to vary considerably and the urine may remain acid even in the 
presence of alkalemia (Temple, 1981; Prescott et al, 1982). In 
approximately 50% of the patients in the present study urine pH did 
not exceed 7.0, despite intravenous sodium bicarbonate. Temple (1981) 
has suggested that urine alkalinisation cannot be accomplished 
adequately until potassium depletion has been corrected and does not 
recommend the treatment for children. Thus, urine alkalinisation is 
not without risk and careful monitoring of patients is required.
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Assessment of thê efficacy of treatment foi salicylate overdose
Frequent serial collections of urine is a reliable approach for 
studying kinetics of salicylate in overdose since it provides a value 
both of the total drug absorbed and of the speed of its excretion.
The present investigation has not attempted to measure plasma SA half- 
life (tl/2) which is only useful as a measure of elimination if 
absorption from the gut is complete. However, plasma SA 
concentrations in patients with acute salicylate poisoning may rise 
for as long as 24 hours despite thorough gastric lavage (Ferguson and 
Boutros, 1970; Kaufman and Dubansky, 1972), and thus may complicate 
tl/ 2  estimations. Various forced diuresis regimens (with or without 
alkali) appear to be effective as judged by the initial rapid fall in 
plasma SA concentrations but a corresponding urine SA excretion is not 
observed (Lawson et al, 1969; Morgan and Polak, 1971; Prescott et al, 
1982). It is likely that the initial rapid fall in plasma SA is due 
to haemodilution resulting from infusion of large volume of fluids. 
Therefore, efficacy of a given treatment for salicylate overdose 
should be assessed on the rate of renal excretion of total salicylate 
rather than by changes in plasma SA half-life.
In conclusion, following aspirin overdose salicyluric acid, the 
glycine conjugate was the major urinary metabolite, but in 
significantly lower amounts compared to the therapeutic (600 mg) dose 
of aspirin. In addition, depletion of plasma glycine concentrations 
also occurs. Enriching the glycine pool in plasma by oral 
administrcfion of glycine or gly-gly does not result in an increase in 
the fraction of total salicylate excreted as salicyluric acid but 
instead an increase in salicylic acid excretion was observed. Mean of 
the individual maximum observed rate of excretion of salicyluric acid
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was significantly higher in patients treated with glycine or gly-gly 
compared to the oral fluids only treatment (control group). Glycine 
and gly-gly treatments were as effective as the urinary alkalinisation 
regimen at enhancing renal excretion of total salicylate, however the 
mechanism of this action is not clear. Thus exogenous glycine may be 
of therapeutic value in salicylate poisoning.
6.2 Aspirin metabolism in rats
6.2.1 Capacity-1 imited metabolism of aspirin in rats
The metabolism of 14^-aspirin was investigated in male and female 
Wistar albino rats (University of Bath strain) over a ten fold dose 
range (10-100 mg/kg). Following a oral administration, the dose was 
rapidly eliminated in the urine with a mean of 85.73% excretion in the 
first 24 hours. Analysis of urine (0-24 hr) by radio-TLC revealed 
the following aspirin metabolites; gentisic acid, salicyluric acid 
(SUA), salicylic acid (SA) and sal icy 1 glucuronides (SG) and is in 
agreement with other studies (Haberland, Medenwald and Koster, 1957; 
Nelson et al, 1966; Yue and Varma, 1982; Baker and Niazi; Varma and 
Yue, 1984). The major urinary metabolite after each dose of aspirin 
was unchanged SA and accounted for approximately 45% of the total dose 
excreted in the urine in the first 24 hour. As the dose was increased 
from 1 0  to 1 0 0  mg/kg there was a significant decrease in the excretion 
of salicyluric acid (19% to 5%). This suggested that salicyluric acid 
formation anchor elimination is capacity limited. There is evidence 
that the rate-limiting step is SUA formation rather than renal 
elimination, because SUA administered intraperitoneally (200 mg/kg) 
to rats is very rapidly excreted and over 80% of the dose was
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recovered in the urine in the first three hours after dose, with 
average excretion half-life of 0.6 hr (Nelson et al, 1966).
Following a 10 mg/kg dose of sodium salicylate to rats (i.v), 
excretion of salicyluric acid was found to proceed at a constant rate 
(Yue and Varma, 1982). Similar observations were also made by Nelson 
et al, (1966) who reported that when the salicylate load in the rat 
exceed about 7 mg/kg, salicyluric acid formation proceeds at an 
apparent constant rate. It would thus appear that the glycine 
conjugation of salicylic acid reaches a saturation level at doses of 
salicylate of 10 mg/kg and possibly lower. However, this could not be 
confirmed in the present study, since the lowest dose of aspirin (1 0  
mg/kg) gave the highest excretion of salicyluric acid in the urine and 
the urine was not collected at frequent intervals during the first 24 
hours for accurate determination of the rate of excretion of SUA. 
Nelson et al (1966) have demonstrated that salicyluric acid formation 
in rat can be described by Michaelis-Menten kinetics and the values of 
Km (expressed as amount of drug in the body and not as concentrations) 
and V ^ ^  (the theoretical maximum rate of formation) were calculated 
to be 5.0 mg/kg and 0.30 mg/kg/hr respectively.
The reduction in the synthesis of salicyluric acid observed in 
the present study by increasing the dose of aspirin was compensated by 
increases in the formation of gentisic acid and salicyl glucuronides 
(Table 4.1.2). No significant changes were observed in the fraction 
of dose excreted as free salicylic acid. There is evidence to suggest 
that sex can influence drug metabolism and pharmacokinetics (O'Malley, 
Crooks, Duke and Stevenson, 1971; Giudicelli and Tillement, 1977). 
Urinary excretion of gentisic acid and salicyluric acid in the female 
and male rats did not differ. However, the fraction of total dose
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excreted in the urine (0-24 hr) as salicyl glucuronides in male rats 
was greater than in female rats after 1 0 , 2 0  and 1 0 0  mg/kg of aspirin 
(see Appendix 13). This was accompanied by a corresponding decrease 
in the urinary excretion of salicylic acid in the male rats and vice 
versa in the females and appears to be consistent with the fact that 
renal excretion of salicylic acid and formation of salicyl 
glucuronides are interdependent process. Since, the mean urine pH 
were similar in both sex of rats, it is unlikely that the increase in 
urinary excretion of salicylic acid in the female rats was due to 
differences in ionisation of salicylic acid. These findings have been 
confirmed, more recently by Varma and Yue (1984) investigating the 
influence of age, sex and pregnancy on the gjiarmacokinetic of sodium 
salicylate (12 mg/kg, i.v) in rats. However, in these studies urinary 
excretion of salicylic acid in adult male and female rats were 
similar. Thus, it appears that female rats are less efficient than 
their male counterparts with respect to glucuronic acid conjugation.
It is possible that the endogenous stores of glucuronic acid in female 
rats is limited or conversely, UDP-glucuronyl transferase activity is 
lower.
6.2.2 Effect of oral administration of glycine on the metabolism of 
aspirin in rats
The metabolism of aspirin was also investigated after 10 mg/kg 
and 1 0 0  mg/kg dose in control (saline treatment) and glycine treated 
rats to determine what effect, if any, exogenous glycine would have on 
the synthesis of salicyluric acid.
In glycine treated rats, after 10 mg/kg dose of aspirin, urinary
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excretion of salicyluric acid (mean value, 38.93%) increased 
significantly compared to the control rats (23.67%) (Table 4.2.2). 
Simiarly, after 100 mg/kg dose, a significant increase in salicyluric 
acid excretion was observed after glycine treatment (8.28%) compared 
to the controls (4.40%) but the salicyluric acid excretion only 
accounted for a third of that observed in control rats after 1 0  mg/kg. 
In addition, it appears that in both instances, increase in glycine 
conjugation was accomplished at the expense of glucuronide formation, 
since it decreased and is consistent with the view that these two 
metabolic pathways are interdependent. Urinary excretion of gentisic 
acid and salicylic acid were unaltered after glycine treatment. These 
findings are at variance with that of Nelson et al (1966) who 
suggested that mobilisation of glycine is not the rate limiting 
process for salicyluric acid synthesis in rat. Their conclusions were 
based on studies in rat where glycine administration did not enhance 
salicyluric acid formation following intraperitoneal injection of 
sodium salicylate at doses of between 20-60 mg/kg.
Since administered glycine is rapidly cleared from rat plasma 
(Adibi and Morse, 1982) it was found necessary in the present study to 
treat rats with high doses of glycine (Section 2.3 b) to maintain high 
plasma glycine concentrations for maximum synthesis of salicyluric 
acid. In addition, the amount of glycine used was approximately 15 
times higher than that used by Nelson et al (1966). It is, therefore, 
likely that this may account for the observed differences between the 
two studies. In another study, intravenous administration of glycine 
resulted in the survival of dogs which had received ordinarily fatal 
doses of sodium salicylate (0.25 g/kg) (Ghazal, 1960). It was also 
observed that after injecting glycine (500 mg/kg, i.v, identical dose
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was used in the present work in rats) urinary excretion of salicyluric 
acid increased from 4.4% to 34% (in the first two hours during glycine 
treatment). In contrast, glycine administration had no effect on the 
intraperitoneal LD50 of salicylate in rats and did not prolong 
survival time after administration of fatal doses (Nelson et al,
1966). Thus, there are conflicting reports in the literature 
regarding the effect of administration of glycine on the synthesis of 
salicyluric acid.
The present study has, nevertheless demonstrated two important 
observations regarding the disposition of aspirin in rats.
(a) Increasing the aspirin dose results in a significant decrease 
in the urinary excretion of salicyluric acid and (b) oral 
administration of glycine increases salicyluric acid formation. From 
these findings it would be tempting to conclude that availability of 
glycine is the rate limiting factor in salicyluric acid formation 
process. However, it would be inconsistent with the observation that 
although salicyluric acid excretion increased after administration of 
glycine in rats at the higher dose of aspirin ( 1 0 0 mg/kg) but the 
fraction of dose recovered in the urine as salicyluric acid (8.3%) was 
still substantially lower than that observed in the control rats after 
10 mg/kg (23.7%), when saturation of salicyluric acid formation is 
unlikely to have occurred. In addition, the findings that depletion 
of plasma glycine concentrations (if they reflect glycine availability 
at the site(s) of conjugation) does not occur in rats after 1 0  mg/kg 
and 1 0 0  mg/kg further suggests that perhaps mobilisation of glycine, 
alone, may not be the major factor controlling overall rate of 
formation of salicyluric acid; however it does make some contribution.
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Conjugation of glycine with salicylic acid proceeds via a two 
step enzymic reaction (Fig. 6.1.3). The activation step i.e. 
formation of salicyl-CoA requires energy in a form of ATP. High 
concentrations of salicylic acid have a profound inhibitory effect on 
ATP synthesis, as discussed previously (Section 6.1.3), becuase it 
uncouples oxidative phosphorylation in the mitochondria, thus reducing 
the ATP content of cellular system. Decrease in cellular ATP could 
then decrease SUA formation by affecting the activation step 
(formation of salicyl-CoA). The data from the present study are more 
consistent with the possibility that availability of ATP and hence the 
energy requiring formation of the activated salicyl-CoA complex is the 
rate limiting factor in salicyluric acid formation in rat. However, 
the subsequent formation of salicyluric acid from this complex through 
the action of glycine N-acyltansferase is also dependent on the 
availability of glycine. Thus, availability of both ATP and glycine 
may be the rate limiting factors, but the precise mechanism still 
remains to be determined.
Renal tubular conversion of salicyluric acid to salicylic acid 
has recently been demonstrated in the isolated perfused rat kidney 
(Berkersky et al, 1980). However, this phenomenon does not appear to 
have played a significant role in the present study since the urinary 
excretion of salicylic acid in the control and glycine treated rats 
after 10 and 100 mg/kg of aspirin were similar. In addition, oral 
administration of glycine (500 mg/kg) to rats also dosed with aspirin 
did not cause any significant changes in urine pH (Table 4.2.3). It 
may be of interest to point out that experimental induced protein- 
calorie malnutrition in rats has been shown to cause a significant
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increase in the urinary excretion of salicyluric acid (Yue and Varma, 
1982). More recently, 36 hour water deprivation in rats also resulted 
in increased half-life of salicylic acid by approximately 72% (Baker 
and Niazi, 1983).
6.3 Gmparative metabolism of aspirin in man and rats
Specific quantitative and qualitative studies on the metabolism 
of aspirin in man and rats after thera^uetic and toxic doses are 
lacking. Consequently, a comprehensive analysis was undertaken of 
urine from volunteers after therapeutic (600 mg) dose of aspirin, from 
patients with aspirin overdose and from rats after increasing doses of 
aspirin (10-100 mg/kg). In the present investigation, metabolites of 
aspirin were found to be similar in both species although there were 
quantitative differences. The major urinary metabolite in rats after 
each dose of aspirin was salicylic acid (Table 5.3.1), whereas in 
volunteers and patients it was salicyluric acid (Table 5.3.2). The 
metabolism of aspirin also appears to be dose dependent in both 
species.
Salicyluric acid excretion
As the dose was increased from 10 to 100 mg/kg in rats there was 
a significant decrease in the excretion of salicyluric acid.
Similarly salicyluric acid excretion was significantly lower in 
patients with aspirin overdose compared to the volunteers after 
therapeutic dose of aspirin. Thus, both species have a limited 
capacity to form salicyluric acid (Levy, 1979; Yue and Varma, 1982), 
since the urinary excretion of salicyluric acid is rate-limited by the 
formation process (Nelson et al, 1966; Levy et al, 1969; Bochner et
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al, 1981). From Michaelis-Menten kinetics of salicylate Nelson et al 
(1966) have calculated that for salicyluric acid formation rate 
(on a body weight basis) is about 4 times higher in man (1.25 mg/kg/hr) 
than in rats (0.30 mg/kg/hr) but the apparent in vivo Km values are 
identical in both species (5.0 mg/kg). These findings suggest that 
the enzyme system(s) responsible for salicyluric acid synthesis in man 
and rats respectively appear to be similar qualitatively but that the 
enzyme activity is appreciably higher in man than in rat. However, 
further work is needed to isolate, purify and characterise the 
respective enzymes.
The consequence of this saturation of salicyluric acid formation 
on the overall elimination of salicylate in the two species appears to 
differ. In man, at low doses of salicylate (< 500 mg aspirin), the 
overall elimination of salicylate proceeds by first-order kinetics but 
at higher doses it occurs by a combination of firs-order and capacity- 
limited processes (Levy, 1965; Levy et al, 1972). However, in the 
rats, salicylate elimination has been shown to occur by first-order 
kinetics over a wide dose range (2-100 mg/kg) (Yue and Varma, 1982), 
because salicyluric acid is a minor metabolite of salicylate in rats 
and hence saturation of this pathway at higher dose will not have a 
profound effect on the overall elimination kinetics.
Urinary excretion of glucuronide conjugates of salicylic and 
salicyluric acids
The urinary recovery of both gentisic acid and salicyl phenolic 
glucuronide increased significantly in rats as the aspirin dose was 
increased from 10-100 mg/kg. This latter observation appears to
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indicate a species difference since salicyl ^enolic glucuronide 
formation in man was reported to be capacity limited (Levy et al,
1972). However, in the present study, the fraction of total salicylate 
excreted in the urine as salicyl phenolic glucuronide was higher in 
patients with aspirin overdose compared to volunteers who took 
therapeutic (600 mg) dose of aspirin (Table 5.3.2), but the increase 
was not statistically significant. Zimmermann et al (1980) have 
characterised, by mass spectrometry, the phenolic glucuronide of 
salicyluric acid (SUA-PG) as an endogenous product in the body fluids 
of uraemic patients. The presence of this double conjugate of 
salicylic acid has recently been confirmed by Hutt et al (1982) as a 
metabolite of aspirin in urine from volunteers who has ingested 1 g of 
aspirin (radiolabelled) by mouth and accounts for a mean of 6 .2% of 
the toal dose excreted in the urine (024 hr). The results from the 
present study are in agreement with this and in addition have 
demonstrated the presence of this metabolite for the first time in 
urine from patients with aspirin overdose and in urine from rats 
following increasing oral doses of aspirin (10-100 mg/kg). Urinary 
excretion of this metabolite decreased with increasing dose in rats 
and was also significantly lower in patients with aspirin overdose 
compared to the volunteers and is therefore consistent with the 
capacity-limited formation of salicyluric acid observed in both species 
with increasing dose.
In many metabolic studies previously reported, total salicylate 
glucuronides are quantified using B-glucuronidase and/or non-specific 
hydrolysis and analytical methods. Evidence suggests that acyl (or 
ester) glucuronides of carboxylic acid (e.g. salicyl acyl glucuronide) 
tend to resist hydroysis with 6-glucuronidase because of
197
intramolecular rearrangement (Tiling and Wilson, 1981; Sinclair and 
Caldwell, 1982). Thus use of 6-glucuronidase alone for quantitation 
of total glucuronides is likely to lead to underestimation and 
therefore results obtained from such studies must cast some doubt on 
the quantities of glucuronides reported. Analysis of salicyl acyl 
glucuronide in the present study was performed by alkaline hydrolysis 
(Section 2.11 c) which is widely used for estimating acyl glucuronides 
of carboxylic acid since they are unstable under such conditions. 
Urinary excretion of salicyl acyl glucuronide increased with 
increasing dose in rats and was also significantly higher in overdose 
patients compared to the volunteers. From these findings it can be 
concluded that salicyl phenolic and acyl glucuronides (SPG and SAG) 
make a significantly greater contribution towards overall salicylate 
elimination after overdose and together they account for some 49% of 
the total salicylate excreted in the urine. Similar conclusions also 
apply to salicylate elimination in rats at the highest dose ( 1 0 0  
mg/kg).
Gentisuric acid excretion
Wilson et al (1978) were first to identify gentisuric acid, the 
glycine conjugate of gentisic acid, as a metabolite of salicylic acid 
in urine from patients with rheumatoid arthritis treated with aspirin. 
As far as the author is aware, the present investigation has 
demonstrated for the first time the formation of gentisuric acid in 
vivo and its relative excretion as a metabolite of salicylic acid in 
urine from rats dosed with aspirin. Wilson et al (1978) also found 
that incubation of gentisic acid with beef and rat liver mitochondrial
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prepartions results in formation of gentisuric acid. In addition, the 
1 , 0 0 0 X g supernatant fraction from rat liver was found to hydroxylate 
salicyluric acid to gentisuric acid. Thus, it can be concluded that 
gentisuric acid is a metabolite of salicylic acid, and can be formed 
either from salicyluric acid by ring hydroxylation or from gentisic 
acid by conjugation with glycine. In rats, at the lowest dose 
administered ( 1 0 mg/kg) this metabolite was found in urine in minor 
amounts (< 1 %), however its excretion increased slightly with 
increasing dose, although the change was not statistically significant 
(Table 5.3.1).
It is conceivable that gentisic acid is a competing substrate 
with salicylic acid for conjugation with glycine. Therefore, the 
presence of gentisic acid in increasing amounts as a competitive 
substrate could saturate the salicyluric acid forming enzyme system 
such that less salicylic acid is metabolised to salicyluric acid. 
However this is inconsistent with the data from the present study 
which suggests that availability of both ATP and glycine are rate- 
limiting factors in salicyluric acid synthesis in rat. In addition 
high body load of salicylic acid which would occur with increasing 
dose of aspirin would be expected to minimise gentisuric acid 
formation by competing with gentisic acid for glycine conjugation. 
Therefore, these findings require further study.
Although, Wilson et al (1978) did not quantify gentisuric acid in 
their study but they have since stated that it could only be detected 
in the urine of patients receiving large daily doses of aspirin and on 
a chronic basis accounts for about 4% of the dose (personal 
communication to Hutt et al, 1982). Results from the present study 
are in agreement with this since gentisuric acid was not detected in
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urine from volunteers after therapeutic (600 mg) dose of aspirin but 
in patients with aspirin overdose it accounted for a mean of 5 .3 % of 
the total salicylate excreted (0-24 hr urine). In another study by 
Haberland et al (1957), gentisic acid glucuronide and salicylic acid 
sulphate conjugate were also found in rat urine but the present study 
was unable to demonstrate their presence in rat or human urine. 
Mitchell et al (1977) have postulated a reactive intermediate, 
involved in the necrosis of renal proximal tubules in experimental 
animals, which may be produced from a quinol metabolite of salicylic 
acid, as the necrosis is decreased by pre-treatment with enzyme 
inhibitors. However, the formation of such an "active" metabolite of 
salicylic acid and it potential for nephrotoxicity and hepatotoxicity 
in man still remains controversial.
In conclusion, it appears that in addition to the known 
metabolites of aspirin, salicylic acid forms a broad spectrum of other 
products both in man and animal species, some of these have been 
quantified here. Despite such an abundance of metabolites, most of 
the metabolic and j^rmacokinetic studies involving salicylates, 
previously reported, have failed to recognise their importance. 
However, the present study has demonstrated that these "minor" 
metabolites make some contribution towards overall elimination of the 
drug from the body and become increasingly important at higher and 
toxic doses when the major metabolic pathways approach saturation. A 
complete understanding of salicylate disposition can only be achieved 
when all the potential metabolites, however small their excretion, are 
taken into account. The metabolism of aspirin was similar in both 
species studied and the rat, like the man, has a limited capacity to
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form salicyluric acid. Thus, the rat may serve as a useful 
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Appendix 1 - Random plasma glycine concentrations in healthy volunteers
Volunteer Age (yr) Sex Plasma glycine 
concentration ( ng/ml)
1 27 M 13.60
2 25 M 14.55
3 29 F 14.10
4 33 F 14.50
5 64 M 24.85
6 6 6 M 16.20
7 45 M 14.80
8 2 2 F 12.45
9 25 M 15.5
1 0 28 M 13.9
1 1 42 M 12.4
1 2 28 M 18.4
13 26 M 23.0
14 27 M 21.4
15 27 M 8.5
16 27 M 12.15
17 6 6 M 9.84
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Appendix 5 - Plasma glycine concentrations in a single healthy 
volunteer (male, 27 yr) at specified times after oral administration
of glycine ( 1 0 g) and N-glycylglycine (4 g)
Time after
Plasam glycine concentrations (yg/ml)
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Appendix 9 - Recovery of aspirin metabolite in patients with aspirin
overdose treated with oral fluids only - CONTROL GROUP
Urine collection
period (hr) Volume(L)
Urine recovery of metabolites (mg as SA) 
GA SUA SA SPG
Patient - Cl (female 42 yr. P.S.A. = 400 mg/1 )
0 - 4.33 0.55 7.0 N.M 282.9 266.7 138.1
4.33 - 8 0 . 6 8 6 . 2 N.M 220.3 53.4 79.1
8 - 9  0.69 5.9 N.M 87.4 13.5 36.7
9 - 11.5 0.52 5.6 N.M 114.9 9.8 55.3
11.5 - 18 0.89 5.4 N.M 414.6 25.3 151.5
18 - 21 0.40 5.8 N.M 320.0 23.3 137.2
21 - 33.8 0.33 5.7 N.M 2 0 2 . 8 7.1 41.7
Total of individual metabolites 1642.91 398.9 639.6
Patiait - C3 (female 21 yr. P.S.A. = 440 mg/1 )
0 - 1 0  0.24 5.9 6 6 . 2 385.8 2 1 2 . 1 212.4
10 - 20 0.14 5.6 43.2 238.6 1 2 . 2 184.5
20 - 42 0.78 5.6 156.1 905.0 103.9 491.7
Total of individual metabolites 265. Î) 1529.4 328.2 8 8 8 . 6
Patient - 04 (female 17 yr. P.S.A. = 370 mg/1, I.A.I. = 2 hr)
0  0.18 5.7 N.D 153.9 28.3 6 6 . 1
0 - 1 0  0.35 5.6 N.D 312.0 22.7 245.5
10 - 16 0.37 5.7 N.D 261.9 8.9 198.5
16 - 20 0.23 5.5 N.D 159.4 9.8 94.5
20 - 23 0.16 5.5 N.D 1 1 0 . 8 N.D 44.6
23 - 36 0.39 5.3 N.D 389.3 2.4 185.0
36 - 40 0.18 5.3 N.D 171.0 N.D 52.8
Total of individual metabolited 1558.4 72.1 887.1
All metabolites expressed as mg salicylic acid equivalent 
N.M - not measured, N.D - not detected 
P.S.A.- Plasma Salicylate on Admission 
I.A.I. - Ingestion-Admission Interval
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Appendix 9 - continued (control group)
Urine collection
period (hr) Volume (L)
Urine recovery of metabolites (mg as SA) 
GA SUA SA SPG
Patient - C5 (female 18 yr. P.S.A. = 530 mg/1, I.A.I. = 5 hr)
0 - 9  0.30 5.8 171.5 395.3 207.6 188.9
9 - 1 2  0.06 5.7 34.4 89.9 3.5 62.4
26 - 36 0.37 5.4 173.1 509.5 36.9 194.4
36 - 42 0.22 5.5 78.8 297.0 3.4 132.8
42 - 60 0.22 5.6 52.7 371.5 8 . 6 148.7
Total of individual metabolites 510.5 1663.2 259.8 727.2
Patient - C6 (female 19 yr. P.S.A. = 260 TBq/1)
0 - 1 2  0.30 5.8 4.6 399.9 13.2 163.6
1 2 - 16 0.60 5.7 1 . 2 387.2 3.3 140.1
16 - 20 0.14 5.6 2 . 2 73.3 0 . 1 21.4
20 - 24 0.31 5.5 5.4 158.6 N.D 38.2
24 - 36 0.63 5.3 1 . 2 409.7 N.D 52.9
Total of individual metabolites 14.6 1428.7 16.6 416.1
Patient - C8 (Female 16 yr. P.S.A. = 500 mg/1, I.A.I. = 14.3 hr)
0 - 1 6  0.69 6 . 1 95.9 505.2 245.2 197.8
16 - 2 0  1 . 0 0 6 . 0 25.6 146.2 36.5 45.3
20 - 24 0.54 6.4 8 . 8 44.7 26.4 14.7
24 - 28 0.67 5.7 38.7 191.7 21.9 55.8
28 - 42 1.07 5.4 64.3 575.9 32.4 149.9
Total of individual metabolites 233.3 1463.6 362.3 463.6
Patient - CIO (female 21 yr, P. S.A.. = 500 mg/1, I.A.I. = 5.5 hr)
0 - 4  0.95 7.0 13.4 416.5 634.0 231.2
4 - 1 1  1.15 6 . 2 34.1 493.2 331.6 323.7
11 - 15 0.94 6.3 2 0 . 1 284.5 236.8 199.2
15 - 17 0.99 7.3 N.D 122.4 359.2 113.2
17 - 23 1.00 7.3 1 2 . 0 357.3 472.1 171.1
Total of individual metabolites 79.6 1673.9 2033.6 1038.4
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Appendix 9 - continued (control group)
Urine recovery of metabolites (mg as SA)
Urine collection
period (hr) Volume (L) pH GA SUA SA SPG
Patients - C U  (female 17 yr, P.S.A. = 253 ing/1, I.A.I. = 3.5 hr)
0 “ 8 0.46 6 . 6  
8 - 1 0  0.35 5.5 













Total of individual metabolites 57.5 1216.1 972.9 438.1
Patiait - C12 (male 27 yr, P.S.A. = 325 mg/1, I.A.I. = 4 hr)
0 - 1 0.72 6.9
1 - 2.5 0.48 6.3 
2.5 - 10.5 0.42 6.1

















Total of individual metabolites 55.5 1450.8 431.9 710.3
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Appendix 10 - Recovery of aspirin metabolite in patients with aspirin
overdose treated with oral glycine
Urine collection
period (hr) Volume(L) pa
Urine recovery of metabolites (mg as SA) 
GA SUA SA SPG
Patient - G1 (male 19 yr, P.S.A. = 295 mg/1)
0 - 2  0.15 6 . 6 6 . 0 82.9 100.4 47.9
2 - 1 0  0.44 6 . 0 62.9 412.1 133.2 156.0
1 0  - 2 0  0.80 6.3 165.8 812.6 396.6 259.6
20 - 24 0.68 6.3 71.6 463.8 133.1 151.1
24 - 28 0.55 7.0 11.5 75.7 56.9 18.5
28 - 32 0.70 7.0 43.8 236.7 113.7 44.1
32 - 36 1.32 6 . 8 13.7 195.2 39.5 38.8
Total of individual metabolites 375.3 2278.9 973.3 716.0
Patieat - G2 (female 17 yr. P.S.A. = 270 mg/1)
0 - 2  • 0.15 6.5 N.D 78.3 76.7 42.1
2 - 8  0 . 6 8 6.7 N.D 324.7 308.9 187.2
8 - 1 0  0.24 6 . 8 N.D 139.4 1 0 0 . 1 70.9
Total of individual metabolites 542.5 485.7 300.2
Patient - G3 (male 22 yr, P.S.A. = 510 mg/1, I.A.I. := 6  hr)
0 - 6  0.65 7.9 48.2 648.5 2524.8 N.D
6 - 1 0  0.27 6.7 50.2 412.1 322.9 116.8
10 - 20 0.37 5.7 58.6 591.6 14.6 275.8
Total of individual metabolites 157.0 1652.2 2862.3 392.6
Patiait - G4 (male 40 yr)
0 - 2  1 . 2 0 5.6 42.5 231.5 90.6 204.8
2 - 6  0.15 6.4 2 0 . 6 99.4 89.4 49.2
6 - 8  0 . 1 2 6 . 2 28.8 1 1 0 . 8 61.7 65.1
8 - 1 0  0.09 5.9 46.4 116.3 23.5 89.0
1 0  - 1 2 0.08 5.4 51.2 113.3 8.3 99.3
12 - 20 0.33 - - - - -
20 - 24 0.12 5.3 82.1 172.4 8 . 0 108.7
24 - 32 0.75 5.1 497.9 907.5 32.5 460.9
32 - 36 0 . 6 8 5.1 62.5 176.1 1 . 2 59.7
36 - 42 0.59 5.1 73.3 198.9 9.5 69.9
Total of individual metabolites 905.3 2126.1 324.4 1206.4
-, Sample not available for analysis, N.D - not detected, P.S.A - 
Plasma Salicylate on Admission, IJLI. - Ingestion-Admission Interval
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Appendix 10 - continued (Glycine group)
Urine collection
period (hr) Volume(L) pa
Urine recovery of 
GA SUA
'metabolites (mg as SA) 
SA SPG
Batiait - G6 (male 18 yr, P.S.A =: 270 mg/1. I.A.I = 4.8 hr)
0 - 2 0.90 6.4 N.D 429.5 275.4 144.8
2 - 6 0.36 7.0 4.5 193.5 192.3 29.5
6 — 8 0.30 7.0 1.7 149.5 138.0 34.0
8 - 1 2 0.41 7.2 5.4 232.3 208.8 31.5
1 2 - 16 0.43 6.9 N.D 146.1 32.5 27.3
16 - 2 0 0.94 6.9 N.D 351.0 N.D 28.9
Total of individual metabolites 1 1 . 6 1501.4 847.1 295.9
Patient - G8 (male 30 yr, P.S.A. = 673 mg/1, I.A.I. = 4 hr)
0 - 2 0.75 7.3 N.D 146.6 402.5 79.9
2 - 4 0.75 7.0 N.D 156.4 334.2 59.8
4 — 8 0.40 6.4 N.D 159.9 153.1 73.6
8 - 1 0 0.65 6.3 N.D 127.5 136.9 44.0
1 0  - 1 2 0.50 6.7 N.D 129.8 2 2 1 . 2 41.5
1 2 - 16 0.54 7.0 N.D 30.4 77.0 5.5
16 - 2 0 2.25 6 . 8 N.D 275.7 175.8 108.7
20 - 24 0.90 6 . 1 N.D 225.4 53.6 84.7
24 - 32 0.80 6 . 1 N.D 182.2 2 2 . 8 75.7
32 - 36 0.46 6 . 1 N.D 234.9 N.D 66.4
36 - 42 0.62 5.7 N.D 391.4 N.D 123.4
Total of individual metabolites 2060.1 1576.9 763.4
Patiait G9 (male 43 yr, P.S.A. = 640 mg/1, I#A»Ie — 4 hr)
0 - 2 0.28 7.9 N.M* 59.5 617.5 60.5
2 - 4 0.35 8.3 N.M* 205.4 1593.5 81.1
4 — 8 0 . 2 0 7.4 N.M* 203.2 706.3 121.5
8 - 1 2 0.80 6.4 N.M* 336.7 294.2 339.0
12 - 24 1.44 6 . 6 N.M* 933.8 791.9 681.8
24 - 28 0.19 6.4 N.M* 174.6 82.2 94.9
28 - 36 0.45 6 . 1 N.M* 441.7 138.7 224.2
36 - 42 0.70 5.9 N.M* 505.9 62.8 234.1
Total of individual metabolites N.M* 2860.8 4286.9 1837.3
N.M* - GA not measured due to interfering endogenous peak
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10 - continued (Glycine group)
Urine collection
period (hr) Volume(L) pH
Urine recovery of metabolites (mg as SA) 
GA SUA SA SPG
Patient - GIO (female 58 yr. P.S.A. = 328 mg/1, I.A.I. = 3.5 hr)
0 - 1.75 0.33 6.5 2.5 1 2 2 . 2 72.5 N.D
1.75 - 3.75 0.30 6 . 2 0 . 1 1 1 1 . 2 35.9 20.4
3.75 - 7.5 0.35 6 . 0 15.0 272.3 51.7 78.2
7.5 - 10 0.31 6 . 0 18.3 278.9 40.6 86.7
1 0  - 16 0.82 6 . 2 N.D 428.8 30.1 162.9
16 - 2 0 0.56 6 . 1 N.D 236.7 15.9 61.2
2 0  - 2 2 0.40 6 . 2 N.D 161.8 14.0 2 1 . 2
2 2 - 26 0.19 5.8 N.D 98.2 N.D N.D
26 - 30 0.23 5.8 N.D 152.5 N.D N.D
30 - 36 0.35 6 . 1 N.D 265.9 N.D N.D
Total of individual metabolites 35.9 2128.3 260.7 430.6
Patient - G12 (female 31 yr. P.S.A. = 550 mg/1, I .A.I. = 5 hr)
0 - 4.5 0.50 7.1 28.3 236.1 338.9 916.2
4.5 - 9 0.70 6 . 8 31.3 162.9 402.2 206.1
9 - 16 0 . 6 6 6 . 1 52.6 305.9 160.8 293.6
16 - 2 0 1.29 5.9 30.0 167.9 140.2 151.5
20 - 24 0.42 5.6 27.5 2 0 0 . 0 45.5 124.8
24 - 36 0.25 5.5 25.3 351.5 26.8 157.7
Total of individual metabolites 195.0 1424.3 1114.4 1849.8
Patient - G13 (female 38 yr. P. S. A. = 390 mg/1 )
0 - 4 0 . 2 0 7.5 3.7 65.0 252.1 64.7
4 — 8 0.26 7.4 15.3 161.9 255.4 132.4
8 - 1 2 0.28 6.7 16.5 165.9 125.5 156.0
1 2 - 16 0.25 6 . 0 17.1 185.6 35.7 130.2
16 - 32 0.77 6 . 0 32.6 597.4 82.4 263.4
32 - 36 0.17 6 . 8 N.D 20.5 19.4 24.5
Total of individual metabolites 85.2 1196.3 770.5 771.2
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Appendix 11 - Recovery of aspirin metabolite in patients with aspirin
overdose treated with oral N-glycylglycine
Urine collection





1 (mg as SA) 
SAG SUA-PG
Patient - GG2 (female 39yr, P.S.A., = 680 mg/1, I.A.I. = 4.5 hr)
2 - 6.5 0.15 5.8 45.3 74.5 58.8 32.2 88.4 N.D
6.5 - 7 0.08 5.8 N.D 65.9 9.1 38.1 73.6 N.D
7 - 1 0 1.29 5.8 N.D 243.8 149.9 142.3 204.8 N.D
1 0  - 1 2 1.52 6 . 0 66.5 111.3 N.D 172.6 183.9 N.D
12 - 14 0.47 5.8 21.3 37.2 N.D 54.5 56.2 N.D
14 - 16 0 . 2 1 5.3 N.D 94.8 N.D 6 8 . 8 84.0 N.D
16 - 19 1.34 5.5 85.5 162.2 N.D 2 0 0 . 8 2 2 2 . 6 N.D
19 - 25 0.60 5.2 54.5 173.9 N.D 116.2 115.3 N.D
Total of individual metabolites 273.1 963.6 217.8 825.4 1028.7
Batieit - GG3 (male 64 yr, P.S.A. = 540 mg/1)
0 - 8 0.70 5.3 62.0 505.8 96.5 414.1 194.9 29.8
9 - 9.8 0.45 5.3 28.3 225.6 52.5 161.5 161.8 8 . 2
9.8 - 12 1.25 5.3 20.5 169.7 132.7 572.9 46.7 15.6
12 - 13 0.43 5.3 3.5 63.8 N.D 58.9 52.9 5.3
13 - 14.5 0.40 5.3 7.3 60.1 N.D 70.0 65.9 2.9
14.5 - 17.25 0.40 5.4 7.6 76.7 N.D 72.4 70.7 N.D
17.25 - 24 1.27 5.2 59.9 315.8 N.D 259.3 244.1 N.D
Total individual metabolites 189.2 1417.4 281.73 1605.8 837.0 61.8
Patient - GQ6 (female 70 yr. P.S.A. = 660 mg/1, :C.A.I. == 7.5 hr)
0 - 1.75 0.07 5.8 8.4 34.8 21.7 21.5 22.5 3.4
1.75 - 4 0 . 6 6 5.6 69.0 273.7 173.4 163.5 182.2 40.3
4 - 5.75 0.15 5.5 17.7 77.4 37.2 46.7 117.9 7.7
5.75 - 8 0.29 5.4 40.4 170.5 55.7 82.0 89.2 2 . 6
8 - 11.5 0.31 5.4 49.4 204.9 73.8 95.1 106.6 18.5
11.5 - 15.25 0.17 5.4 26.7 116.4 35.5 50.2 59.6 8.3
15.25 - 18 0.26 5.3 49.0 174.9 33.7 63.4 75.4 19.8
18 - 21.75 0.69 5.4 1 1 2 . 1 388.1 83.5 128.9 143.5 68.9
21.75 - 23 0.25 5.4 37.9 134.9 28.1 41.4 42.5 16.6
23 - 36 1.69 5.8 185.9 764.3 N.D 334.3 337.9 90.7
Total of individual metabolites 596.4 2340.0 542.6 1026.1 1180.2 276.8
N.D - not detected, P.S.A. - Plasma Salicylate on Admission 
I.A.I. - Ingestion-Admission Interval
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i^pendiz 11 - continued (Gly-Gly group)
Urine collection 





(mg as SA) 
SAG SUA-PG
Patient - GG7 (female 16, P.S.A == 470 mg/1, I.A.I. = 3 hr)
0 - 2.5 0.62 6 . 2 94.7 317.5 205.7 187.9 229.1 N.D
2.5 - 8 1.30 5.9 268.7 647.0 176.5 397.8 414.3 8.5
8 - 9 0.60 6 . 0 54.7 118.4 77.2 63.5 66.9 1 . 2
9 - 10.5 0.65 6 . 2 38.2 86.5 79.1 40.8 40.3 1.7
10.5 - 12.25 0.62 5.9 65.1 181.4 72.8 82.6 78.7 N.D
12.25 - 14.33 0.62 5.9 68.9 222.5 95.1 116.7 107.6 N.D
14.33 - 20.66 0.38 6 . 2 78.3 276.7 75.7 148.7 125.4 1 . 6
20.66 - 31.33 0.99 5.4 112.5 777.2 190.7 159.8 83.4 11.9
Total of individual metabolites 781.1 2627.2 972.8 1186.1 1145.6 24.9
Patient - GG8 (female 17 yr. P-S.A. = 460 mg/1)
0 - 1 0.95 7.5 28.4 178.1 988.4 117.2 176.2 N.D
1 - 2 0.36 7.7 15.0 56.2 366.4 N.D 11.4 N.D
2 - 7 0.25 7.2 6.3 113.9 N.D 38.2 31.1 N.D
7 - 8.5 0.37 6.4 12.5 58.1 58.9 23.7 2 2 . 2 N.D
8.5-12 0.29 6.4 17.6 113.5 83.1 39.7 33.7 N.D
12 - 23.5 0.43 5.5 28.1 358.1 46.9 114.3 72.8 17.7
23.5 - 27 0.17 5.3 3.5 1 0 0 . 2 1 . 8 33.2 25.0 45.0
27 - 32 0.32 7.3 45.1 211.5 436.9 N.D 55.3 N.D
Total of individual metabolites 156.5 1189.6 1982.5 366.4 427.6 70.3
Patient - GG9 (female 17 yr. P.S..A. = 630 mg/1)
0 - 2 0.77 7.1 24.8 67.5 500.9 7.1 81.4 N.D
2 - 6 2.25 7.1 86.3 166.3 1346.2 98.4 177.7 N.D
6 - 9.5 1.05 7.3 81.5 135.2 824.4 46.6 110.3 N.D
9.5 - 10.5 0.74 7.3 38.1 59.2 360.3 33.3 60.5 N.D
10.5 - 12.25 0 . 8 6 7.3 25.7 40.5 258.1 2 0 . 6 29.1 N.D
12.25 - 15.5 0.69 7.7 81.2 139.3 608.4 39.4 73.0 N.D
15.5 - 21.5 1.75 7.8 98.1 178.1 700.3 85.1 116.0 N.D
21.5 - 24 0.92 7.3 51.6 159.2 245.6 92.8 98.0 N.D
24 - 31.5 0.30 6.5 55.7 251.8 99.8 122.3 136.1 N.D
31.5 - 36 0.18 5.6 6 . 8 36.2 19.6 14.1 11.7 N.D
Total of individual metabolites 549.8 1233.5 4963.6 559.7 893.8
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Rppesnâix 11 - continued (Gly-Gly group)
Urine recovery of metabolites (mg as SA)
Urine collection
period (hr) Volume (L) pH GA SUA SA SPG SAG SUA-PG
Batioit - GGIO (male 32 yr. P-S.A. = 510 mg/1, I.A.I. = 7 hr)
0 - 0.5 0.32 5.5 50.7 255.8 56.1 227.7 N.M N.M
0.5 - 3.25 0.32 6.3 25.3 139.5 124.7 131.6 N.M N.M
3.25 - 7.75 0.55 5.4 54.6 289.0 15.5 279.5 N.M N.M
7.75 - 11.75 0.35 5.9 59.8 313.7 1 0 . 1 297.3 N.M N.M
11.75 - 16 0.77 5.9 58.0 256.9 2 1 . 1 250.5 N.M N.M
16 - 2 0 2.27 5.9 8 8 . 8 395.1 60.3 452.8 N.M N.M
20 - 23.5 1.65 6 . 0 42.9 171.6 43.8 220.9 N.M N.M
23.5 - 27 1 . 0 1 6 . 2 34.9 209.8 142.8 125.3 N.M N.M
27 - 35.75 0.55 5.5 54.2 543.2 61.5 339.7 N.M N.M
Total of individual metabolites 469.2 2574.7 535.9 2325.2
Patient - GGU (female 17 yr, P.S.A. = 545 mg/1, I.A.I. = 16 hr)
0  - 3.5 0 . 2 0 5.9 28.9 2 0 2 . 2 62.0 180.2 N.M N.M
3.5 - 5 0.67 6.5 15.4 52.1 110.3 30.7 N.M N.M
5 - 8.75 0.64 6 . 0 17.2 105.7 83.7 69.5 N.M N.M
8.75 - 12.5 0.55 6 . 6 17.3 138.2 173.2 77.9 N.M N.M
12.5 - 16 0.70 6.9 25.2 116.3 251.5 27.6 N.M N.M
Total of individual metabolites 104.0 614.6 680.7 385.9
N.M - not measured
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Appendix 12 - Recovery of aspirin metabolite in patients with aspirin
overdose treated with sodium bicarbonate (i.v.)
Urine collection
period (hr) Volume (L)
Urine recovery of metabolites 





Patient - B3 (female 16 yr. P.S.A. = 510,r I.A.I. = 3.5 hr)
0 - 2  0.40 7.4 N.D 47.1 620.3 N.D 44.0 N.D
2 - 5  0.33 7.5 28.9 48.9 509.5 N.D 38.5 5.8
5 - 1 2  0.93 7.1 99.7 365.7 1204.2 N.D 181.6 17.9
12 - 14 0.70 7.1 62.4 112.9 239.4 42.7 56.9 17.5
14 - 18 0.55 7.4 37.7 124.7 208.6 38.2 44.7 44.9
Total of individual metabolites 228.8 699.3 2781.8 80.9 365.7 8 6 . 1
Patient - B4 (male 21 yr, P.S.A. = 580 mg/1, I.A.I. = 13 hr)
0 - 7  0.70 6.3 223.3 337.2 85.3 182.5 157.6 35.2
7 - 1 2  0.50 6 . 2 268.8 515.9 83.8 263.3 245.5 8 6 . 1
12 - 24 0.61 6 . 0 291.5 765.1 96.0 357.3 276.7 117.8
24 - 36 0.70 5.5 66.3 1000.1 72.3 363.8 258.3 N.D
Total of individual metabolites 849.9 2618.3 337.4 1166.9 938.1 239.1
Patient - B9 (male 16 yr, P.S.A. = 460 mg/1, I.A.I. = !) hr)
0 - 6  0.29 6 . 8 125.0 445.1 631.7 158.3 211.9 7.8
6 - 1 0  0.60 6.5 80.2 212.4 165.5 170.9 105.8 44.8
10 - 16.5 0.78 6.5 74.3 236.3 186.5 82.5 91.3 7.7
16.5 - 27.5 0.40 5.9 212.5 789.3 135.6 389.2 20.4 62.5
Total of individual metabolites 492.0 1683.1 1119.3 800.9 429.4 1 2 2 . 8
N.D - not detected, P.S.A - Plasma Salicylate on Admission 
I.A.I. - Ingestion-Admission Interval
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Appaidix 12 - continued (Bicarbonate group)
Urine collection 





(mg as SA) 
SAG SUA-PG
Patient - B7 (male 17 yr. P.S.A. = 420 mg/1, I.A.I. = 4.5 hr)
2 - 5  0.27 7.0 61.9 133.4 230.9 51.4 39.6 34.8
5 - 9  0.20 7.2 94.8 171.3 218.5 59.0 71.1 9.8
9 - 14.5 0.45 6 . 8 213.4 394.3 292.3 184.0 180.9 17.4
14.5 - 19 0.99 6 . 6 234.6 450.9 242.3 215.0 217.8 25.3
19 - 22.5 0.32 6.3 120.7 288.6 1 0 1 . 8 141.7 1 2 0 . 0 N.D
22.5 - 37.5 2.07 5.9 174.5 751.2 N.D 636.4 557.8 82.5
Total of individual metabolites 899.8 2189.7 1085.8 1287.5 1187.2 169.8
Patieit - B8 (male 21 yr. P.S.A. = 485 mg/1, I.A.I = 7 hr)
1 - 1 0  0.57 7.9 68.3 505.1 877.4 138.3 N.M N.M
10 - 11.5 0.72 7.7 25.3 68.7 193.5 26.4 N.M N.M
11.5 - 12.7 0.56 7.5 13.6 30.3 121.3 7.9 N.M N.M
12.7 - 15.5 0.42 7.9 10.9 56.8 112.3 17.2 N.M N.M
15.5 - 18 0.45 7.9 11.7 80.9 137.4 25.4 N.M N.M
20 - 22 0.41 8 . 2 13.8 83.7 146.6 16.8 N.M N.M
22 - 32 0.66 7.4 29.3 475.1 237.8 126.6 N.M N.M
Total of individual metabolites 172.8 1300.7 1826.3 358.5
N.M - not measured
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j^pmdix 13 - Percentage recovery of metabolite in urine (0-24 hr) following 
oral administration of 14^-aspirin to rats
Aspirin metabolites (0-24 hr urine)
ASA Rat (sex)
Dose GA SUA SA SG
1 M 0.60 17.89 50.42 25.90
2 M 0.75 19.49 38.54 36.56
1 0  mg/kg 3 F 1.25 17.56 51.56 24.24
4 F 1.04 19.95 41.32 28.53
1 M 2.16 16.75 31.11 44.04
2 M 1 . 6 6 14.99 31.82 42.93
2 0  mg/kg 3 F 1.39 10.16 59.91 20.84
4 F 1 . 1 1 9.71 50.05 30.06
1 M 2.06 9.49 47.97 38.55
2 M 2.92 8.55 55.36 31.22
50 mg/kg 3 F 3.07 8.98 53.18 32.90
4 F 1 0 . 1 1 7.69 41.00 37.90
1 M 6.80 4.52 28.33 58.45
2 M 6 . 6 8 4.29 37.29 50.14
1 0 0  mg/kg 3 F 9.70 4.55 47.04 36.10
4 F 7.37 5.06 51.16 34.38
TLC metabolite profile in solvent System A
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i^jpendix 14 - Percentage recovery of metabolite in urine following 




Aspirin metabolites (0-24 hr urine)
GA SÜA SA SG
1 1.40 21.36 40.51 32.27
1 0  mg/kg 2 1.27 23.44 40.25 30.15
+ Saline 3 1.28 27.81 44.17 21.42
4 1.46 22.05 50.72 21.35
1 0.45 41.78 44.02 1 1 . 2 1
1 0  mg/kg 2 1.36 36.56 42.45 17.07
+ Glycine 3 0.76 38.74 36.41 2 1 . 0 2
4 1.24 38.71 37.48 17.41
1 4.93 3.64 53.31 35.27
1 0 0  mg/kg 2 3.77 5.13 37.20 49.54
+ Saline 3 7.73 4.14 37.70 48.04
4 10.84 4.69 33.44 48.19
1 6.35 1 0 . 1 2 34.29 46.00
1 0 0  mg/kg 2 3.57 7.96 50.84 34.48
+ Glycine 3 8.07 7.80 46.18 35.37
4 5.25 7.25 47.49 37.90
TLC metabolite profile in solvent system A
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